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ABSTRACT: Of the forms of reproductive labor in which legal scholars have been
interested, placenta, the organ developed during pregnancy, has been
overlooked. As placenta becomes an object of value for a growing number of
individuals, researchers, clinicians, biobanks, and biotech companies, among
others, its cultural meaning is changing. At the same time, these various
constituencies may be at odds. Some postpartum parents and their families want
to repossess their placenta for personal use, while third parties use placentas for
a variety of research, medical, and commercial purposes. This Article contributes
to the scholarship on reproductive justice and agency by asking who should have
access to placentas and under what conditions. The Article emphasizes the
insufficient protection the law affords pregnant people wishing to decide what
happens to their placenta. Generally considered clinical waste under federal and
state law, placental tissue is sometimes made inaccessible to its producers on the
ground that it is infectious at the same time as it is made available to third parties
on the ground that placenta is discarded and de-identified tissue. Less privileged
people who lack the ability to shop for obstetric and other pregnancy-related
services that allow them to keep their placentas are at a disadvantage in this chain
of supply and demand. While calling for further research on the modus operandi
of placenta markets and how pregnant people think about them, this Article
concludes that lawmakers should take steps to protect decision-making
autonomy over placental labor and offers a range of proposals to operationalize
this idea.
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The Law of Placenta
INTRODUCTION
When we think about or describe childbirth, we typically have in mind the
process that begins with labor and ends with the birth of a baby. We rarely
consider what happens after the baby is born, yet anyone familiar with
childbearing knows that what follows: the so-called "third stage of labor" is the
delivery of the placenta or afterbirth. The birthing person's uterus continues to
contract to push out the placenta, which is usually delivered fifteen to thirty
minutes after the baby.' Often ignored or treated as a waste product to be
discarded, the placenta is typically not the focus of attention among parents,
maternity-care professionals, or legal scholars.2 Yet the social life of placentas
barely begins with pregnancy. 3 Some placentas are destroyed by healthcare
facilities, but others are eaten, buried, planted, or transformed into art, while still
more are banked, used for research, or made into prized components in medical,
health, and cosmetic treatments. Though it is difficult to trace their paths, as little
information is publicly available, the circulation of placentas outside of pregnant
bodies across the bioeconomy raises a number of factual and legal questions.
Who decides the fate of placentas? How are placenta supply chains regulated?
Do placenta markets raise new questions or do they duplicate the characteristics
of other markets for human tissue?
Rebecca Skloot's The Immortal Life of Henrietta Lacks has generated
significant attention and debate around the property and privacy rights of patients
when their data and tissues are appropriated by healthcare providers, earning the
providers reputational and financial benefits about which patients often are not
aware and from which they do not benefit.4 What is unique about the placenta,
as opposed to other tissues, is that it has practical as well as spiritual and cultural
uses for the person who grows it and their family, as well as scientific, clinical,
and commercial potential for third parties such as researchers, clinicians,
1. Throughout the Article I strive to use gender-neutral language to designate the producers of
placentas in recognition that people who do not identify as women or as any gender grow placentas
and may have an interest in them. I occasionally use the word woman and other gendered terms
when paraphrasing others or to emphasize the female coding of placental labor in our culture and its
attendant subordination.
2. But see Elizabeth Kukura, Obstetric Violence, 106 GEO. L.J. 721, 730, 734, 735 (2018) (mentioning
the unconsented manual removal of placenta by medical personnel as an element of obstetric
violence).
3. See THE SOCIAL LIFE OF THINGS: COMMODITIES IN CULTURAL PERSPECTIVE (Aijun Appadurai
ed., 1988) (showing that things lead social lives through the meanings people attribute to them in
their uses and transactions).
4. Henrietta Lacks was a poor, Black woman and tobacco farmer whose contribution to medicine had
gone unrecognized. In 1951, Lacks's cervical cancer cells served to create the first immortal cell
fine, called the HeLa line, which became invaluable for research. Her cells led to several medical
breakthroughs, served as the basis for several thousands of patents, and generated drug companies
billions of dollars in profits. Lacks was the unwitting source for these cells and did not benefit
medically or financially from any of these discoveries. See REBECCA SKLOOT, THE IMMORTAL LIFE
OF HENRIETTA LACKS (2010).
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biobanks, biotech companies, and drug and cosmetic companies.5 Patients rarely
ask for their excised body parts to be returned to them after a diagnostic or
medical procedure (though some amputees have been known to request and
obtain their limbs to take home).6 But in many cultures, including Native
American cultures such as the Navajo, 7 the placenta has long been saved for
ritual purposes, and a growing number of postpartum parents from diverse
backgrounds seek to repossess their placenta to bury it, eat it, or bank it.
Individuals' interests in their placentas have disruptive effects on the market for
placentas. These interests are less salient in other body markets, such as those of
blood, semen, or organs, in which donors typically do not seek to repossess their
own materials for self-consumption. By taking their tissue out of the supply and
demand chain, patients who claim their placenta expose the irony of the
dominant legal characterization of placentas (and other excised body parts) as
"medical waste" when in reality they are in high demand for a variety of uses.
Placental tissues not only are collected at the end of a pregnancy, but also
are collected from leftover tissues following prenatal tests or surgical procedures
conducted for pregnancy termination or loss. 8 The wide range of sources for
placental tissue implies that the majority of people who can become pregnant
are, have been, or will be in a position to donate their placenta during their
reproductive years. Those who have undergone a chorionic villus sampling (CVS
test, a prenatal diagnostic test to detect congenital abnormalities in the fetus by
removing and analyzing a small placenta sample),9 experienced dilation and
curettage (D&C) or dilation and evacuation (D&E) following a miscarriage, had
a surgical abortion, or delivered a baby, may have relinquished parts or the
entirety of their placenta at the healthcare facility unless they purposefully
5. That said, instances of self-eating have been reported for virtually every body part, as a medicinal
practice or as a form of pathology. See Mathilde Cohen, The Law of Self-Eating. The Consumption
of Milk, Placenta, andFeces (Sept. 30, 2018) (unpublished manuscript) (on file with the author).
6. Kristin Hugo, She Took Her Amputated Leg Home, and You Can Too, PBS (Jan. 4, 2017, 5:38 PM
EST), https ://www.pbs.org/newshour/science/took-amputated-leg-home-can
[https://perma.cc/3BV5-ZFEP]; see also Margaret Atwood, Kat, NEW YORKER, Mar. 5, 1990, at 38
(a short story in which the main character, Kat, takes home her ovarian tumor after surgical removal,
preserving it in formaldehyde, displaying it on her mantelpiece, and naming it Hairball).
7. See Louise Lamphere, Migration, Assimilation and the Cultural Construction of Identity: Navajo
Perspectives, 30 ETHNIC & RACIAL STUD. 1132,1141 (2007).
8. See Judith E. Cartwright & Guy StJ. Whitley, Strategies for Investigating the Maternal-Fetal
Interface in the First Trimester ofPregnancy: What Can We Learn About Pathology?, 60 PLACENTA
145, 147 fig.1 (2017) (discussing the question of "[t]issue accessibility at different stages of
pregnancy" and the "limitations and advantages" of what can be studied from tissue obtained at
different stages).
9. See Giovanni Monni, Rosa Maria Ibba, & Maria Angelica Zoppi, Prenatal Genetic Diagnosis
through Chorionic Villus Sampling, in GENETIC DISORDERS AND THE FETUS: DIAGNOSIS,
PREVENTION AND TREATMENT 160 (Aubrey Milunsky & Jeff M. Milunsky eds., 6th ed. 2010)
(describing chorionic villus sampling (CVS), a procedure involving a biopsy of the placenta, which
is usually performed during the first trimester of pregnancy to diagnose certain genetic or
chromosomal disorders).
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obtained it for themselves. Considering that, in the United States, 86% of women
aged 40 to 44 are mothers, 10 nearly 1 in 4 women (23.7%) will have an abortion
by age 45,11 and miscarriages occur in 10 to 25% of known pregnancies, it may
well be that the vast majority of people who were ever pregnant have (wittingly
or unwittingly) contributed placental tissues to placenta markets.' 3
This Article exposes the insufficient protection afforded by the law to people
wishing to have agency over their placental labor, an often-overlooked
dimension of reproductive labor. Under federal and state laws, placental tissue
is typically treated as medical waste and disposed of according to standard waste
management procedures. 14 Because placentas usually contain no identifiers
linking them to particular donors, they can be used for research without requiring
donors' consent.'15 Healthcare facilities can also donate them to biobanks or
procurement organizations for clinical or commercial uses. That being said, there
has been progress toward the legal recognition that individuals may have special
interests in their placentas. In traditional Hawaiian culture, the proper care of the
placenta of a newborn has tremendous cultural and spiritual significance-it
must be buried, usually under a tree, to keep the child connected to its home.' 6
When the State of Hawai'i declared the placenta to be infectious waste in 2005,
Native Hawaiian groups fought back successfully. As a result, in 2006 the state
became the first in the nation to statutorily protect the right of birthing parents to
repossess their placenta following a hospital birth. 17 Since then, though hospitals
10. Claire Cain Miller, The U.S. Fertility Rate Is Down, Yet More Women Are Mothers, N.Y. TJMES
(Jan. 18, 2018), https://www.nytimes.com/2018/01/18/upshot/the-us-fertility-rate-is-down-yet-
more-women-are-mothers.html [https://perma.cc/4LS2-9YM2].
11. Rachel K. Jones & Jenna Jerman, Population Group Abortion Rates and Lifetime Incidence of
Abortion: United States, 2008-2014, 107 AM. J. PUB. HEALTH 1904 (2017).
12. Miscarriage: Signs, Symptoms, Treatment, andPrevention, AM. PREGNANCY ASS'N, (Oct. 10, 2019,
2:02 PM), https://americanpregnancy.org/pregnancy-complications/miscarriage
[https://perma.cc/JQ9Y-DWPF].
13. See, e.g., Steven Petrow, Who Owns Your Medical Data? Most Likely Not You, WASH. POST (Nov.
25, 2018, 6:00 AM MST), https://www.washingtonpost.com/national/health-science/who-owns-
your-medical-data-most-likely-not-you/2018/11/23/28785efc-e77d-I le8-a939-
9469fl 166f9dstory.html [https://perma.cc/8E9H-GBEZ] (reporting that healthcare facilities
typically require that patients admitted for treatment or testing sign blanket consent forms giving the
doctor or institution permission to use their data or tissue samples as they see fit without having to
notify or compensate them and noting that health data is routinely sold or licensed to commercial,
for-profit companies).
14. See infra Part II.A.1.
15. See Rebecca Scott Yoshizawa et al., Postpartum Women's Perspectives on the Donation of
Placentas for Scientific Research in Campinas, Brazil, 10 J. EMPIRICAL RES. ON HUM. RES. ETHICS-
76, 77 (2015) (citing scientists who reported using placentas without explicit, informed consent
because placentas are "considered a throwaway tissue"); see also infra Part III.B. 1.
16. See Melody Kapilialoha MacKenzie, Hawaiian Custom in Hawai'i State Law, 13-14 Y.B. N.Z.
JURiS. 112, 149 (2010-2011).
17. See Nancy Cook Lauer, Hawaiian Law Now Permits Parents to Keep Placentas, WOMEN'S ENEWS
(July 28, 2006), https://womensenews.org/2006/07/hawaiian-law-now-permits-parents-keep-
placentas [https://perma.cc/MGR5-H6VL].
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and birthing centers around the country have become more lenient in releasing
placentas, some still refuse or make it so difficult that they interfere with birthing
parents' planned use. For instance, in 2016, Jordan Thiering, a pregnant
Mississippi woman, found out that the hospital where she planned to deliver
considered placentas medical waste which could not be released without a court
order.18 She made the national headlines by going to court to obtain the order to
take her placenta home. Meanwhile, placentas have become embroiled in
abortion wars with the passage of state fetal burial laws, which prohibit abortion
providers from disposing of fetal remains as they would surgical waste. 9 The
result is that in some states individuals have more access to their placenta in the
context of an abortion or miscarriage than a live birth, evidencing the
entanglement between the law of placenta and reproductive justice.
There is little predictability or clear information available on whether and
how people can retain their placentas, which are defined and regulated by a
patchwork of federal and state regulations related to medical waste, anatomical
gifts and tissues, food and drug laws, cord-blood donation programs, and
cosmetics regulation, among other sources of law. Even less is known about how
discarded placentas circulate among medical facilities, researchers, biobanks,
procurement organizations, and other stakeholders. 20 Legal scholarship is
practically nonexistent on the topic of placentas in the United States. To the best
of my knowledge, only three law review articles specifically address placentas,
all focusing on the regulation of placentophagy, that is, whether and how women
should be allowed to eat their own placentas.21
This Article is the first to provide a comprehensive legal analysis of the
various uses and modes of consumption of placentas today. It builds upon two
strands of feminist scholarship. First, the analysis of placenta markets is inspired
by legal scholars such as Donna Dickenson 22 , Michele Goodwin, 23 Kimberly
18. See Corky Siemaszko, Pregnant Mississippi Woman Wins Court FightforHer Placenta, NBC NEWS
(June 5, 2016, 9:43 AM MST), https://www.nbcnews.com/news/us-news/pregnant-mississippi-
woman-wins-court-fight-her-placenta-n584846 [https://perma.cc/3D6W-XMSC].
19. See infra Part II.B.3.
20. Because placenta is collected, processed, and marketed by live industries at the forefront of research,
an added challenge to the lack of publicly available information is the constantly changing nature of
the markets. My learning about the topic will continue and I welcome input from stakeholders.
21. See Carmen M. Cusack, Placentophagy and Embryophagy: An Analysis of Social Deviance Within
Gender, Families, or the Home (Etude 1), 1 J.L. & Soc. DEVIANCE 112 (2011) (arguing that
placentophagy and embryophagy are not illegal); Greer Donley, Regulation of Encapsulated
Placenta, 86 TENN. L. REV. 225 (2019) (considering the legal implications of placenta
encapsulation); Amber Goeden, Placentophagy: A Woman's Right to Her Placenta, 3 CONCORDIA
L. REV. 170 (2018) (regulation of placentophagy).
22. DONNA DICKENSON, PROPERTY IN THE BODY: FEMINIST PERSPECTIVES (2007).
23. THE GLOBAL BODY MARKET: ALTRUISM'S LIMITS (Michele Goodwin ed., 2013).
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Krawiec,2 4 Judit Sdndor,25 Radhika Rao,26 Kara Swanson, 27 and Catherine
Waldby and Melinda Cooper28 who theorize human body markets and the rise of
biocommodities regulation. Their writing explores the gender inequities as well
as other forms of intersectional oppressions underlying these markets and the
changing dynamics of value for female embodied labor. Second, I draw on
scholarship on women's distinctive experiences with their placentas. The
scientific, social science, and humanities literature on placentas has grown
dramatically in the past decade, with pioneering work in particular by
sociologists Julie Kent and Rebecca Yoshizawa, 29 cultural studies scholar
Charlotte Krolokke, 30 geographer Maria Fannin, 31 and philosopher Cressida
Heyes, 32 whose writings make visible the feminized form of reproductive labor
at stake in placenta markets. In different ways, these scholars critique the erasure
of women's work in the matter of reproduction, emphasizing that pregnant
people are not passive objects or containers from which doctors pull out children
and tissues such as placentas.
The Article proceeds in three Parts. Part I situates placentas in society and
biomedicine, presenting their uses by various stakeholders and the discourses
surrounding them. Part II turns to the law, exploring some of the inequities of
the placental economy, including the barriers preventing some individuals from
repossessing their own placentas when third party actors enjoy relatively easy
access. By placental economy, I mean the circulation of placentas outside of
pregnant bodies from healthcare facilities to third parties and to consumers-
including back to women themselves as consumers. Part I advocates in favor
of granting individuals more control over their placentas, identifying possible
24. Kimberly D. Krawiec, A Woman's Worth, 88 N.C. L. REV. 1739 (2010) (proposing the notion of
"taboo trades" in the context of body product markets).
25. Judit Sbndor, Commodified Bodies: Is It a Gender Issue?, in NEW CANNIBAL MARKETS:
GLOBALIZATION AND COMMODIFICATION OF THE HUMAN BODY 325 (Jean-Daniel Rainhorn &
Samira El Boudamoussi eds., 2015).
26. Radhika Rao, Informed Consent, Body Property, andSelf-Sovereignty, 44 J.L., MED. & ETHICS 437,
440 (2016).
27. Kara W. Swanson, Rethinking Body Property, 44 FLA. ST. U. L. REV. 193 (2016).
28. Catherine Waldby & Melinda Cooper, The Biopolitics ofReproduction: Post-Fordist Biotechnology
and Women's ClinicalLabour, 23 AUSTL. FEMINIST STUD. 57 (2008); Catherine Waldby & Melinda
Cooper, From Reproductive Work to Regenerative Labour: The Female Body and the Stem Cell
Industries, 11 FEMINIST THEORY 3 (2010).
29. See, e.g., R.S. Yoshizawa, Review: Public Perspectives on the Utilization of Human Placentas in
Scientific Research and Medicine, 34 PLACENTA 9 (2013).
30. CHARLOTTE KROLOKKE, GLOBAL FLUIDS: THE CULTURAL POLITICS OF REPRODUCTIVE WASTE
AND VALUE (2018).
31. Maria Fannin, PlacentalRelations, 15 FEMINIST THEORY 289 (2014); Maud Perrier & Maria Fannin,
Belly Casts and Placenta Pills: Refiguring Postmaternal Entrepreneurialism, 31 AUSTL. FEMINIST
STUD. 448 (2016).
32. Cressida Heyes, Placenta-Eating and the Epistemology of Ignorance, 37 ATLANTIS 111 (2016).
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choice architectures to that end, and examines avenues to regulate third parties'
access to and use of placentas.
I. THE USES OF PLACENTA
This Part describes the various purposes for which placentas are used, be it
by birthing parents and their families or by third parties such as researchers,
clinicians, biobanks, biotech, drug, and cosmetic companies. Before detailing
theses usages, this Part provides an overview of the placenta as an organ.
The placenta is a critical but temporary organ, which develops as a result of
pregnancy and undergoes structural and functional changes throughout
gestation. 33 A term placenta delivered following thirty-seven to forty-two weeks
of pregnancy typically weighs about a pound and is roughly the size of a small
dinner plate. 34 The placenta is often presented as a major "interface" between the
pregnant person and the fetus.35 Over the course of a pregnancy, its principal
function is to supply the fetus with oxygen and nutrients, protect the fetus from
environmental exposures by serving as a crossing guard for substances travelling
between woman and fetus, and remove waste products. In a way the placenta
acts as every organ the fetus needs to survive-heart, lungs, gut, liver, even the
endocrine system---producing nutrients, enzymes, and hormones; 36 removing
waste; providing a barrier against viruses and bacteria; and passing along
essential antibodies.37 The placenta impacts the pregnant person, affecting their
metabolism and fending off dangers such as viral infections. 38 Despite the
placenta's importance in the health of women and fetuses, in-depth
understanding of its function and properties is still lacking. In 2014, the National
Institute of Child Health and Human Development (NICHD) launched a multi-
disciplinary project called the "Human Placenta Project" to address this lack of
knowledge.
39
33. Graham J. Burton & Abigail L. Fowden, The Placenta: A Multifaceted, Transient Organ, PHIL.
TRANSACTIONS ROYAL SOC'Y B, Mar. 2015, at 1; see also Kurt Benirschke, Remarkable Placenta,
11 CLINICAL ANATOMY 194, 196 (1998) (noting that three principal tissues make up the placenta:
(1) the trophoblast, (2) connective tissue with chorionic membrane and blood vessels, and (3) the
amnion).
34. See Burton & Fowden, supra note 33, at 2.
35. See Rebecca Scott Yoshizawa, Fetal-Maternal Intra-action: Politics of New Placental Biologies,
22 BODY & SOC'Y 79 (2016) (critiquing the notion of the fetal-maternal interface for presuming a
separation between "mother" and "fetus").
36. MICHAEL L. POWER & JAY SCHULKIN, THE EVOLUTION OF THE HUMAN PLACENTA 166-67 (2012).
37. See Burton & Fowden, supra note 33, at 375.
38. Id. at 371.
39. Human Placenta Project, EUNICE KENNEDY SHRIVER NAT'L INST. CHILD HEALTH & HUM. DEV.
(Oct. 31, 2018), https://www.nichd.nih.gov/research/supported/HPP/default
[https://perma.cc/AA75-PK7X].
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Historically, medical practitioners, religious authorities, and philosophers
have been divided as to whether the placenta belongs to the pregnant person or
to the fetus. The placenta is composed of both maternal and fetal tissues, but
from a regulatory perspective it is not considered fetal tissue and thus is exempt
from the strict federal legal regime governing fetal tissue donation and
research. 40 According to philosopher Cressida Heyes, "[t]he body of the
mother/fetus is neither self-evidently one nor two and the placenta is the liminal
organ through which that mutual incorporation is most apparent."41 The placenta
challenges our way of classifying the world and its inhabitants into separate
beings with their own distinct bodies and organs. In some cultures, the placenta
is considered a twin, sibling, or friend to the fetus/child, in others, it is thought
to harbor the power to protect and heal the living body, to be related to fertility,
to connect newborns to their place of birth, to establish fatherhood, among other
functions.4 2 As soon as a baby is born in the United States, the placenta is
disconnected from them by cutting the umbilical cord, suggesting a cultural
commitment to an ontology of separation, though delayed clamping has grown
in popularity. 43 Typically, the placenta is removed or caught by the birth
attendant, depending on whether the delivery is vaginal or via C-section. It is
often discarded as its biologic function has been accomplished and it no longer
appears useful. Yet a growing number of parents and their families question this
course, seeking to repossess their placenta so as to make use of it.
A. Self-Consumption
Postpartum people and their families consume their placentas in three main
ways. First, in certain cultures and communities, placentas have a social,
religious, or spiritual significance dictating that the postpartum woman and her
family accomplish a number of rituals with them. Second, a rising trend is for
birthing parents to eat their placenta or employ it in other Do-It-Yourself
("DIY") ways. Third, new parents can bank their placenta for future use.
40. The law governing fetal tissue donation and research defines "human fetal tissue" as "tissue or cells
obtained from a dead human embryo or fetus after a spontaneous or induced abortion, or after a
stillbirth." 42 U.S.C. § 289g-l(g); see also V. Noah Gimbel, Fetal Tissue Research & Abortion:
Conscription, Commodification, and the Future of Choice, 40 HARv. J.L. & GENDER 229, 235-37
(2017) (examining critically the federal requirements governing fetal tissue donation and research).
41. See Heyes, supra note 32, at 113.
42. Gwynne L. Jenkins & Jeremy Sugarman, The Importance of Cultural Considerations in the
Promotion of Ethical Research with Human Biologic Material, 145 J. LABORATORY & CLINICAL
MED. 118, 119 (2005).
43. Committee Opinion No. 684. Delayed Umbilical Cord Clamping After Birth, AM. C.
OBSTETRICIANS & GYNECOLOGISTS (Jan. 2017), https://www.acog.org/Clinical-Guidance-and-
Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Delayed-Umbilical-Cord-
Clamping-After-Birth? [https://perma.cc/CV2Z-TACU] (recognizing the beneficial effects of
delayed cord clamping in the majority of births and recommending a delay of at least thirty to sixty
seconds after birth).
2020]
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1. Spirituality
The placenta has long held spiritual meaning cross-culturally, particularly in
the form of ceremonial burial. 44 Each community has its own beliefs and
traditions associated with the placenta, but a common thread is the idea that the
proper care and disposal of the placenta and umbilical cord of newborns will
affect their and their families' health and well-being. The placenta must therefore
be placed or buried in a special spot-be it at or under the parental house, at one
of the parents' childhood homes, or under a tree, often with the idea that it will
keep the child connected to their home.45 Traditionally, Native Hawaiians plant
the placenta ('iewe) in the earth following a religious ritual to establish a
connection between the mother, child, people, and place.46 Native Americans4
such as the Navajos bury the placenta so as to return it to Mother Earth.48 The
Chamorros of Guam have traditional placental burial practices, which Christine
Taitano DeLisle argues have represented a form of "indigenous feminism"
deployed against U.S. naval colonialism. 49 These various traditions have
inspired Americans from all cultural, ethnic, and racial backgrounds to plant their
placentas, often with a tree that grows along with their children, commemorating
their birth.5°
2. Placentophagy and Other DIY Uses
Though almost all mammals consume their placentas, the practice is not
common in humans. 51 Some humans do eat their placentas, a practice
anthropologists call "maternal placentophagy." The first documented accounts
of postpartum women practicing placentophagy were in North America in the
44. Sharon M. Young & Daniel C. Benyshek, In Search of Human Placentophagy: A Cross-Cultural
Survey of Human Placenta Consumption, Disposal Practices, and Cultural Beliefs, 49 ECOLOGY
FOOD & NUTRITION 467,473 (2010).
45. See Young & Benyshek, supra note 44, at 482 (reporting on a survey regarding the consumption,
treatment, and disposal of placentas in 179 societies).
46. See MacKenzie, supra note 16, at 149-50; see also MARY KAWENA PUKUI, HAWAIIAN BELIEFS AND
CUSTOMS DURING BIRTH, INFANCY, AND CHILDHOOD (2011).
47. See, e.g., William M. Birdsong, The Placenta and Cultural Values, 168 W. J. MED. 190,190 (1998)
(reporting the case of a Native American woman requesting her placenta be returned for ceremonial
disposition in California but failing to indicate her tribal membership).
48. See Lamphere, supra note 7, at 1141.
49. Christine Taitano DeLisle, A History of Chamorro Nurse-Midwives in Guam and a 'Placental
Politics 'for Indigenous Feminism, INTERSECTIONS: GENDER & SEXUALITY ASIA & PACIFIC, Mar.
2015.
50. Lisa Milbrand, Planting Your Placenta, PARENTS (2013), https://www.parents.com/pregnancy/my-
body/pregnancy-health/planting-your-placenta [https://perma.cc/4H4H-4FWG].
51. Young & Benyshek, supra note 44, at 467.
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1970s.52 But there is a long history of using the placenta in folk and traditional
medicine on other continents. French historian Jacques Gdlis reports:
Placentophagy, the custom of eating the newly expelled placenta, has
existed at various times amongst people of very different cultures. From
the sixteenth century onwards, European travellers to the new world
were much struck by this custom, which they unfailingly reported ....
In Europe, however, doctors and churchmen were more and more
repelled, from the end of the seventeenth century onwards, by this
custom of placentophagy, so 'repugnant to humanity.' 53
In other words, when placentophagy became degraded in the colonizers' eyes by
its association with the colonized, it fell out of fashion. The downgrading of
placentophagy may also have been connected to the demise of the traditional
midwifery model controlled by women in favor of the medicalization of birth at
the hands of male doctors. 54
In the United States, placentophagy has become more widely practiced since
the mid-2000s. In 2005, natural health enthusiast Jodi Selander began to build
an "afterbirth empire. She coined the term placenta encapsulation and
standardized the method of transforming afterbirth into pills. In 2006, she began
selling encapsulation kits and instructional pamphlets, which ship worldwide,
through her website, placentabenefits.info."" Fascination with the placenta
boomed in the media after New York Magazine ran a feature story in 2011 titled
The Placenta Cookbook.56 According to nursing-midwifery professor Emily
Hart Hayes, "[a]lthough the number of women who consume their placentas is
not known, the large number of placenta encapsulation businesses suggests that
it is significant.",57 Less medicalized birth experiences appear conducive to
placentophagy. A 2018 study of 23,525 women who planned a home birth or
birthing center delivery as opposed to a hospital birth revealed that nearly one
third consumed their placenta.58
How is the placenta consumed? The, placenta can be consumed raw (by
swallowing small pieces or blending it with fruits and other ingredients into
smoothies), cooked (e.g., placenta stew or steak), or in a processed form (such
52. See Jodi Selander et al., Human Maternal Placentophagy: A Survey of Self-Reported Motivations
and Experiences Associated with Placenta Consumption, 52 ECOLOGY FOOD NUTRITION 93 (2013).
53. JACQUES GtiLIS, HISTORY OF CHILDBIRTH 170 (1996).
54. See generally JEAN DONNSON, MIDWIVES AND MEDICAL MEN: A HISTORY OF THE STRUGGLE FOR
THE CONTROL OF CH.ILDBIRTH (1988) (recounting the history of this transition in Europe).
55. Atossa Araxia Abraharnian, The Placenta Cookbook, N.Y. MAG. (Aug. 18, 2011),
https://nymag.com/news/features/placenta-2011-8 [https://perma.cc/66SA-Z7P9].
56. Id.
57. Emily Hart Hayes, Consumption of the Placenta in the Postpartut Period, 45 J. OBSTETRIC,
GYNECOLOGIC & NEONATAL NURSING 78,80 (2016).
58. Daniel C. Benyshek et al., Placentophagy Among Women Planning Community Births in the United
States: Frequency, Rationale, and Associated Neonatal Outcomes, 45 BIRTH 459, 464 (2018).
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as capsules and tinctures, as well as preparations for external use such as salves,
body butters, oils, and ointments).59 Cressida Heyes recounts her own experience
of eating her placenta after childbirth:
I was ready for the dinner my partner cooked: whole wheat spaghetti
tossed in butter and served with placenta bolognese. It was the best meal
I have ever had. What does placenta taste like? As you would expect, it
is halfway between muscle and organ, a bit like mince and a bit like
liver. There is nothing remarkable about it, especially cooked in a nice
sauce. I could have served you my placenta for your dinner and you
would never have known the difference.
60
Encapsulation is a popular method of consumption for those wishing to consume
their placenta over a stretch of time or disinclined to eat it in meat form. It
involves dehydrating raw or steamed placenta and grinding it into a powder
which is encapsulated. According to Jodi Selander and her co-authors, less than
15% of the women surveyed online in 2010 ate their placentas raw while 70% to
80% consumed it encapsulated-and some probably combined the two.61 Most
women hire preparers to encapsulate their placentas for them. In 2007, Selander
launched a program designed to train specialists in the process of placenta
encapsulation through her Placenta Benefits organization in response to
increasing demand for skillful providers.
62
Why do people eat their placentas? Advocates of placentophagy suggest that
it offers a wide array of postpartum benefits, including hormonal balancing, pain
relief, nutrition (such as iron supplementation), improved lactation, more energy,
and prevention of postpartum depression. 63 Much as traditional placenta rituals
have been hypothesized to operate as an anxiety-release mechanism at a time of
intense concern for the well-being of new parents and babies, 64 present-day
placentophagy can be analyzed as a coping mechanism for postpartum parents
often expected to perform intensive forms of motherhood yet lacking the support
they need. Charlotte Krolokke has argued that new mothers are terrified that they
will be physically and emotionally unable to provide the type of care for their
newborns and other family members for which they hold themselves responsible,
including exclusive breastfeeding, attachment parenting, and other time-
intensive and demanding forms of child-rearing. 65 Placentophagy promises the
hope that by popping a pill they will have the ability to live up to these standards.
59. See Hayes, supra note 57, at 81; see also Selander et al., supra note 52, at 103-04.
60. Heyes, supra note 32, at 113.
61. See Selander et al., supra note 52.
62. Id. at 103.
63. See, e.g., Hayes, supra note 57, at 78.
64. See J.R. Davidson, The Shadow of Life: Psychosocial Explanations for Placenta Rituals, 9
CULTURE, MED. & PSYCHIATRY 75, 75 (1985).
65. See KROLOKKE, supra note 30, at 122-23.
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Tellingly, recent empirical work suggests that women who have experienced
anxiety or depression prior to pregnancy are more likely to engage in
placentophagy in the hope of warding off postpartum depression.6 6
What are the risks and benefits ofplacentophagy? No serious adverse effects
from consuming placentas have been positively established, but clinicians and
public health professionals warn of a range of potential risks related to pathogen
transmission such as viruses, toxins (heavy metals), and high concentrations of
hormones such as estrogen.67 The placenta, after all, is (human) meat, which can
transmit harmful bacteria and blood-borne diseases such as HIV or hepatitis
when consumed raw or undercooked In 2017 the Centers for Disease Control
and Prevention (CDC) issued a report from the Oregon Health Authority
announcing that a newborn had contracted late-onset Group B Streptococcus
disease, one of the most common causes of life-threatening infections in
newborns, due to his mother's consumption of her encapsulated placenta.68 This
case was intensely debated in the placentophagy literature and community as
some observers questioned the causality posited by the CDC or suggested that
the placenta had not been properly cooked and dehydrated in this case. 69 In a
2018 study based on a medical records dataset of 23,525, one third of whom had
consumed their placentas, no adverse neonatal outcomes were found for babies
whose mothers consumed their placenta, whether cooked or uncooked. 7 0 The
placenta as human meat may even be safer than animal meat, at least to its own
producer. As an obstetrician-gynecologist (OBGYN) with whom I talked for this
Article underlined, "It's your own placenta so presumably anything that's there
you already had.",
7 1
The purported benefits of placenta consumption have been attributed to
mineral, vitamin, and hormonal replenishment, but they are still to be
substantiated in clinical studies. In 2017, three medical researchers scrutinized
the nutritional content of placentas, suggesting a nutrition facts label for it-234
66. Benyshek et al., supra note 58, at 466.
67. See, e.g., Hayes, supra note 57, at 53-85; see also David Issacs, Perplexing Perinatal Practices, 54
J. PAEDIATRICS & CHILD HEALTH 113 (2018). Other risks include the possibility that placentophagy
will trigger alloimmunization in women and therefore cause problems in future pregnancies. See
Alex Farr et al., Human Placentophagy: A Review, 218 AM. J. OBSTETRICS & GYNECOLOGY 401,
403 (2018).
68. Genevieve L. Buser et al., Notes from the Field: Late-Onset Infant Group B Streptococcus Infection
Associated with Maternal Consumption of Capsules Containing Dehydrated Placenta-Oregon,
2016, 66 MORBIDITY &MORTALITY WKLY. REP. 677 (2017).
69. See, e.g., Jodi Selander, Can I Get Group B Strep from Placenta Capsules?,
PLACENTABENEFITS.INFO (June 29, 2017), https://placentabenefits.info/group-b-strep-from-
placenta-capsules [https://perma.cc/5FZD-BM5Y] (noting that the placenta was not cooked before
it was dehydrated and that the dehydration temperature had been too low to reduce the bacteria
present in the tissue).
70. Benyshek et al., supra note 58.
71. Interview with OBGYN (Nov. 6,2018) (the source requested to remain anonymous).
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calories for the serving size of an average placenta of 450 grams.72 They noted
that the "[p]lacenta has significantly less protein than both ground beef and
chicken (48 g vs. 77 g and 78 g, respectively), but more iron than both ground
beef, ground chicken, and spinach., 73 A few studies about the beneficial effects
of placentophagy on lactation were conducted in the 191 Os and 195 Os, 7 4 but have
since been discredited due to their flawed research design. A 2015 review
concluded that the existing data did not support the claims that placentophagy
"helps to enhance lactation, reduce pain, facilitate uterine contraction, or
replenish hormones . . . associated with postpartum recovery." 75 The same
review noted that some of the positive reports on placenta consumption could
result from "placebo effects, which could be addressed through a randomized
placebo-controlled clinical trial."76 Since this review article, new studies have
been released on the mineral 77 and hormonal 78 content of placentas. Results of
the first randomized, double-blind, placebo-controlled trials evaluating the
effects of placentophagy on maternal salivary hormones, 79 iron status,8 ° and
mood, bonding, and fatigue81 were published in 2017. They uncovered few, if
any definite benefits, such as improved postpartum iron status or mood for
people who consumed their placentas, compared to those who ingested a
placebo. So far, the evidence for positive effects of placentophagy in humans
72. Sydney Chang, Laura Lodico & Zev Williams, Nutritional Composition and Heavy Metal Content
of the Human Placenta, 60 PLACENTA 100, 101 (2017).
73. Id.
74. Frederick S. Hammett & Lyle G. McNeile, Concerning the Effect of Ingested Placenta on the
Growth-Promoting Properties of Human Milk, 46 SCIENCE 345 (1917); Frederick S. Hammett &
Lyle G. McNeile, The Effect of the Ingestion of Desiccated Placenta on the Variations in the
Composition of Human Milk During the First Eleven Days After Parturition, 30 J. BIOLOGICAL
CHEMISTRY 145 (1917); Eva Soykov~i-PachnerovA et al., Placenta as a Lactagagon, 138
GYNAECOLOGiA 617 (1954).
75. Cynthia W. Coyle et al., Placentophagy: Therapeutic Miracle or Myth?, 18 ARCHIVES WOMEN'S
MENTAL HEALTH 673, 678 (2015) (reviewing ten articles, including four on humans and six on
animals).
76. Id. at 678.
77. Sharon M. Young et al., Human Placenta Processed for Encapsulation Contains Modest
Concentrations of14 Trace Minerals andElements, 36 NUTRITION RES. 872 (2016); see also Chang,
Lodico & Williams, supra note 72, at 101 (noting that "[d]espite reports of placentas containing
harmful levels of heavy metals, there was no arsenic, cadmium, lead, or mercury detected within our
pooled placenta sample").
78. Sharon M. Young et al., Presence and Concentration ofl7 Hormones in Human Placenta Processed
for Encapsulation and Consumption, 43 PLACENTA 86 (2016).
79. Sharon M. Young et al., Effects of Placentophagy on Maternal Salivary Hormones: A Pilot Trial,
Part 1, 31 WOMEN & BIRTH e245 (2017).
80. Laura K. Gryder et. al., Effects of Human Maternal Placentophagy on Maternal Postpartum Iron
Status: A Randomized, Double-Blind, Placebo-Controlled Pilot Study, 62 J. MIDWIFERY &
WOMEN'S HEALTH 68 (2017).
81. Sharon M. Young et al., Placentophagy's Effects on Mood, Bonding, and Fatigue: A Pilot Trial,
Part 2, 31 WOMEN & BIRTH e258 (2017).
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remains limited to self-reported surveys,8 2 but future trials may shed further light
on the risks and benefits of the practice.
Who eats their placentas? The existing literature suggests that
placentophagy is most common among privileged white women. In 2013, Jodi
Selander and others conducted a web survey of 189 women in Canada and the
United States who self-reported consuming their placentas.83 Survey participants
were primarily educated, married (90%), middle-class white women (93%; N =
189), 58% of which had a family income above $50,000/year.84 A 2014-2015
study conducted in the Midwest confirmed "that sociodemographic factors play
a role in patients' familiarity with and attitudes toward placentophagy.
Participants with higher household income (>$ 100,000) and a bachelor's degree
or higher showed a greater willingness to try placentophagy. ' 85 The authors
explained these findings by pointing out that individuals with higher
socioeconomic status and education are more likely to have access to and to try
integrative medical treatment, which are often accompanied by increased out-of-
pocket expenses that are not covered by health insurance.8 6 These different
studies on the demographics of placenta eaters come to similar conclusions, but
it would be worth considering whether the methods used to recruit participants
account for some of the findings. The question remains whether the social media
groups, online message boards, clinics, and providers used to solicit participation
were frequented by diverse groups of parents or whether they were tilted toward
white, middle-class women.
Other DIY Uses. Placentas are increasingly employed as an alternative birth
phenomenon and to make art. Some parents opt for what is known as a lotus
birth, that is, a birth in which the baby is left connected to the placenta until the
umbilical cord falls off naturally, which can take up to ten days.87 The prolonged
contact is seen as a time of transition allowing baby and birthing parent to slowly
separate. Other families view placenta arts and crafts as a way of memorializing
82. See Farr et al., supra note 67, at 404 tbl.1 (summarizing existing studies on the alleged benefits of
placentophagy).
83. See Selander et al., supra note 52, at 100. Selander also discusses placenta consumption by people
other than the person who grew it, that is, "nonmatemal placentophagia." Id. at 96.
84. See id. at 100.
85. Stephanie A. Schuette et al., Perspectives from Patients and Healthcare Providers on the Practice
of MaternalPlacentophagy, 23 J. ALTERNATIVE & COMPLEMENTARY MED. 60, 64 (2017); see also
Sharon M. Young et al, supra note 79, at 4 (noting that in their sample of twenty-seven Nevadan
women who decided to consume their placenta, "[p]articipants were primarily Caucasian (n = 22;
81.5%), college educated (n = 15; 55.6%), with an average annual household income over $50,000
(n = 16; 59.3%)").
86. Schuette et al., supra note 85, at 64.
87. See Laura A. Zinsser, Lotus Birth, a Holistic Approach on Physiological Cord Clamping, 31
WOMEN & BIRTH e73 (2018) (noting that the practice was first reported in humans in 1974 with the
case of Californian Clair Lotus Day, who wanted to emulate a chimpanzee practice).
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and honoring their child's birth.88 Placenta photography documents the placenta,
showing it from various angles, or still attached to the baby. 89 Placenta prints can
be made by placing the placenta and the umbilical cord on acid-free paper with
the resulting image often resembling a tree, making visually apparent why the
placenta is sometimes likened to a tree of life. 90 Placenta keepsakes can be made
with dehydrated umbilical cord shaped into hearts or other symbols. The
placental membrane can also be used to make art?' and powdered placenta turns
into a component for custom-made jewelry. 92 Placenta encapsulators often
acquaint their clients with placenta art and offer to produce it as part of their
services or for an additional fee.
3. Private Banking
Private placenta banking is the relatively new option to pay a bank to save
placental tissue for potential future use, either for the donor's own therapeutic
use or for use by other family members. 93 Placental tissue has gained a new status
as a potential source of multipotent stem cells used to treat a number of
diseases.9 4 Private banks that also bank tissues such as cord blood have begun to
market their services to expectant parents by emphasizing the promises of
regenerative medicine for themselves and their families. 95 These services operate
on the expectation that placental stem cells, once collected, may be regenerated
to grow into different types of tissues which will be available for new
88. Melissa Locker, A New Trend for Parents: Placenta Art Prints, TIME (Sept. 27, 2013),
https ://newsfeed.time.com/2013/09/27/a-new-trend-for-parents-placenta-art-prints
[https://perma.cc/U7B2-X8XT].
89. See, e.g., Amy Packham, Birth Photographer Wants to Show Placentas are 'Unique and Beautiful'
in Fascinating Photo Series, HUFFfNGTON POST U.K. (Mar. 13, 2016, 1:03 PM BST),
https://www.huffingtonpost.co.uk/entry/placenta-photos-birth-
photography uk_56fdOO6ae4bO69ef5bffe2f6 [https://perma.cc/4QG7-AWSV]; Genevieve Shaw
Brown, Placenta Photos Latest Trend in Birth Photography, ABC NEWS (June 8, 2016),
https://abcnews.go.com/Lifestyle/placenta-photos-latest-trend-birth-
photography/story?id=39701285 [https://perma.cc/X53Z-TLCJ].
90. Locker, supra note 88.
91. Honoring the Placenta Through Art: Placenta Prints and Cord Keepsakes, TREE LIFE PLACENTA
SERV., https ://www.portlandplacentaservices.com/placenta-prints--keepsakes.htmli
[https://perma.cc/8SQC-4J5C].
92. See, e.g., Anneli Knight, The Woman MakingJewelleryfrom Placentas, SYDNEY MORNING HERALD
(Aug. 6, 2014, 1:23 PM), https://www.smh.com.au/business/small-business/the-woman-making-
jewellery-from-placentas-20140716-3c0ql .html [https://perma.cc/FM6B-5K9N].
93. See Eleni Antoniadou & Anna L. David, Placental Stem Cells, 31 BEST PRAC. & RES. CLINICAL
OBSTETRICS & GYNAECOLOGY 13, 24 (2016) (noting that Celgene Cellular Therapeutics was the
first company to introduce placental stem cell biobanking in 2012).
94. But see Caroline Chen, The Birth-Tissue Profiteers, NEW YORKER (May 7, 2019) (journalistic
expos6 critiquing the stem cell industry's use of placenta, arguing that placentas are not a source of
viable stem cells for treatment and an even poorer source of multipotent stem cells).
95. See KROLOKKE, supra note 30, at 130.
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personalized therapies in the future. Like cord-blood banking, 96 placenta
banking is future-oriented property that serves as a form of biological insurance,
ensuring access to stem cells if a medical need arises. But there are no guarantees
that the cells will be usable or that these potential future applications will come
to fruition and obtain approval from the United States Food and Drug
Administration (FDA) and other agencies.
Private bank Americord currently offers a package for placenta-tissue
banking for $3,499.97 Given the hefty price tag, private placenta banking is
primarily available to affluent families. In addition to overcoming the significant
cost, potential purchasers need to be informed of the option. To solicit customers,
most banking services distribute marketing materials in clinical spaces such as
private OBGYN and midwives' waiting rooms or prenatal classes. Banking also
requires work, as Jennie Haw pointed out in the context of umbilical-cord
banking. 98 Expecting parents must have the time and ability to research
organizations offering placenta banking, compare prices and services, attend
information sessions, talk to representatives, and coordinate the various
institutional and technical processes required to collect the placenta
successfully-such as bringing a collection kit with them to the delivery room,
ensuring that the placenta is immediately refrigerated, and calling a medical
courier promptly for retrieval. Despite the uncertain outcomes, high price tag,
and added labor, placenta banks offer to preserve the placenta as an ostensibly
valuable future asset.
In brief, the rise of placentophagy, placenta banking, and other personal uses
of placentas has endowed them with a new meaning for the mainstream
American public-away from waste and toward a private, personal good. But
the self-consumption of placentas by birthing parents and their families remains
relatively rare. Instead, consumption primarily occurs in conjunction with the
use of placentas by third parties. Like other body parts such as organs, tissues,
gametes, and blood, placental tissue is fragmented for research and biomedical
uses, becoming a scientific resource and public good.
B. Third-Party Uses
This section presents various uses for which third parties collect placentas
from healthcare facilities-mainly research, medicine, and cosmetics-before
exploring how the placenta supply and demand chain functions.
96. See CATHERINE WALDBY & ROBERT MITCHELL, TISSUE ECONOMIES: BLOOD, ORGANS, AND CELL
LINES IN LATE CAPITALISM 126 (2006).
97. Multi-Product Discounts, AMERICORD, https://www.americordblood.com/sign-up
[https://perma.cc/N4GY-E7KR].
98. Jennie Haw, Corporeal Commodification and Women's Work: Feminist Analysis of Private
Umbilical Cord Blood Banking, 22 BODY & SOC'Y 33 (2016).
2020]
Yale Journal of Law and Feminism
1. Research
The scientific study of placentas and their biochemical and physiological
properties can be traced back to the end of the nineteenth century. In past
decades, the field of placenta research developed rapidly as new applications for
placental tissue were uncovered. As sociologist of science Rebecca Yoshizawa
explains:
Because they are large, fresh, and widely available tissues, delivered
placentas proffer many opportunities to study human physiology and
pathology and are uniquely suited to aid in the advancement of human
health and well-being through therapeutic applications. As such, tissues
and cells from human placentas are regularly collected in hospitals
around the world and used in scientific research in diverse fields
including reproductive biology, immunology, cancer research, and
tissue engineering.
99
Depending on the type of research and protocol, researchers select placentas of
different developmental stages.100 Full-term placentas (delivered following a
full-term pregnancy, which lasts thirty-seven to forty-two weeks) are particularly
valuable to study transplacental transfers-that is, whether certain drugs or other
substances to which pregnant people are exposed can cross the placental
"barrier" and affect the fetus.101 Placentas of various gestational ages are key to
understanding pregnancy and its complications, as evidenced by the various
biobanks and repositories that not only collect placentas, but also study the
functioning of the placenta during pregnancies using MRI scans and other
techniques.
10 2
Full-term placentas are also used to investigate cohort health, as in the
British Avon Longitudinal Study of Parents and Children, which recruited
pregnant women from 1990 to 1992, collecting 8,933 placentas and storing them
99. Yoshizawa et al., supra note 15.
100. See, e.g., L.M. Wolfe et al., Banking Placental Tissue: An Optimized Collection Procedure for
Genome-Wide Analysis of Nucleic Acids, 35 PLACENTA 645, 646 (2014).
101. See, e.g., Judith A. Smith et. al., Utilization of an Ex Vivo Human Placental Perfusion Model to
Predict Potential Fetal Exposure to Carboplatin During Pregnancy, 210 AM. J. OBSTETRIC
GYNECOLOGY_275.el (2014) (using ex vivo term placentas collected after delivery to determine
whether carboplatin, a common anticancer drug used during pregnancy, crosses the placental
barrier).
102. See, e.g., Ctr. for Women's Health, Placenta Repository, OR. HEALTH & SCI. U.,
https://www.ohsu.edu/womens-health/placenta-repository [https://perma.cc/9EZ8-7LPY]; see also
About Bioservices, GLOBAL ALLIANCE TO PREVENT PREMATURITY & STILLBIRTH,
https://www.gapps.org/Home/AboutBioservices [https://perma.cc/R3T7-5VZ6] (describing the
mission of the biobank, which includes collecting placentas as a means of fulfilling the "urgent need
for biological specimens to support research on complications in pregnancy"). Yale is another
example, with its Reproductive and Placental Research Unit, which offers a range of innovative
research and testing on the placenta. See Welcome to the Reproductive and Placental Research Unit,
YALE SCH. MED., https://medicine.yale.edu/obgyn/kliman [https://perma.cc/QX63-N46C].
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in formalin. 103 The study was designed to determine how biological,
environmentdl, social, genetic, psychological and psychosocial factors impact
individuals' survival and health. 10 4 Geographer Maria Fannin and sociologist
Julie Kent argue that the study's researchers viewed the placenta as "an 'archive'
of potential information about the future health of the child."' 10 5 In practice,
though, the collection was hardly studied by scientists, in part because the
method of preservation, formalin, limited research questions. 106
Stem-cell research also relies heavily on placental tissues. 10 7 First-trimester
placentas may be advantageous for this type of research as they are less
differentiated than term placentas.10 8 Stem cells obtained from first trimester
placentas are also offered as a more "ethical" alternative to stem cells harvested
from embryos, which are controversial because embryos are destroyed in the
harvesting process. 10 9 The most vocal opposition to the use of embryonic stem
cells is premised on the view that embryos should have the same legal and moral
status as fully developed humans. 110 The law partly reflects this position, as
federal law, as well as a number of state laws, restricts the conditions under
which fetal tissue can be used for research. 11 By contrast, the placenta, being a
temporary organ, is generally not thought to deserve any special level of
consideration. Accordingly, the popularity of placentas as a source of stem cells
is such that in 2007, legislative attempts were made to create a regulated national
placental stem cell bank under the Stem Cell Research Enhancement Act of
2007.112 The bill was vetoed by President Bush, but it would have established a
network of banks to store amniotic fluids and placental cells to maintain a
103. Maria Fannin & Julie Kent, Origin Stories from a Regional Placenta Tissue Collection, 34 NEW
GENETICS & SoC'Y 25, 30 (2015).
104. Id. at 27.
105. Id. at 34.
106. Id. at42.
107. Marco Evangelista, Maddalena Soncini & Omella Parolini, Placenta-Derived Stem Cells: New Hope
for Cell Therapy?, 58 CYTOTECH. 33 (2008).
108. Saeyoung Park et al., Comparison of Human First and Third Trimester Placental Mesenchymal
Stem Cell, 37 CELL BIOLOGY INT'L 242, 243 (2013) (comparing stem cells obtained from first- and
third-trimester placentas and noting that the former were obtained following miscarriages and the
latter following full-term deliveries).
109. See, e.g., Antoniadou & David, supra note 93, at 14 ("Fetal stem cells are an alternative plentiful
source, and the placenta is now recognized as a rich source of multipotent stem cells.").
110. See Joanna K. Sax, The Separation of Politics and Science, 7 STAN. J.L. SCt. & POL'Y 1, 16 (2014).
111. See Gimbel, supra note 40.
112. Stem Cell Research Enhancement Act of 2007, S. 5, 110th Cong (2007). The Act would have
allowed federal funding for stem cell research using discarded embryos donated from fertility
clinics.
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"The idea of using the placenta in medicine goes back a long way,"1 14 noted
Jacques G61is, citing examples of placenta therapies in Europe from antiquity
until the seventeenth century. The placenta was thought to be effective to treat a
variety of ailments, including skin disorders, epilepsy, apoplexy, erectile tumors,
insufficient milk production, infertility, and low libido. 11 5 The placenta was also
recognized as a traditional medicine in other regions of the world, 1 6 in particular
China, where Li Shizen's sixteenth century herbology treatise Compendium of
Materia Medica, regarded as the most complete and comprehensive medical
book in the history of traditional Chinese medicine, recommended dried human
placenta "to increase energy and vitality and for the treatment of impotence,
infertility, liver and kidney problems.""
' 17
In the nineteenth century, Europe witnessed "a renewal of interest in the
human placenta, whose immunizing and galactogenic properties were then being
discovered, or rather, rediscovered."'1 8 In contemporary medicine, placentas are
used in various forms. Whole, term placentas serve training purposes such as
allowing residents to improve their surgical skills. 119 Placentas are also
employed in barely processed form (as placental blood, membrane, or tissue) for
tissue repair (especially of non-healing wounds and bums 20 ), for ophthalmic
113. Sheryl Gay Stolberg, Bush Vetoes Measure on Stem Cell Research, N.Y. TIMES (June 21, 2007),
https://www.nytimes.com/2007/06/21/washington/21 stem.html [https://perma.cc/BU8S-AD4U].
114. See GtLIS, supra note 53, at 168.
115. Id. at 169-70.
116. See Willam B. Ober, Notes on Placentophagy, 55 BULL. N.Y. ACAD. MED. 591 (1979).
117. Li SHIZHEN, COMPENDIUM OF MATERIA MEDICA: BENCAO GANGMU 4182-4186 (Luo Xiwen trans.,
2003) (1593).
118. See GtLIS, supra note 53, at 9.
119. Marcelo Magaldi Ribeiro de Oliveira et al., Learning Brain Aneurysm Microsurgical Skills in a
Human Placenta Model: Predictive Validity, 128 J. NEUROSURGERY 846 (2018).
120. See, e.g., Ji Suk Choi et al., Full-Thickness Skin Wound Healing Using Human Placenta-Derived
Extracellular Matrix Containing Bioactive Molecules, 19 TISSUE ENGINEERING 329 (2013); Jong
Won Hong et al., The Effect of Human Placenta Extract in a Wound Healing Model, 65 ANNALS
PLASTIC SURGERY 96 (2010) (double-blind mice study concluding that human placental extracts
promote wound healing); U. Manuelpillai et al., Amniotic Membrane andAmniotic Cells: Potential
Therapeutic Tools to Combat Tissue Inflammation and Fibrosis?, 32 PLACENTA S320 (2011);
Adrian L. Watson & Graham J. Burton, A Microscopical Study of Wound Repair in the Human
Placenta, 42 MICROSCOPY RES. & TECH. 351 (1998); see also Martin C. Robson & Thomas J.
Krizek, The Effect of Human Amniotic Membranes on the Bacterial Population of Infected Rat
Burns, 177 ANNALS SURGERY 144 (1973) (discussing the use of placental tissue to heal bums).
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use, 121 for skin grafts, 122 and for the prevention of postoperative adhesions,
among others. Wound specialists Donald Fetterolf and Robert Snyder reported
that placental membranes have been employed in the treatment of wounds for
almost a century for these purposes.1 23 They are now commercially available via
companies marketing fetal membranes and their derivatives. 124 Additionally,
microscopic compounds and cells are extracted from placentas to produce
laboratory developed drugs and products. For instance, until the 1990s, enzymes
were commonly harvested from placentas to manufacture notoriously expensive
drugs 125 to treat the Gaucher disease.126 Albumin was purified from placentas for
use in vaccines. 127 Nowadays, placental extract is still used in experimental and
standard therapies to treat chronic liver disease, 128 menopause, 129 periodontal
121. Augusto Azuara-Blanco, C.T. Pillai & Harminder S. Dua, Amniotic Membrane Transplantation for
Ocular Surface Reconstruction, 83 BRIT. J. OPHTHALMOLOGY 399 (1999) (describing the use of
human placenta for restoration of the cornea).
122. M. Subrahmanyam, Amniotic Membrane as a Cover for Microskin Grafts, 48 BRIT. J. PLASTIC
SURGERY 477 (1995) (studying the placental membrane in biologic dressing materials for large
defect areas in which skin grafts do not suffice).
123. Donald F. Fetterolf& Robert J. Snyder, Scientific and Clinical Support for the Use of Dehydrated
Amniotic Membrane in Wound Management, 24 WOUNDS 299, 299 (2012). Note that authors and
practitioners may mean different things when they use the expression "membranes" in relation to
the placenta, which is often described as having a fetal side (the amnion or amniotic membrane) and
a maternal side (the chorion or chorionic membrane). See Benirschke, supra note 33, at 200 (noting
that the "entire afterbirth is often referred to as to the fetal membranes").
124. See Fetterolf & Snyder, supra note 123, at 299 (listing examples of placenta-based products and
drugs).
125. See James R. Hagerty, Dutchman Who Had Trouble Finding Job at Home Became CEO of a U.S.
Biotech Pioneer, WALL ST. J. (May 19, 2017, 10:00 AM ET),
https://www.wsj .com/articles/dutchman-who-had-trouble-finding-job-at-home-became-ceo-of-a-u-
s-biotech-pioneer-1495202400 [https://perma.cc/C53Z-98BS] (noting that some of the drugs cost
patients hundreds of thousands of dollars a year).
126. See Ernest Beutler, Enzyme Replacement in Gaucher Disease, 1 PLOS MED. 118 (2004); see also
Wall St. Journal Staff Reporter, Genzyme Is Approved to Make a New Drug, Posts Quarterly Loss,
WALL ST. J., Oct. 25, 1996, at B6 (reporting on the FDA's approval of human placenta-based
Cerezyme to treat Gaucher disease).
127. Joaquin Cabrera-Crespo et al., Albumin Purification from Human Placenta, 31 BIOTECH. & APPLIED
BIOCHEMISTRY 101 (2000); see also New Polio Virus Discovery Uses Human Instead of Monkey
Tissue, NEW YORK TIMES 1, July 1, 1955, at 19 (reporting on the discovery of a new way of growing
polio virus for vaccines using human placental tissues instead of "expensive monkey kidneys").
128. Hideto Shimokobe et al., Human Placental Extract Treatment for Non-Alcoholic Steatohepatitis
Non-Responsive to Lifestyle Intervention: A Pilot Study, 45 HEPATOLOGY REs. 1034 (2015) (finding
human placental extract to be a promising treatment for chronic liver disease).
129. Mi-Hee Kong et al., Effect of Human Placental Extract on Menopausal Symptoms, Fatigue, and
Risk Factors for Cardiovascular Disease in Middle-Aged Korean Women, 15 MENOPAUSE 296
(2008).
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disease, 130 respiratory infections, 131 skin disorders, 132 rheumatic arthritis, 133
ulcers, 134 and wounds, among other indications. The mechanisms by which
placental extract produces positive outcomes have yet to be fully clarified and
are the subject of ongoing research. 135 Finally, placenta stem cells figure
prominently in tissue engineering and regenerative medicine with the
expectation that tissue replacements could be made from patients' own cells or
cells retrieved from others.136 In 2018, the FDA approved a stem-cell-based
therapy derived from the human placenta for emergency treatment following a




Human placentas have a long history of use in beauty products, Cleopatra
and Marie Antoinette being cited as early adopters.' 39 Charlotte Krolokke writes
that in "the 1950s and 1960s, the placenta became an ingredient in mass-
marketed cosmetic products to be consumed by bourgeois, European women.,'
140
In the 1950s, placental extract was also prescribed for "the efficacious treatment
130. G. Calvarano, F. De Polis, G. Sabatini, Trattamento con estratto placentare [Treatment with
Placental Extract in Periodontal Disease], 57 DENTAL CADMOS 85 (1989) (It.).
131. F. Lo Polito, Sulla azione di un preparato d'estrazione placentare umano usato per la profilassi
delle infezioni respiratorie recidivanti [Action of a Human Placenta Extract Used for Prevention of
Recurring Respiratory Infections], 32 MINERVA PEDIATRICA 261 (1980) (It.).
132. A. Lodi et al., Terapia locale di psoriasi con estratto placentare [Local Therapy of Psoriasis with
Placental Extract], 121 GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA XV-XVII
(1986); S.K. Sharma, R.K. Jain & A.K. Sharma, Topical Human Placental Extract for the Treatment
of Vitiligo, 54 INDIAN J. DERMATOLOGY, VENERALOGY & LEPROLOGY 199 (1988).
133. M. Rosenthal, The Application of an Extract of Human Placenta in the Treatment of Rheumatic
Affections, 4 INT'L J. TISSUE REACTIONS 147 (1982).
134. Isabelle Mermet et al., Use of Amniotic Membrane Transplantation in the Treatment of Venous Leg
Ulcers, 15 WOUND REPAIR & REGENERATION 459 (2007).
135. See, e.g., Hong et al., supra note 120, at 96 (noting that "the mechanism by which HPE enhances
wound healing has not been clarified").
136. Antonietta R. Silini et al., The Long Path of Human Placenta, and Its Derivatives, in Regenerative
Medicine, FRONTIERS IN BIOENGINEERING & BIOTECH., Oct. 2015, at 1.
137. Human Placenta-Derived Stem Cell Therapy Approved by USA for Emergency Treatment of
Radiation Exposure Following a Nuclear Event, WIDEACADEMY (Apr. 29, 2018),
https://www.wideacademy.co/2018/04/pluristem-fda-usa-plx-rl 8-human-placenta-derived-stem-
cell-therapy-approved-for-emergency-use/ [https://perma.cc/2EHZ-2UMP] (reporting that the FDA
cleared Israeli company Pluristem Therapeutics's Investigational New Drug Application for its
PLX-R18 therapy in the treatment of acute radiation syndrome).
138. See Antoniadou & David, supra note 93, at 21-22 tbl.2.
139. POWER & SC HULKIN, supra note 36.
140. See KROLOKKE, supra note 30, at 123 (citing W.W. Myddleton, Modern Trends in Cosmetic
Formulation, 11 J. SOC'Y COSM. CHEMISTS 192,202 (1959)).
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of underdeveloped bust," or breast augmentation.' As of 1998, placenta in
various forms (protein, enzymes, lipids, and extract) was reported in the United
States in over a dozen cosmetic formulations such as hair conditioners,
shampoos, tonics, douches, face and body care, and moisturizers. 142 Human
placenta-based facials could still be arranged until recently. 143 Placenta-based
beauty products purported to offer a range of benefits including skin
hydration, 44 hair growth and anti-hair loss, 145 skin whitening, and anti-aging. 146
Though it appears that American cosmetic companies have stopped using human
placentas in their formulations, placenta-based cosmetics can be purchased
abroad, particularly in countries like Japan where they are very popular,
especially in the form of whitening creams. 147
4. Other Uses
Beyond the uses described above, human placentas have other,
unconventional uses. For instance, since human cadaver material is not easy to
obtain, placentas are employed to train police dogs to locate missing persons or
bodies. 148 Even more curious, in Berlin, Germany, Peter Sloterdijk claims that in
the 1990s, placentas were "granulated together with stillborn fetuses and
employed as combustive agents in garbage incinerators."' 49 In other words, they
were treated as hyperbolic waste-waste used to dispose of other waste.
141. Horst Gohlke, Use of Placenta Extracts in Cosmetics, 63 AM. PERFUMER & ESSENTIAL OIL REV.
97, 99 (1954).
142. Bindu Nair & Amy R. Elmore, Final Report on the Safety Assessment of Human Placental Protein,
HydrolyzedHuman Placental Protein, Human Placental Enzymes, Human Placental Lipids, Human
Umbilical Extract, Placental Protein, Hydrolyzed Placental Protein, Placental Enzymes, Placental
Lipids, and Umbilical Extract, 21 INT'L J. TOXICOLOGY 81, 84-85 tbl.1 (2002).
143. See Kate Spicer, Extreme Makeover?, SUNDAY TIMES (Oct. 21, 2012, 1:01 AM),
https://www.thetimes.co.uk/article/extreme-makeover-kjfbqrtbOOg [https://perma.cc/VW23-36X7]
(reporting that a California dermatologist and enthusiast of placental facials sourced human
placentas from Russian maternity wards before turning to sheep).
144. See POWER & SCHULKIN supra note 36, at 26.
145. Tae-Rin Kwon et al., Human Placental Extract Exerts Hair Growth-Promoting Effects Through the
GSK-3fi Signaling Pathway in Human Dermal Papilla Cells, 36 INT'L J. MOLECULAR MEDICINE
1088 (2015) (studying the effectiveness of human placental extract on promoting hair growth and
finding that it could potentially treat hair loss).
146. G.A. Hauser, Placental Extract Injections in the Treatment of Loss of Hair in Women, 4 INT'L J.
TISSUE REACTIONS 159 (1982) (noting that placenta-based products have been popular since the
1930s for whitening and anti-aging creams, but also for hair products and treating the loss of hair).
147. See KROLOKKE, supra note 30, at 124-27.
148. See Malia Wollan, How to Train a Cadaver Dog, N.Y. TIMES (June 19, 2015),
https://www.nytimes.com/2015/06/21/magazine/how-to-train-a-cadaver-dog.html
[https://perma.cc/9D5L-85C8] (reporting that in the United States "dog handlers can legally obtain
bodily components like human placenta and blood").
149. PETER SLOTERDLIK, BUBBLES: SPHERES I, at 384 (2011).
2020]
Yale Journal of Law and Feminism
At the other extreme, placentas have been used by the medical profession,
the insurance industry, and lawyers as valuable evidence in obstetrical
malpractice litigation. 150 When a dispute arises between parents and medical
providers as to whether a birth defect or another health issue was caused by
improper care before and during the delivery or by other, unrelated causes, the
placenta, if it has been collected, examined, and stored in the pathology
department, stands witness.1 51 Expert witnesses are summoned to evaluate the
placenta-a healthy placenta typically suggesting a higher likelihood of failure
or delay in intervention or inappropriate delivery management, while the
detection of placental abnormalities could indicate intrauterine conditions likely
to have caused or contributed to the adverse outcome in a way that exonerates
medical providers. Considering that obstetric malpractice cases can settle or
result in jury verdicts in the millions, placentas have become prized tools of
defensive medicine. For example, from 1996 to 2003, the "Cascadia Placenta
Registry" preemptively collected hundreds of placentas in Oregon, California,
and Washington, unbeknownst to birthing parents, in order to protect doctors and
hospitals from potential malpractice lawsuits related to difficult births.1 52 The
Registry quite literally capitalized on the fact that the placenta is increasingly
seen as a "witness" of pregnancy that can provide "valuable information on the
cause and timing of many adverse events and conditions."
153
5. Sourcing
One of the greatest unknowns in the current bioeconomy is how and where
third parties obtain placental tissue. Researchers conducting studies on placental
tissues and companies marketing placenta-based products provide varying levels
of information about the provenance of their tissues. While some research groups
such as the Yale Reproductive Sciences Division, which has its own placenta
biorepository, emphasize that they only collect consented placentas 54 from their
150. In 2006 and 2013 noted placenta scientist Harvey Kliman filed patent applications for a "library of
biological material" whereby samples of placental tissues would be stored to create a placental
library "that may be used for a variety of purposes, including reducing the incidence of medical
malpractice claims, identification of members such as paternity testing or suspect identification,
pharmaceutical development and epidemiological surveys and research." See Patents, Patents by
Inventor Harvey J. Kliman, JUSTIA (Nov. 14, 2013), https://patents.justia.com/inventor/harvey-j-
kliman [https://perma.cc/BWG9-XTXQ].
151. See Kenneth Tou-En Chang, Examination of the Placenta: Medico-Legal Implications, 19
SEMINARS FETAL & NEONATAL MED. 279 (2014) (describing the role of placental findings in the.
adjudication of cases of adverse neonatal outcome).
152. See Up to 700 Women in West Not Told About Placenta Registry, INS. J. (Feb. 13, 2006),
https://www.insurancejournal.com/news/west/200 6 /02 /13/65318.htm [https://perma.cc/KZ5D-
4YHZ].
153. See Rebecca N. Baergen, The Placenta as Witness, 34 CLIN. IN PERINATOLOGY 393, 394 (2007).
154. See Yale University Reproductive Sciences Biobank, supra note 102 (noting that they ensure that
their biospecimens are "properly consented" and protect "participant safety and privacy").
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affiliated Labor and Delivery units, 55 other researchers or institutions are not as
forthcoming.156 For example, one scientist describes the preparation of human
placental extract as follows: "[t]he organs are taken out according to a strict cold
chain and frozen at once."' 1 57 One is left to wonder: Who were the people
donating? Were they asked for their consent? If so, when were they approached?
By whom? What was the quality of the informed consent? What information was
provided to them? Was there any formal agreement or relationship between the
healthcare facility treating donors and the organization obtaining placental
tissue? These questions often remain unanswered in the literature. In the best
case scenario, researchers or placenta product companies mention the name of
the hospital from which their placentas are collected or indicate whether
informed consent was secured from participants1 58 For example, Judith Smith
and colleagues report that, for their study on the transplacental transfer of an
anticancer drug from the pregnant woman to the fetus,' 59 they obtained placentas
"immediately after delivery from either cesarean or vaginal deliveries in
accordance with the University of Texas Health Science Center at Houston
Medical School Institutional Review Board for Human Studies between August
2009 and May 2011. The Institutional Review Board Committee granted a
waiver for obtaining an informed consent for the use of discarded tissues in these
studies."'
60
Based on the information available, there seem to be three main sources for
placental tissue: 1) leftover tissue from the prenatal test chorionic villus
sampling, which is performed around 11 weeks of gestation, 6 1 2) placental
tissue from a miscarried or aborted fetus retrieved surgically,1 62 and 3) term
155. Harvey J. Kliman et al., Pathway of Maternal Serotonin to the Human Embryo and Fetus, 159
ENDOCRINOLOGY 1609, 1626 (2018).
156. I reached out to a dozen private organizations involved in placenta collection, research, processing,
or marketing so as to obtain information on their sourcing and procedures, but my requests were
largely ignored or refused. Only two tissue procurement organizations handling placental tissue
agreed to talk to me.
157. Jean M. Cotte, A Contribution to the Study ofSome Organ Extracts, AM. PERFUMER & AROMATICS,
May 1959, at 60, 61.
158. See, e.g., Method for Collecting Placental Stem Cells, U.S. Patent 7,045,148 B2 (filed Dec. 5, 2001)
(issued May 16, 2006) (patent noting "Placenta donors were recruited from expectant mothers that
enrolled in private umbilical cord blood banking programs and provided informed consent
permitting the use of the exsanguinated placenta following recovery of cord blood for research
purposes.").
159. See Smith et al., supra note 101, at 275.e2.
160. Id.
161. See, e.g., Antoniadou & David, supra note 93, at 14 ("Placental tissue can be obtained at a variety
of gestational ages if invasive prenatal diagnosis is undertaken.").
162. See, e.g., Wolfe et al., supra note 100, at 646 (using small fragments of placenta collected from
women who underwent abortion procedures). Placental tissues from medical abortions or
miscarriages passed at home are usually unusable for research and medicine because of bacterial
contamination in both abortions and miscarriages and a high rate of genetic abnormalities in
miscarriages. See D. Ware Branch et al., Suitability of Fetal Tissues from Spontaneous Abortions
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placentas collected after the delivery of a live or stillborn baby. The first is
described as first-trimester placentas, the second, as first- or second-trimester
placentas, and the third, as third-trimester placentas. 163 Each source has
advantages and disadvantages depending on the intended use-namely, for
medical therapy or for research. Therapies in which placental tissue is
transplanted into patients require donor screening and testing, which is best
conducted without haste before a term delivery. By contrast, such testing is not
necessary for most research uses. A downside of term placentas is the
unpredictability of delivery, making immediate tissue collection difficult. 164 This
is one of the reasons why biotech companies and some researchers appear to
favor placentas obtained during scheduled C-sections, the other reason being that
this collection procedures ensures aseptic retrieval. 165 In addition, there is
evidence that placentas delivered vaginally may be structurally different due to
compression during the contractions, impacting the data that can be collected for
certain studies.
16 6
Scientists and other stakeholders may be disinclined to broadcast the
sourcing of their placentas because a portion comes from miscarried or aborted
fetuses. Rebecca Yoshizawa wrote in 2013 that "[f]irst trimester placentas are of
increasing interest in placenta science, samples of which are only practically
obtained from elective abortion."' 67 Similarly, a multi-disciplinary group of
medical researchers and lawyers reported in 2017 that "induced abortion of
apparently normal pregnancies is a source of much of the tissue ultimately used
for research. ' 168 Researchers may understandably seek to avoid becoming the
and from Ectopic Pregnancies for Transplantation, 273 J. AM. MED. ASS'N 66 (1995) (examining
embryos obtained from miscarriages and ectopic pregnancies and finding that only 0.05% of the
embryos are suitable for human transplantation therapy).
163. See, e.g., Antoniadou & David, supra note 93, at 14; Wolfe et al., supra note 100, at 646.
164. Wolfe et al., supra note 100, at 646.
165. Royal Biologics Launches Amnio-MaxxTM , a Stem Cell Product Derived from Human Amniotic
Placental Tissue, PR NEWSWIRE (Feb. 6, 2018, 2:06 ET), https://www.pmewswire.com/news-
releases/royal-biologics-launches-ani-maxx-a-stem-cell-product-derived-from-human-
amniotic-placental-tissue-300593566.html [https://perma.cc/PZS7-YEGK] (an announcement by
Royal Biologics, a New Jersey-based company, of the launch of a placenta-based product to be used
in a variety of surgeries, sports medicine, wound care, trauma, and more, priding itself that "[t]he
collection of the donor tissue is performed in an aseptic manner by appropriately licensed tissue
establishments. All placentas utilized are from planned C-sections, which help to minimize potential
contamination during recovery. In addition, placental donors go through rigorous pre-screening
qualification and are tested to confirm they are free from disease."); see also G.J. Burton et al.,
Optimising Sample Collectionfor Placental Research, 35 PLACENTA 9,13 (2014) (discussing timing
and contamination considerations in the collection of placentas for research).
166. Burton et al., supra note 165, at 10.
167. Yoshizawa, supra note 29, at 10.
168. Lynn Borgatta et al., Applications for Research Concerning Fetal or Placental Tissue and Expected
Institutional Review BoardResponses, 12 J. EMPIRICAL RES. ON HUM. RES. ETHICS 150, 150 (2017).
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targets of heated criticism considering that fetal tissue donation and research 69
is controversial due to antiabortion politics. 170 Federal law governing fetal tissue
research essentially prohibits the purchase or sale of the products of
conception.' 71 Human fetal tissue may only be used for research if donors give
their informed consent after they have already decided to end the pregnancy, 172
and it must be collected in accordance with state and local law. 173 Some states
forbid any research with aborted tissue174 and some Institutional Review Boards
(IRBs) refuse to consider research proposals on fetal tissues, delay review of
such proposals, or impose other barriers upon them. 175 The issue came to the fore
in 2015 after an antiabortion group, the Center for Medical Progress, wrongly
accused Planned Parenthood of profiting from a fetal-tissue donation program
using undercover video reporting. 176 Most recently, in June 2019, the Trump
administration ordered scientists who work at the National Institutes of Health
(NIH) to stop using fetal tissues from aborted fetuses in their research, prompting
concerns that medical discoveries that could advance new treatments to save
lives, in particular among infants, would be impeded. 177
What types of institutional and other arrangements are made between
healthcare facilities or donors, on the one hand, and individuals or organizations
seeking placentas, on the other hand? At least three types of procurements can
be identified in light of the information I garnered. First, placental product
companies, especially if they have ample resources, appear to create their own
sources of supply by soliciting donations directly from pregnant women and
coordinating with obstetric teams for retrieval. 178 Second, researchers affiliated
with a medical center may enter into direct agreements with its prenatal care and
169. Fetal tissue or cells from diagnostic procedures ofamniocentesis or chorionic villus sampling do not
meet the definition of fetal tissue. They also do not appear to have specific statutory restrictions
related to tissue research. See supra note 40 and accompanying text.
170. R. Alta Charo, Fetal Tissue Fallout, 373 NEW ENG. J. MED. 890 (2015) (arguing that we have a duty
to use fetal tissue for research and therapy because it benefits everyone).
171. See NIH Revitalization Act of 1993, Pub L. No. 103-43, 107 Stat. 122 (1993) (codified at 42 U.S.C.
§ 289g-l & g-2).
172. 42 U.S.C. § 289g-1.
173. 45 C.F.R. § 46.206 ("Research involving, after delivery, the placenta; the dead fetus; macerated fetal
material; or cells, tissue, or organs excised from a dead fetus, shall be conducted only in accord with
any applicable Federal, State, or local laws and regulations regarding such activities.").
174. See Borgatta et al., supra note 168, at 155.
175. Id. at 150.
176. Denise Grady & Nicholas St. Fleur, Fetal Tissue from Abortions for Research is Traded in a Gray
Zone, N.Y. TIMES (July 27, 2015), https://www.nytimes.com/2015/07/28/health/fetal-tissue-from-
abortions-for-research-is-traded-in-a-gray-zone.html [https://perma.cc/GS4E-TCAU].
177. See Susan Jaffe, Trump Administration Limits Fetal Tissue Research, 393 LANCET 2381 (2019).
178. This is the model endorsed by MiMedx and Celularity (a New Jersey startup that recently raised
$250 million in seed capital for placenta-derived therapies).
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labor and delivery units to obtain placental samples.1 79 Finally, the placenta
supply chain operates via intermediary entities such as non-profit or for-profit
procurement organizations and biobanks that secure placental tissues from
medical centers, store them, and offer them to academic, medical, or other
organizations. Examples of go-between entities that collect and distribute
placental tissue include the company Advanced Tissue Services 180 and
AlloSource, one of the largest non-profit cellular and tissue networks in the
country that launched a placental donation program in 2017.81
In all of these situations, donors are uncompensated, even though placental
tissue was bought and sold between organizations until recently, and perhaps still
is. According to an account dating from the 1980s, "[w]hile most hospitals
incinerate placentas along with other biological waste, some hospitals sell them
to pharmaceutical or cosmetic companies that extract hormones and proteins for
use in manufacturing drugs or beauty products."'1 82 In 2006, Michelle Oberman
wrote:
[C]onsider the former practice of the University of Michigan hospital,
which recognized the value it was deriving from the sale of discarded
placentas to downstream users by offering new mothers a minor rebate
(twenty dollars) on their hospital bills in exchange for their permission
to use the placenta. This practice was discontinued when federal
regulations on tissue banking foreclosed the practice of selling tissue.
1 83
Some of today's placental-tissue procurement agreements include payments
for the medical entities and biobanks that collect and distribute samples. These
contracts have the potential to create a revenue stream that can be put back into
operations. These organizations must cover the costs of hiring and training staff,
purchasing equipment and supplies, developing IT infrastructure to manage data,
179. See, e.g., Dep't of Obstetrics & Gynecology, Placenta and Cord Blood Distribution Policy for the
Labor and Delivery (L&D) Unit at the Hospital of the University of Pennsylvania (HUP), U. PA.
HEALTH SYs. (Aug. 24, 2012), http://www.obgyn.upenn.edu/res/biospecimen.pdf
[https://perma.cc/SU2S-Q6NA ].
180. See Placental Tissues, ADVANCED TISSUE SERV., https://advancedtissueservices.com/placenta-and-
post-natal-products [https://perma.cc/CTT6-MFK5].
181. See AlloSource Launches Placental Donation Program, PR NEWSWIRE (Dec. 20, 2017, 12:18 ET),
https://www.pmewswire.com/news-releases/allosource-launches-placental-donation-program-
300574034.html [https://perma.cc/UW22-9L7U].
182. Karen Janszen, "Meat of Life ", SCI. DIG., Nov/Dec. 1980, at 78; see also Sandy Rovner, Birth of a
Lotion: The Secret Life of Placentas, WASH. POST, May 13, 1982, at Cl (noting that at the time the
George Washington University Medical Center was paid $1.50 per placenta by pharmaceutical
companies to cover hospital handling costs and that "[b]y the time the placental residue is processed
for sale to cosmetic manufacturers its price ranges ... from $3,000 to almost $4,000 a pound").
183. Michelle Oberman, When the Truth Is Not Enough: Tissue Donation, Altruism, and the Market, 55
DEPAUL L. REV. 903, 940 (2006) (referring to the National Organ Transplant Act § 301(a), 42
U.S.C. § 274e(a), which states: "It shall be unlawful for any person to knowingly acquire, receive,
or otherwise transfer any human organ for valuable consideration for use in human transplantation
if the transfer affects interstate commerce."). Note that the placenta arguably does not meet the
federal definition of organs. See infra Part II.A.3.i.a.
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obtaining donors' consent (when they do), processing, and preserving placentas,
inter alia 18 4 The Pennsylvania Health System's guidelines, for example, specify
that investigators may be asked to cover the cost of obtaining placental tissue
from them, such as staff, space, and equipment. 18 5 The State of Texas excludes
from its 2018 fetal-tissue disposal regulations "placentas designated for sale and
obtained from a licensed hospital or a licensed birthing center,' 1 86 suggesting
that placenta selling may still occur.1 87 This language was initially included in a
1990 Texas regulation in order to "allow the sale of placentas" 188 and so as not
"to preclude the sale of placentas from certain facilities for acceptable purposes"
because "certain types of pathological waste may be useful to medical research
programs." 189 Presumably the 1990 regulation was the basis of the 2018
language since other portions of the provisions are also similar.
In summary, though little is known about the supply chain of placentas for
third-party use, a variety of different arrangements likely exist. The next Part
turns to the laws that currently regulate the placenta in its multiple social lives,
including as an object of self-consumption, research, therapy, cosmetic
treatment, and waste.
II. INEQUITIES OF PLACENTAL ECONOMIES
There is no single definition of the placenta under federal law. Instead,
different uses of the placenta have been regulated separately, including as waste;
tissue; research subject; drug; and food, dietary, or cosmetic ingredient. Less
than a dozen states have adopted an explicit definition of the placenta, be it to
exclude it from the category of fetal tissue' 90 or to classify it as an organ,1 91 a
184. See generally Chris Andry et al., Biobanking-Budgets and the Role of Pathology Biobanks in
Precision Medicine, 4 ACAD. PATHOLOGY 1 (2017) (discussing the start-up and operational costs of
biobanking).
185. Dep't of Obstetrics & Gynecology, supra note 179, at 2-3.
186. 25 TEx. ADMIN. CODE § 138.3(c)(1) (2018).
187. 25 TEx. ADMIN. CODE § 1.133(a)(2)(C) (2018) (exempting "placentas designated for sale and
obtained from a licensed hospital or a licensed birthing center" from the coverage of certain waste
disposal standards).
188. 15 Tex. Reg. 2235 (Apr. 20, 1990).
189. 15 Tex. Reg. 4818 (Aug. 21, 1990).
190. MINN. STAT. § 137.47(c) (2018) ("'Fetal tissue' means any body part, organ, or cell of an unborn
human child. Fetal tissue does not include tissue or cells obtained from a placenta, umbilical cord,
or amniotic fluid."); TEX. HEALTH & SAFETY CODE ANN. § 697.002(3) (2018) ("'Embryonic and
fetal tissue remains' means an embryo, a fetus, body parts, or organs from a pregnancy that
terminates in the death of the embryo or fetus and for which the issuance of a fetal death certificate
is not required by state law. The term does not include the umbilical cord, placenta, gestational sac,
blood, or body fluids.").
191. ARK. CODE ANN. § 20-8-503(3) (2018) ("'Placenta' means the organ that forms on the inner wall of
the human uterus during pregnancy"); GA. CODE. ANN. § 31-46-2(3) (2018) ("'Placenta' means the
organ that forms on the inner wall of the human uterus during pregnancy.").
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human tissue,192 a specimen,' 93 a component of the broader notion of product of
conception, 194 as medical or pathological waste, 195 or as several of the above
depending on the purpose for which the placenta is considered.
This hodgepodge of federal and state laws results in simultaneously granting
third parties wide access to placentas while insufficiently protecting individuals'
autonomy over their placentas. On the one hand, birthing parents and their
families may be prevented from keeping their placenta or making informed
decisions about donating it, while, on the other hand, third parties may
sometimes procure placental tissue without obtaining the specific and explicit
consent of the producers. 196 This asymmetry creates a cycle.of dispossession for
pregnant people whereby their reproductive and placental labor may be
transformed into products and therapies, which are sold on the medical and
cosmetic markets. In what follows, I argue that the current legal framework
facilitates third-party access to placentas in a way that reinforces the
192. ARK. CODE ANN. § 20-8-503(4) (2018) ("'Postnatal tissue and fluid' means the placenta, umbilical
cord, and amniotic fluid expelled or extracted in connection with the birth of a human being"); ARK.
CODE ANN. § 20-17-801(C) (2018) ("'Human tissue' means any tissue of the human body, including
without limitation an external member of the human body, placenta, or fetal connective tissue");
GA. CODE. ANN. § 31-46-2(4) (2018) ("'Postnatal tissue and fluid' means the placenta, umbilical
cord, and amniotic fluid expelled or extracted in connection with the birth of a human being.").
193. 28 PA. CODE § 135.15 (2018) ("A hospital may elect not to send the following categories of
specimens to the laboratory for pathologic examination... (5) Placentas that are grossly normal and
have been removed in the course of operative and nonoperative obstetrics.").
194. LA. ADMIN. CODE tit. 48, § 4401 (2018) ("Products of Conception-placenta, amniotic sac or
membrane, embryo, or fetal elements that result from a human pregnancy."); MICH. COMw. LAWS
ANN. § 333.13807 (West 2019) ("(5) 'Products of conception' means any tissues or fluids, placenta,
umbilical cord, or other uterine contents resulting from a pregnancy."); N.M. STAT. ANN. § 24-9A-
1(G) (2018). ("'fetus' means the product of conception from the time of conception until the
expulsion or extraction of the fetus or the opening of the uterine cavity, but shall not include
the placenta"). In Arkansas and Mississippi, on the other hand, the placenta is explicitly excluded
from the definition of product of conception. See ARK. CODE ANN. § 20-17-801 (b)(2)(A) (West
2019) (.""Dead fetus" means a product of human conception exclusive of its placenta"); MISS. CODE.
ANN. § 41-39-1 (2019) ("a dead foetus is defined as a product ofhuman conception, exclusive of its
placenta").
195. GA. COmp. R. & REGS. 391-3-4.15(2)(a) (2018) ("Pathological waste, which means all recognizable
human tissues and body parts except teeth which are removed during surgery, obstetrical procedures,
autopsy, and laboratory procedures."); HAW. CODE R. § 11-104.1-2 (LexisNexis 2018) ("Human
pathological waste' means all tissue, organs (including placenta, tonsils, and gall bladder"); ILL.
ADMIN. CODE tit. 77, § 265.2050(a) (2018) (providing that, for birth centers, "[a]ll pathological and
bacteriological waste, including blood, body fluids, placentas, sharps and biological indicators, shall
be disposed of by a waste hauler"); 28 PA. CODE § 501.84 (2018) ("Disposal of Placenta.
Pathological and bacteriological waste, surgical and obstetrical wastes, contaminated wastes, and
similar materials shall be incinerated on the premises or disposed of by a method approved by the
Department of Environmental Resources and in compliance with local regulations."); 25 TEX.
ADMIN. CODE § 1.132(42) (2018) ("Pathological waste ... includes but is not limited to: (A) human
materials removed during surgery, labor and delivery"); 25 TEX. ADMIN. CODE § 137.38(1) (2018)
("All special waste including blood, body fluids, placentas").
196. See supra note 9 and accompanying text (noting that patients typically sign blanket consent forms
saying that all the data or tissue samples collected as part.of their medical care belong to the doctor
of the institution providing the care, thus implicitly including the collection of the placentas of
pregnant patients who undergo CVS testing, experience D&Cs and D&Es, have surgical abortions,
and give birth).
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vulnerability of already marginalized groups-pregnant people, especially those
who are also low-income or of color.
A. The Law of Third-Party Access to Placentas
Third parties such as researchers, clinicians, biobanks, biotech firms, and
cosmetic companies enjoy relatively easy access to placentas, which are often
presented as free from ethical quandaries and available for the taking.
1. The Placenta as Waste
Federal law regards bodily parts and fluids collected in healthcare facilities
in the course of diagnosis and treatment as medical or pathological waste. 19 7 No
uniform definition exists as to what constitutes medical waste according to state
law, 198 but a majority of states define the placentas as medical or pathological
waste, be it explicitly1 99 or implicitly, as the practical outcome of not defining
placentas is that they typically fall under the category of medical or pathological
197. See Elizabeth Kimball Key, The Forced Choice of Dignified Disposal: Government Mandate of
Interment or Cremation of Fetal Remains, 51 U.C. DAVIS L. REv. 305, 313 (2017) (noting that
medical waste is "potentially infectious waste material generated by healthcare facilities, including
but not limited to: bloodied bandages, discarded surgical gloves, removed body organs, discarded
needles, and cultures of infectious agents. Pathological waste, a subset of medical waste, consists of
recognizable human or animal body parts."); see also Sarah Dry, Who Owns Diagnostic Tissue
Blocks?, 40 LABORATORY MED. 69, 70 (2009) (noting that under state law tissues collected for
diagnostic use and processed into paraffin blocks must typically be kept in medical facilities' storage
for a number of years before they can be discarded).
198. Kimball Key, supra note 197, at 312.
199. GA. COMP. R. & REGS. 391-3-4.15(2)(a) (2018) ("Pathological waste, which means all recognizable
human tissues and body parts except teeth which are removed during surgery, obstetrical procedures,
autopsy, and laboratory procedures."); HAW. CODE R. § 11-104.1-2 (LexisNexis 2018) ("'Human
pathological waste' means all tissue, organs (including placenta, tonsils, and gall bladder)"); ILL.
ADMIN. CODE tit. 77, § 265.2050(a) (2018) (providing that, for birth centers, "[a]ll pathological and
bacteriological waste, including blood, body fluids, placentas, sharps and biological indicators, shall
be disposed of by a waste hauler"); MiCH. COMP. LAWS § 333.13807 (2018) ("(2) 'Pathological
waste' means human organs ... [and] products of conception ..... (5) 'Products of conception'
means any tissues or fluids, placenta, umbilical cord, or other uterine contents resulting from a
pregnancy."); 28 PA. CODE § 501.84 (2018) ("Disposal of Placenta. Pathological and bacteriological
waste, surgical and obstetrical wastes, contaminated wastes, and similar materials shall be
incinerated on the premises or disposed of by a method approved by the Department of
Environmental Resources and in compliance with local regulations."); 25 TEX. ADMIN. CODE §
1.132(42) (2018) ("Pathological waste ... includes but is not limited to: (A) human materials
removed during surgery, labor and delivery"); 25 TEX. ADMIN. CODE § 137.38(1) (2018) ("All
special waste including blood, body fluids, placentas").
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waste.2 °0 Many states also incorporate the relevant federal law by reference.
More often than not, medical providers and regulators consider placental tissue
to be a waste product described as "discarded," "residual," or "leftover" tissue.
202
This classification conforms with both the common law tradition2 0 3 and the
Roman law notions of res nullius (a thing that belongs to no one) or res derelictae
(a thing which has been abandoned by its owner). As such, placentas are
regulated through medical-waste disposal regulations, in particular the federal
Occupational Safety and Health Act (OSHA) and its state counterparts. OSHA
defines medical/infectious waste requiring special discard as "[h]uman
pathological waste, including tissues, organs, and body parts and body fluids that
are removed during surgery or autopsy, or other medical procedures, and
,,204esowatmutb
specimens of body fluids and their containers. These types of waste must be
sequestered from other, not infectious wastes, and burned in federally licensed
incinerators. 205 To comply with OSHA, all professionals exposed to any
infectious materials must take "universal precautions ... to prevent contact with
blood or any other infectious materials. 20 6
But what is waste? Something that has no use or value and must be disposed
of. Categorizing the placenta as waste is convenient. It justifies both denying
individuals access to it on the ground that it is infectious and granting third
200. ALA. CODE § 22-27-2 (2018); ARIZ. ADMIN. CODE § 13-200-212 (2018); CAL. HEALTH & SAFETY
CODE § 117690 (West 2018); COLO. REV. STAT. § 25-15-402 (2018); DEL. CODE ANN. tit. 7, § 6402
(2018); D.C. CODE § 8-901 (2018); FLA. STAT. § 403.703 (2018); IDAHO CODE § 39-103 (2018); 415
ILL. COMP. STAT. § 5/3.360 (2018); IND. CODE ANN. § 16-41-16-5 (West 2018); IOWA CODE §
455B.501 (2018); KAN. ADMIN. REGS. § 28-19-729a (2018); 401 KY. ADMIN. REGS. 61:013 (2018);
06-096-100 ME. CODE R. § 096-100-178-E (LexisNexis 2018); 105 MASS. CODE REGS. 480.010
(2018); MINN. STAT. § 116.76 (2018); MISS. CODE R. § 15-16-1:52:26 (2018); Mo. CODE REGS.
ANN. tit. 10, § 80-7.010 (2018); MONT. CODE ANN. § 75-10-1003 (2018); 132 NEB. ADMIN. CODE
§ 1-053 (2018); NEV. ADMIN. CODE § 444.600 (2018); N.H. REV. STAT. ANN. § 125-M:2 (2018);
N.Y. PUB. HEALTH LAW § 1389-aa (McKinney 2018); 15A N.C. ADMIN. CODE 13B.1201 (2018);
N.D. ADMIN. CODE 33-20-12-01 (2018); OHIO REV. CODE ANN. § 3734.01 (West 2018); OKLA.
ADMIN. CODE § 310:616-5-2 (2018); 23 R.I. GEN. LAWS § 23-19.12-3 (2018); S.D. CODIFIED LAWS
§ 34A-6-93 (2018); TENN. COMP. R. & REGS. 1200-08-10-.10 (2018); UTAHCODE ANN. § 19-6-102
(West 2018); 16-3 VT. CODE R. § 200 (2018); 9 VA. ADMIN. CODE § 20-120-150 (2018); WASH.
REV. CODE § 70.95K.010 (2018); W. VA. CODE § 20-5J-3 (2018); WIS. STAT. § 287.07 (2018); 020-
0002 WYO. CODER. § 4 (2018).
201. 40 C.F.R. § 60.51 (2018).
202. See Yoshizawa, supra note 29, at 9, 11.
203. See Jean McHale, Waste, Ownership and Bodily Products, 8 HEALTH CARE ANALYSIS 123 (2000)
(discussing English laws' approach to bodily parts as waste).
204. 40 C.F.R. § 60.51 c(2) (2018). Taken literally, however, federal regulations of medical waste should
in theory only apply to placentas delivered via diagnostic procedures, surgical abortions, D&Cs, and
C-sections, not to those obtained after a vaginal delivery. Vaginal birth is a normal physiologic
process, not a pathology requiring medical interventions. Nonetheless, all placental tissues extracted
or expelled from the body in a healthcare facility appear to be considered medical waste. The
placenta could also fall within the "other potentially infectious materials" definitions provided by
the statute, which includes "[a]ny unfixed tissue or organ (other than intact skin) from a human
(living or dead)." 29 C.F.R. § 1910.1030(b)(1) (2019).
205. Id.
206. Id. at § 1910.1030(d)(1).
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parties access to it on the ground that it is abandoned and will be put to good
use.2 °7 This classification has been criticized by others before.20 8 It poses at least
two interrelated problems: 1) it constructs placentas as available and
unproblematic by contrast to embryonic or fetal tissues, perpetuating the
representation of the female body itself as waste; and 2) it pathologizes people's
DIY use of their placentas as hazardous.
i. The Placenta as Available Tissue
According to Rebecca Yoshizawa and her colleagues, "[w]aste is a rhetorical
category adjudicating powers to decide the meaning of, and what happens to,
alienated bodily fleshes in biomedicine., 20 9 Their study underlines that the waste
categorization serves as a rationale for collecting placentas for research or
clinical use without obtaining consent. 210 Under federal research law, when
tissues are de-identified, that is, so long as donors' identifiers (such as name,
record or social security numbers, date of birth, and so on 2 1 ) do not accompany
samples, they are typically not considered "human subjects. '212 According to the
Common Rule developed by the U.S. Department of Health and Human
Services, 213 leftover clinical samples may be used for research when no longer
needed for patient care without securing patient consent, as long as the physical
sample and any associated data sets cannot be linked to specific, living
individuals. In practice, because placentas are treated as discarded tissue by
healthcare facilities, they most often meet the requirements for de-identified
tissues.214 Sociologists investigating pregnant people's perceptions of their
placentas through individual interviews would be considered as conducting
human subjects research. They would likely be required by their institution's
Institutional Review Board to obtain participants' informed consent and to take
207. Rachel Ariss, Theorizing Waste in Abortion and Fetal Ovarian Tissue Use, 15 CAN. J. WOMEN &
L. 255,256 (2003) ("A recurrent thread supporting ethical discussion in favour of using reproductive
materials is found in concepts of waste and wastefulness. It is assumed, rather than argued, that using
reproductive materials (such as fetal tissue, frozen embryos, and umbilical cords), which have no
other purpose and, therefore, will be wasted, is an inherent 'good."').
208. See, e.g., McHale, supra note 203; Yoshizawa, supra note 29; see also Charlotte Krolokke, Elizabeth
Dickinson & Karen A Foss, The Placenta Economy: From Trashed to Treasured Bio-Products, 25
EUR. J. WOMEN's STUD. 138, 148-50 (2016).
209. Yoshizawa et al., supra note 15, at 77 (citing scientists who reported using placentas without
explicit, informed consent because placentas are "considered throwaway tissue").
210. Id.
211. Other participant information may accompany the sample and still be considered "de-identified."
Information that may accompany the sample includes approximate date of collection; certain
diagnoses and medical history; and gender, age, race, or ethnic group.
212. 45 CFR § 46.102(e) (2016).
213. See generally 45 C.F.R. §§ 46.101-46.124 (2014).
214. See Div. of Microbiology & Infectious Diseases, Good Clinical Practice Resource Guide, U.S.
DEP'T HEALTH & HUM. SERV. (Dec. 2015).
2020]
Yale Journal of Law and Feminism
steps to protect their confidentiality. By contrast, investigators using actual, de-
identified placentas are typically not required to obtain donors' consent given
that their activities fall under the category of non-human research.
215
When discarded placental tissue is sought for clinical or commercial use as
opposed to research, healthcare facilities are not bound by Institutional Review
Board rules. These facilities' ethical (or other internal) committees have
discretion as to whether to donate or sell the tissues, and whether to obtain
donors' specific consent. A number of organizations do seek donors' specific
consent rather than relying on the blanket consent forms patients sign at the time
of admission.216 Yet, even when consent is actively sought, the waste paradigm
continues to dominate the discourse surrounding placenta donation and research.
Celularity, for example, a New Jersey biotech company that uses placenta stem
cells to produce therapies to augment immunity and longevity, features on its
website a chart depicting the placenta as under-utilized, accompanied by the
following formula: "130M births per year globally <.01% of placentas are
utilized 1 placenta = 100K+ medical treatments. 217
When construed as waste, placentas are viewed as available for the taking,
both practically and ethically. Practically, collecting them can be as easy as
dumpster diving-the perfectly legal activity of foraging through another
person's garbage left in the public space to obtain discarded materials.218
Ethically, researchers and other stakeholders contend that placentas are free from
the controversies 219 raised by other female reproductive tissues such as eggs,
embryos, and fetuses.220 From a regulatory perspective, the placenta is not
considered fetal tissue, and thus is exempt from the federal and state laws
governing fetal tissue donation and research.221 Halkoaho notes that the claim
215. See 45 C.F.R. § 46.102(e); see also Human Subject Regulations Decision Charts, U.S. DEP'T
HEALTH & HUM. SERV. (Feb. 16, 2016), https://www.hhs.gov/ohrp/regulations-and-policy/decision-
charts/index.html [https://perma.cc/MQV2-3ZTK] (explaining when research will be considered
human subject research under 45 C.F.R. 46).
216. See Petrow, supra note 13.
217. CELULARITY, https://www.celularity.com [https://perma.cc/697H-GEEN].
218. California v. Greenwood, 486 U.S. 35 (1988) (holding that there is no reasonable expectation of
privacy for garbage that is accessible to members of the public); see also Arielle Zionts, Placenta
Taken Without Warrant Will Be Used as Evidence in Rape Case, RAPID CITY J. (Nov. 16, 2019),
https://rapidcityj oumal.com/news/local/crime-and-courts/lacenta-taken-without-warrant-will-be-
used-as-evidence-in/articlef77dc0bc-5686-5e30-984b-4067702 1 dfl d.html
[https://perma.cc/6B79-2Z6A] (reporting that, according to some law enforcement officers and
judges, no warrant is necessary to seize placentas from abortion clinics because they are medical
waste).
219. Julie Kent, Maria Fannin & Sally Dowling, Gender Dynamics in the Donation Field: Human Tissue
Donation for Research, Therapy and Feeding, 41 SOC. HEALTH & ILLNESS 567, 575 (2018).
220. See Yoshizawa, supra note 29.
221. 42 U.S.C. § 289g-l(g).
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that the placenta is waste has even been deployed to advocate for less-strict
ethical guidelines for its collection.222
Treating placentas as waste also perpetuates the long Western tradition of
suspicion and debasement of the female body and its secretions. 223 Rachel
Ariss's discussion of waste tissue highlights how the reproductive labor of
women is generally tied to notions of wastefulness, as "reproduction is simply
another form of commodity production, and either a new product, or waste, must
be the result., 224 Emily Martin's feminist anthropology of science helps explain
why female reproductive tissues in particular tend to be seen as waste. 225 For
generations, the female reproductive functions have been represented in medical
texts as a cycle of degeneration and decay generating waste at every stage-
unfertilized eggs, falling away uterine lining, menopause, and so on.226 The
placenta could be added to the list, whether obtained following diagnostic
testing, pregnancy termination, loss, or birth. In all of these instances, it is no
longer needed to physically nourish and protect valued fetuses, transitioning
from essential to support life to useless remnant of a pregnancy.
ii. The Pathologizing of Self-Consumption
Still another persistent problem with the categorization of the placenta as
waste is that it pathologizes DIY uses as risky and deviant, while vindicating
taking and transforming placenta into processed products in the hands of
research, medical, and cosmetic organizations. State statutes and regulations as
well as medical centers' internal guidelines construct placentas as dirty, polluting
waste, to use notions famously articulated by anthropologist Mary Douglas.
Douglas defined "dirt as matter out of place."227 According to her, in human
cultures, dirt must typically be excluded to preserve pattern or sense of order.228
Framing the placenta as infectious waste to be excluded may be another way of
imposing a form of order on childbirth, contributing to its medicalization and
.prescribing conditions on pregnant and birthing people's engagement with their
own body. This waste conception empowers legal and medical institutions to
222. A. Halkoaho, A.-M. Pietild & K. Vlhakangas, EthicalAspects in PlacentalPerfusion Studies: Views
of the Researchers, 32 PLACENTA 511 (2011).
223. See, e.g., Ros Bramwell, Blood and Milk: Constructions of Female Bodily Fluids in Western Society,
34 WOMEN & HEALTH 85 (2001).
224. Ariss, supra note 207, at 264.
225. See generally EMILY MARTIN, THE WOMAN IN THE BODY: A CULTURAL ANALYSIS OF
REPRODUCTION (2001).
226. See Emily Martin, The Egg and the Sperm: How Science Has Constructed a Romance Based on
Stereotypical Male-Female Roles, 16 SIGNS 485, 489 (1991).
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regulate individuals' relationship with their own placentas even when allowed to
keep them. It justifies restrictive clauses placed on release such as the
requirement that producers test negative for a variety of blood-borne illnesses
and be educated in safe handling practices, or that the placenta itself be tested
for germs. While the health concerns behind these restrictions are real, people
who grow placentas should retain greater autonomy in what to do with their own
tissue. After all, people of reproductive age routinely handle bodily materials
such as menses safely on their own. Should drinking one's own menstrual blood
become a trend, it would be difficult to fathom how health authorities could enact
and enforce limitations similar to those placed on placenta.
229
When the placenta is not depicted as waste, it is framed as a gift to be
expected from selfless feminized donors.
2. The Placenta as Gift
In the recruitment of placenta donors, banks and biotech companies rely on
gendered stereotypical notions, according to which women are altruistic and
motivated by the desire to help others rather than by financial incentives. These
assumptions are not specific to placental donation, as gender appears to shape
the dynamics of tissue donation generally. Julie Kent, Maria Fannin, and Sally
Dowling have argued that "in general, and across comparative country contexts,
more women donate organs than men, and more men are recipients of donated
organs than women., 230 Physician Naomi Duke notes that some bodies are
"forced, trained, and programmed to give.'231 Women, particularly women of
color, are culturally constructed as selfless and giving, bearing responsibility for
the care of their family. Their bodies are seen as without border, especially in
relation to pregnancy, which is treated as a public event-from ultrasounds,
which bare wombs for all to see, to reproductive decisions, which are often made
by parties other than women themselves.
Georgia biopharmaceutical company MiMedx's donation website illustrates
this construction of the female body as both wasteful and altruistic. The home
page intimates, "Donate your placenta," "Give the gift of healing," "Help dozens
229. "Womb Witch" Urges Women to Drink Their Own Menstrual Blood to Boost Energy Levels,
MIRROR (Feb. 12, 2018), https://www.mirror.co.uk/news/weird-news/womb-witch-urges-women-
drink-12015423 [https://perma.cc/BW6W-LN4X] (suggesting that the idea of drinking one's own
menstrual blood is actively practiced).
230. Kent, Fannin & Dowling, supra note 219, at 3.
231. Naomi N. Duke, Situated Bodies in Medicine and Research: Altruism versus Compelled Sacrifice,
in THE GLOBAL BODY MARKET, supra note 23, at 107, 107-109 (critiquing how altruism is often
deployed in medicine and research, and in particular denouncing in the exploitation of African-
Americans as "altruistic bodies").
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of patients," accompanied by pictures of smiting babies.232 MiMedx's donation
brochure expounds further:
It is vital that you donate. The amniotic membrane (amnion) within the
placenta has unique healing properties not found in other tissues. It
consists of a special combination of cells with specific functions that aid
the healing process. Why let it go to waste? One placenta donation can
improve the quality of life for dozens of people.23
The website does not indicate that MiMedx is a for-profit company that uses
placental tissue to manufacture and market lucrative products, cultivating instead
the perception of a charitable organization. The FAQs page includes the
following Q&A:
-Will I be given monetary compensation for my donation?
-No. We are extremely appreciative of this act of charity; however,
due to federal laws, we cannot provide any monetary compensation.234
This passage is puzzling considering that the federal government does not
classify the placenta as an organ and, therefore, does not make it illegal to
compensate donors. It also contradicts a statement, made by a MiMedx
spokesman to journalist Matilda Battesby in 2018, that the company has "not
taken a position relative to incentivizing donors, but believe[s] it could become
an important topic for policy discussion. 235
The gendering of placental tissue donation is compounded by the fact that it
is overwhelmingly men who reap the reputational and economic benefits
associated with the research, processing, and selling of ideas and products
derived from placentas. The leading biotechnology companies using placentas
are run by men. MiMedx, though it has faced a reshuffling of its executives in
2018, counts nine men on its management team for one woman, and eight men
for one woman on its Board of Directors. 236 New Jersey company Celularity was
232. PLACENTA DONATION PROGRAM, https://www.placentadonation.com [https://perma.cc/F6SJ-
VS89].
233. Placenta Donation Program, Give the Gift of Healing, MIMEDX TISSUE SERV.,
https://www.placentadonation.com/sites/default/files/PlacentaDonationBrochure.pdf
[https://pemia.cc/UHY9-489F].
234. FAQs, PLACENTA DONATION PROGRAM, https://www.placentadonation.com/questions
[https://perma.cc/9ARY-R2UU].
235. Matilda Battersby, Should We Pay Mothers to Donate Placentas?, MEDIUM (July 25, 2018),
https://medium.com/s/story/should-we-pay-mothers-to-donate-placentas-607283042efl
[https://perma.cc/RL6B-FZV5].
236. Board of Directors, MIMEDX, https://mimedx.com/board-of-directors [https://perma.cc/K4TB-
ZXRN]; Management Team, IMEDX, https://mimedx.com/management-team
[https://perma.cc/6TVT-UB7D].
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founded by two men237 and its Board of Directors consists exclusively of men.238
Noveome Biotherapeutics, Inc., a Pennsylvania biotech company founded and
headed by a man, counts five men and one woman on its "leadership team"
239
and all of its Directors are men.240 Though this gender disparity is typical of the
biotech sector, it strikes as especially problematic when the raw material
capitalized upon is produced by female reproductive labor. Placental economies
offer a vivid reminder that the age-old paradigmatic sexual division of labor-
women reproduce while men produce-is still alive and well.
3. The Placenta as Product
Within the complex cycle of placental economies, some individuals may be
in the position to become (symbolically at least) customers of their own bodies.
Their buying back of their placenta takes several forms, from placenta-based
drugs and clinical products that show promise for medical indications ranging
from cancer to wound care, to cosmetics such as skin lotions and hair treatments.
Some of these products seem to be safe, effective, and much needed for patient
care, while others entail serious health risks. In what follows, I review the
bifurcated federal regulation of the placenta as a tissue, dietary ingredient, food,
and cosmetic ingredient, highlighting the different risk calculus at work under
each category.
i. The Placenta as Tissue
The placenta is often referred to as an organ in the scientific literature, but it
does not meet the federal definition of organs under the National Organ
Transplant Act given that it cannot be used for direct transplantation.241 Instead,
when used for therapeutic purposes, the placenta is regulated under the Public
Health Service Act as a "Human Cell Tissue Product" (HCT/Ps) on the basis that
it consists "of human cells or tissues" which may be "intended for implantation,
transplantation, infusion, or transfer into a human recipient., 242 The regulation
of the placenta as tissue is highly complex. The FDA has developed a three-tier
classification system for HCT/Ps based on the degree of risk posed to public
237. Matthew Herper, Celgene Spinout Celularity Raises $250 Million to Develop Placental Cells to
Attack Cancer, FORBES (Feb. 15, 2018, 9:00 AM),
https://www.forbes.com/sites/matthewherper/2018/02/15/celgene-spinout-celularity-raises-250-
million-to-develop-placental-cells-to-atttack-cancer [https://perma.cc/NQ6R-9WTW].
238. Board of Directors, CELULARITY, https://www.celularity.com [https://perma.cc/697H-GEEN].
239. Leadership, NOvEOME, https://noveome.com/company/#1eadership [https://perma.cc/R6B5-
NXTY].
240. Id.
241. National Organ Transplant Act, 42 U.S.C. § 274e(a)(e).
242. 21 C.F.R. § 1271.3(d) (2018).
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health and individual recipients. 243 There has been some controversy as to
whether certain placental products fall under the second (middle-risk) or the third
(high-risk) tier. For companies using placentas, marketing their products as
outside the high-risk category presents the enormous advantage of
circumventing the lengthy and expensive regulatory process applied to high-risk
HCT/Ps and getting them on the market faster.24 4 The consequences for failing
to adhere to HCT/Ps regulation, however, can be severe, as experienced in 2013
by MiMedx. This publicly traded, for-profit biopharmaceutical company
develops and markets regenerative and therapeutic biologics utilizing human
placentas.245 That year, the FDA notified the company that some of its injectable
products containing ground placenta (a process called micronization) could
violate the law because they likely did not qualify as minimally manipulated,
that is, they fell into the higher risk category. 246 The FDA letter resulted in a
sudden drop in the value of MiMedx's shares,247 precipitating a securities class
action alleging that the company made misleading statements and falsely inflated
stock market prices.2 48
The regulation of placenta as tissue is not only intricate, but also, according
to bioethicist Leigh Turner and stem cell scientist Paul Knoepfler, may be
underenforced. 249 In their 2016 study of direct-to-consumer marketing of
unapproved stem-cell therapies, they found that 17% of businesses marketing
allogenic cell-based interventions25° sourced their cells from amniotic materials,
3.4% from placental tissue, and 0.6% from umbilical cords.251 These businesses
promote stem-cell interventions to treat a wide range of diseases and injuries, as
well as for cosmetic applications, generating "regulatory concerns due to
243. Kazuo Yano, Alessondra T. Speidel & Masayuki Yamato, Four Food and Drug Administration
Draft Guidance Documents and the REGROW Act: A Litmus Test for Future Changes in Human
Cell- and Tissue-Based Products Regulatory Policy in the United States?, 12 J. TISSUE
ENGINEERING & REGENERATIVE MED. 1579, 1580 (2018).
244. See Warning Letter from Joseph Saleski, Acting Dir., Div. of Sci. Investigations, U.S. Food & Drug
Admin., to Terry A. Colip, Chief Fin. Officer, Cell Point (June 15, 2006) (finding Cell Point in
violation of the regulation governing the use of investigational drugs and the conduct of clinical
trials because it sponsored studies in which human subjects received investigational drug products
prepared from raw human placentas with the objective of evaluating detection and treatment of
apoptosis in patients with breast cancer).
245. Sara Germano, Placenta-Products Maker MiMedx Draws FDA Attention, WALL ST. J. (Sept. 11,
2013, 8:22 PM ET), https://www.wsj.conr/articles/placentaproducts-maker-mimedx-draws-fda-




248. In re MiMedx Group Sec. Litig., No. 1:13-cv-03074-TWT, 2015 WL 5969357 (N.D. Ga. Apr. 16,
2015).
249. Leigh Turner & Paul Knoepfler, Selling Stem Cells in the USA: Assessing the Direct-to-Consumer
Industry, 19 CELL STEM CELL 154 (2016).
250. That is, procedures in which the stem cells originate from donors other than the patients.
251. Turner & Knoepfler, supra note 249, at 155.
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apparent noncompliance with federal regulations." 2 52 In light of the 351
businesses they identified as actively advertising stem cells products nationally,
Turner and Knoepfler "ask whether regulatory inaction has emboldened
entrepreneurial physicians and other market participants., 253 In a subsequent
publication, Turner observed that the market in direct-to-consumer stem cell
interventions is even larger than he originally thought 254 Despite apparent
noncompliance, few such businesses have been subject to enforcement actions
by the FDA or other agencies.
2 55
ii. The Placenta as Dietary Ingredient
Inasmuch as a placenta-based product is not intended to treat, cure, mitigate
or prevent disease, it may come under a different regulatory regime--dietary
supplements and food regulation. As early as 2000, the FDA declared that the
human placenta is neither a food nor a dietary ingredient under the Federal Food,
Drug, and Cosmetic Act2 5 6 (FD&C Act) in a warning letter to New York based
Chinese medicinal herbs provider Blue Light, which had marketed two products
containing placenta. 257 The agency explained that human tissue is not
"customarily used as human food or drink" and may transmit disease, concluding
that a dietary or food product containing human placenta is adulterated under the
statute and can therefore not be marketed in the United States.2 58 Since then, the
FDA consistently reaffirmed this stance in its correspondence with other
providers of Chinese medicinal herbs who included, or planned to include,
human placenta in their products. 259 Mainstream American personal care
252. Id. at 155-56.
253. Id. at 157.
254. Leigh Turner, The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions, 61
PERSP. BIOLOGY & MED. 7, 8-9 (2018) (noting that, as of May 2017, 432 distinct U.S. businesses
sell stem cell-based interventions provided at 716 clinics and that, among businesses advertising
allogeneic treatment, 80 companies reportedly sourced from amniotic material, 13 from placental
tissue, and 5 from umbilical cord blood).
255. Id. at 13.
256. This is the set of laws giving authority to the FDA to oversee the safety of food, drugs, medical
devices, and cosmetics. See 21 U.S.C. § 321(f), (ff)(1) (2019).
257. Warning Letter from Edward W. Thomas, Acting Dist. Dir., N.Y. Dist. Office, U.S. Food & Drug
Admin., to Chao Zhang, President, Blue Light (June 15, 2006).
258. Id.
259. See Warning Letter from U.S. Food & Drug Admin. to Hui Fen Li, President, N.Y. Healthy Herbs
(Oct. 7, 2002) (advising that Youth Plus, a product containing human placenta intended to help
"woman to revitalize her body's feminine activities and energy" could not be marketed because it
was adulterated); Warning Letter from James S. Cohen, Acting Dir., Office of Compliance &
Biologics Quality, U.S. Food & Drug Admin. to Maria Annecchino, Belleza Integral (Aug. 31,2004)
(putting the company on notice that some of the products it sells online, such as its "anti-ageing
vaccine" H-Ultracell, composed of human placenta, and "syringes with placental liquid of human
origin" were considered drugs or biological products and therefore required a valid biologics license
or new drug application to be legally marketed); U.S. Food & Drug Admin., Herbal Science
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companies appear to have stopped using human placenta in cosmetics in the past
couple of decades, 260 but dried or ground placenta has long been a popular
ingredient in traditional Chinese medicine, which may explain why the FDA
enforcement actions have targeted this particular source of placenta
commerce. 261 The issue came to the fore anew in 2011, when Chinese medicine
manufacturer Fang Ding filed a "new dietary ingredient" (NDI) application with
FDA seeking approval of a dietary supplement product called Placentake, which
contained human placenta extract. 262 Ding was following the FDA rule
according to which, if a supplement contains a dietary ingredient that has not
"been present in the food supply as an article used for food in a form in which
the food has not been chemically altered," it is a "new dietary ingredient" and
must undergo its own form of premarket review. 263 In response to his
application, the agency restated its view that a product containing human
placenta is not a dietary ingredient and is as such adulterated, thus declining to
take a position on its safety.
264
International, Inc Recalls Twelve Dietary Herbal Supplements Nationwide Because Of Possible
Health Risk Associated With Ephedra, Aristolochic Acid And Human Placenta, U.S. DEP'T HEALTH
& HUM. SERV., (Apr. 10, 2007), https://wayback.archive-
it.org/7993/20170406122205/https://www.fda.gov/Safety/Recalls/ArchiveRecalls/2008/ucm 11242
7.htm [https://perma.cc/VEX7-W98C] (reporting that the FDA issued a warning letter to Herbal
Science International because several of its dietary supplements were adulterated, including "Seng
Jong Tzu Tong Tan," because it contained human placenta); Solstice Medicine Recall Notice (Feb.
21, 2016) (noting that an herbal supplement was recalled because it contained human placenta).
260. See Renee Jacques, You Probably Shouldn't Be Using Products with Placentas in Them, ALLURE
(July 16, 2015), https://www.allure.com/story/placenta-beauty-products [https://perma.cc/CT5J-
SNKK].
261. See Zheng Xin, E-Sales of Placenta Continue to Thrive Under Ban, CHINA DAILY (Oct. 25, 2011,
8:15 AM), https://www.chinadaily.com.cn/china/2011-10/25/content__13966723 .htm
[https://perma.cc/U8QU-AKEF] (noting that the Chinese government has banned the trade of human
placentas since 2005 on the premise that it could contribute to the spread of diseases, but that in spite
of the ban "Taobao, the country's largest online marketplace, is awash with vendors offering dried
or ground placenta.").
262. Memorandum from Dan D. Levy, Senior Microbiologist & Acting Supervisor, New Dietary
Ingredient Review Team, U.S. Food & Drug Admin., to Mr. Fang Ding, Healthkord (USA) (Apr. 6,
2011) (responding to a premarket notification filed by a company that planned to market Placentake
tablets containing human placenta extract).
263. 21 U.S.C. § 350b(a)(1); see also New Dietary Ingredients in Dietary Supplements - Backgroundfor
Industry, U.S. FOOD & DRUG ADMIN. (Oct. 4, 2019), https://www.fda.gov/food/new-dietary-
ingredients-ndi-notification-process/new-dietary-ingredients-dietary-supplements-background-
industry [https://perma.cc/5QTK-VGSA].
264. Memorandum from Dan D. Levy to Mr. Fang Ding, supra note 262; see also U.S. FOOD & DRUG
ADMIN., INVESTIGATIONAL NEW DRUG APPLICATIONS (INDs)--DETERMINING WHETHER HUMAN
RESEARCH STUDIES CAN BE CONDUCTED WITHOUT AN IND: GUIDANCE FOR CLINICAL
INVESTIGATORS, SPONSORS, AND IRBs 11 (2013) ("[A] study of the effect of a cosmetic product
containing human or animal biological material (such as placenta) on skin repair mechanisms would
require an IND, even if the study is intended only to support a claim of younger looking skin.").
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iii. Placentophagy, or the Placenta as Food
In contrast to commercial uses of placentas in supplements, maternal
placentophagy and other forms of DIY placenta consumption are not explicitly
banned by the federal government even though several agencies intervened in
the past decade or so to discourage or proscribe associated practices on personal
and public health and safety grounds. 265 The FDA "has adopted a hands-off
policy as long as placentas and pills don't cross state lines, 26 6 but it has been
willing to get involved when placentas are collected and prepared for
consumption by people other than the donor or on a wide scale. For instance, in
2008, in conjunction with Florida state authorities, the FDA raided a Miami
birthing center owned and operated by a diverse group of women,267 and accused
the staff of mixing ground placentas from various donors into large batches and
dispensing them to their postpartum patients.2 68 In other words, for now, self-
consumption slips under the agency's radar, while consumption by others may
trigger scrutiny.
The business of placenta encapsulation, so far unregulated by the FDA, is
thriving. Encapsulators are typically self-employed female entrepreneurs-
"mumpreneurs" 269 -offering placenta preparation alongside services combining
work and care such as doula work, massage, and other forms of pre- and postnatal
support.270 The medical profession has a long history of regulating itself, both
for patient protection and to maintain a monopoly over healthcare by setting
standards for entry, recredentialing, and conduct.27 1 In the absence of any form
of occupational licensure or other laws regulating their practice, placenta
265. See supra note 68 and accompanying text.
266. Florida Department of Health Joint Investigation Leads to Federal Search Warrant in Miami,
WCTV (Dec. 31, 2008, 3:55 PM), https://www.wctv.tv/home/headlines/36945319.html
[https://perma.cc/E52U-5LMA] (reporting ajoint FDA-Florida Department of State investigation of
a Miami birthing facility that provided its clients with placenta pills made of placentas pooled from
different donors as a prophylactic measure in order to mitigate or prevent postpartum depression)
[hereinafter Florida Department].
267. See Our Staff .. , MIAMI MATERNITY CTR., https://www.miamimaternitycenter.net/staff.htm
[https://perma.cc/3682-QWPG].
268. See Florida Department, supra note 266. Florida state law probably helped the Department of Health
to secure a warrant for enforcement operation against the birthing facility milling placenta pills,
since encapsulated placenta designed for the purpose of preventing or treating a disease or illness
meets the definition of a drug under the Florida Drug and Cosmetic Act, requiring a licensed
pharmacist to compound and manufacture. See FLA. STAT. § 499.003(17) (2018).
269. Perrier & Fannin, supra note 31, at 449.
270. Id. at 451 (showing based on their fieldwork in Bristol that those "complementary therapies" include
"hypnobirthing, pregnancy yoga, doula services, postnatal fitness training, alternative therapies,
creative workshops and other forms of 'care' work for pregnant women and mothers."). In my own
exploration of the placenta encapsulation market in New York City, which was conducted through
web searches in the spring of2018, most placenta encapsulators are also doulas.
271. See William D. White, Professional Self-Regulation in Medicine, 16 VIRTUAL MENTOR: AM. MED.
Ass'N J. ETHICS 275 (2014) (delineating the public and private forms of regulation of the medical
profession).
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encapsulators have sought to emulate the self-regulation of medicine. A few
organizations, such as the Association of Placenta Preparation Arts (APPA),272
the International Placenta and Postpartum Association (IPPA),273 and Placenta
Benefits (PBiU) 274 have emerged to organize the growing business. Each
organization offers its own training and certification program, aspiring to high
safety and ethics standards. These standards are largely unenforceable, however,
as the organizations lack regulatory oversight and licensing power. Nonetheless,
their goals include the creation of professional education, the exchange of
knowledge, and the promotion of competence-based decision-making and
professional behavior.
The Association of Placenta Preparation Arts claims that its online program
is "the most comprehensive placenta preparation training available," calling it
the "Bachelor's Degree in Placenta Arts., 275 Once certified, providers must
abide by the Association's Code of Ethical Conduct, which includes client
confidentiality, privacy rules, and a requirement of compliance with any
applicable black letter law health and safety regulations.276 While calling for
legal compliance, the Association expects its members to make clear on all of
their materials that their service "has not been evaluated by the FDA. ' 277
Similarly, the International Placenta and Postpartum Association declares that is
has "trained over 3,000 placenta specialists since 2011." It offers both in-person
and distance education that covers preparation techniques such as sanitizing and
adhering to OSHA guidelines for handling blood-borne pathogens.278
The current regulation of the placenta as a non-food or dietary ingredient, as
well as the self-regulation of placenta self-consumption, seem to be functioning
satisfactorily given the rarity of reported adverse events. 279 By contrast, as the
next subsection argues, the FDA's historically lenient approach to the human
placenta as a cosmetic ingredient has proved problematic due to placenta-based
272. ASS'N OF PLACENTA PREPARATION ARTS, https://placentaassociation.com [https://perma.cc/G9ZT-
FK59].
273. INT'L PLACENTA & POSTPARTUM ASS'N, https://www.ippatraining.com [https://perma.cc/6WG3-
E864].
274. PLACENTA BENEFITS, https://placentabenefits.info [https://perma.cc/LHF4-698V].
275. ASS'N OF PLACENTA PREPARATION ARTS, supra note 272.
276. Standards, ASS'N. OF PLACENTA PREPARATION ARTS, https://placentaassociation.com/standards
[https://perma.cc/CH7Y-XF3M].
277. Id.
278. Distance Self Paced Learning, INT'L PLACENTA & POSTPARTUM ASS'N,
https://www.ippatraining.com/distance [https://perma.cc/AP5D-VS23].
279. See supra notes 67-70 and accompanying text. But see Donley, supra note 21, at 229 (advocating
for the regulation of encapsulated placenta by the FDA as a 361 HCT/P in order to avert two harms:
"(1) the spread of communicable diseases resulting from improperly handled tissue and (2) the
public's deception when manufacturers claim without proof that their product will cure, mitigate, or
prevent disease").
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personal care products' health risks and disproportionate use by already
vulnerable groups.
iv. The Placenta as Cosmetic Ingredient
Starting in 1959 and until the 1990s, human placentas figured among the
ingredients of many mainstream personal care products and beauty treatments in
the United States. 280 Today's cosmetics are more likely to be sourced from
animal placentas because American companies and distributors have become
wary of marketing human placenta-based products and the FDA seems more
willing to intervene when they do. Human placentas continue to be used in
cosmetics manufactured in East Asian countries, in particular in Japan and South
Korea, where placenta-based skin whitening and anti-aging lotions are
popular.28
1
The cosmetic market for placental creams promising younger or whiter skin
relies on entrenched forms of racial and skin-tone stratification. Charlotte
Krolokke notes that in "the Japanese cosmetic industry, a preference for
whiteness and Japanese origin is embedded in the choice of 'carefully selected'
Japanese-made placenta extract or in the claim of the product being '100%
Japanese.' ' 282 Worldwide, skin tone is a major marker of status and a form of
symbolic capital despite national ideologies of colorblindness and racial
democracy. 283 Hierarchies of skin color inherited from European colonialism
284
that systematically privilege whiteness are alive and well in North America.
These hierarchies rely on the connected systemic racism and colorism-that is,
a system that privileges the lighter-skinned over the darker-skinned people
within a community of color.285 Pregnant people's reproductive labor is thus
recycled into a product that perpetuates legacies of colonialism as well as "the
penetration of multinational capital and Western consumer culture." 286 One
280. Myddleton, supra note 140, at 202; see also Nair & Elmore, supra note 142 (noting that, as of 1998,
human placenta was still found in a few cosmetic products marketed in the United States); Marianne
Taylor, Beauty May Be Only.Placenta-Deep, CHICAGO TRIBUNE, June 29, 1980, at 11 (reporting
that, at the time, a significant portion of lotions and shampoos contained human placentas "collected
regularly from hospitals across the nation" and that beauty salons also used placental proteins for
their treatments).
281. See KROLOKKE, supra note 30, at 6.
282. See KROLOKKE, supra note 30, at 125.
283. See Tanya Kateri Hernkndez, Envisioning the United States in the Latin American Myth of Racial
Democracy Mestizaje', 11 LATIN AM. & CARIBBEAN ETHNIC STUD. 189, 189 (2016) (debunking the
racial democracy myth of Latin American post racialism and connecting it to the U.S. ideology of
colorblindness).
284. Evelyn Nakano Glenn, Yearning for Witness: Transnational Circuits in the Marketing and
Consumption of Skin Lighteners, 22 GENDER & SOC'Y 281, 281 (2008).
285. Id.
286. Id. at 286.
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person's placenta is transformed into an expensive product purchased by another
(or the same) person who hopes to partake in some of the benefits attached to
light skin. In the United States, Margaret Hunter has shown that educational
attainment, income, and spousal status are related to skin color hierarchies,
leading to attempts to buy "racial capital" through skin whitening creams or
surgeries.287 There is little science corroborating the whitening effects of
placenta-based products, and with a few exceptions, the existing literature
concludes that the effect of placental extract on the formation of melanin is
largely unknown. 88
The use of hair products containing placenta of human or animal origin used
to be relatively common in the United States.289 These products, however, have
detrimental side effects, particularly for children, given that exposure to
placental hormones is associated with premature sexual development and higher
cancer risks. This risk was unevenly distributed as the primary consumers of the
placenta-based products were African-American and Latina women and their
children. A study conducted in the U.S. Army in the early 2000s pointed out that
the use of hair products containing hormones or placenta was highly gendered,
raced, and classed. 9° More specifically, the study found the highest probability
of use "among non-white female enlisted personnel" 29 1-that is, mostly African-
American and Latinx employees who occupied a low rank in the Army
287. Margaret L. Hunter, "If You 're Light You're Alright": Light Skin Color as Social Capitalfor Women
of Color, 16 GENDER& SOC'Y 175 (2002).
288. See Hiromi Itoh, A -- 0 * L- IL A ©* Km: 7, i L 5/ © w O L A 3
A [Control of Melanin Pigment andResearch and Development of Whitening Cosmetics: Functions
and Whitening Effect ofPlacenta], 6 FRAGRANCE J. 67, 67 (1990) (suggesting that the author found
a whitening effect in placenta) (Japan); Hyun-Jin Kim et al., - SK30 0_1 NJ]-At
'I- Ai ]-'1 tyrosinase, TRP-1 34 TRP-2 86 1V]S Al I [The Effect of Placental
Extract on the Expression of Tyrosinase, TRP-1 and TRP-2 in SK30 Melanoma Cells], 41 KOR. J.
DERMATOLOGY 1612, 1612 (2003) (claiming that the authors' research showed that "placental
extract inhibited the melanogenesis of SK30 melanoma cells" and "showed antimelanogenic effect
by inhibiting the synthesis of tyrosinase, TRP-1 and TRP-2 mRNA," and concluding that "placental
extract might be a good therapeutic regimens [sic] for UV-aggravated pigment disorders including
melasma"); Prajnamoy Pal et al., A Human Placental Extract: In Vivo and In Vitro Assessments of
Its Melanocyte Growth and Pigment-Inducing Activities, 41 INT'L J. DERMATOLOGY 760, 760
(2002) (study conducted in India on a guinea pig and mice that purports to show that human placental
extract has "therapeutic potential for the repigmentation of vitiligo patches").
289. Maryann Donovan et al., Personal Care Products that Contain Estrogens or Xenoestrogens May
Increase Breast Cancer Risk, 68 MED. HYPOTHESES 756, 758 tbl. 1 (2007) (noting that, as of 1994
and among the widely-used personal care products that contained estrogen, at least four skin
products from the brand Nu Skin contained human placental extract).
290. Chandra M. Tiwary & John A. Ward, Use of Hair Products Containing Hormone or Placenta by
US Military Personnel, 16 J. PEDIATRIC ENDOCRINOLOGY & METABOLISM 1025 (2003).
291. Id. at 1027.
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hierarchy.292 Use was more frequent among African-Americans than other racial
groups.293
The raced dimension of human and animal placenta-based hair products
marketing and consumption is particularly concerning for Black children given
that the use of cosmetic products among children parallels use by their parents.
294
A 1998 case study investigated the effects of hair care products containing
estrogens and human or bovine placenta on four African-American girls between
the ages of 1.2 years and 7.8 years.29 5 The study found that the girls began to
develop breasts and pubic hair two to twenty-four months after starting to use
the products and that regression of sexual characteristics occurred after they
discontinued use.2 96 Maryann Donovan and her colleagues hypothesized that the
use of hormone-containing personal care products "in young African American
women accounts, in part, for their increased risk of breast cancer prior to
menopause, by subjecting breast buds to elevated estrogen exposure during
critical windows of vulnerability in utero and in early life. '297 They underlined
that consumers were unaware of their exposure given that not all products listed
hormones or placenta as an ingredient.298 The application of placenta-containing
products thus contributed to cumulative lifetime exposure to estrogen-a risk
factor for breast cancer.
299
That human placenta-based personal care products circulated widely until
recently should not come as a surprise considering the lenient federal regulation
of cosmetics compared to the regulation of drugs and medical devices. The
FD&C Act does not require cosmetic products and ingredients to be approved
by the FDA before they go on the market.300 Marie Boyd and other scholars have
argued that this lax regime has a disparate impact on people who identify as
women and members of other excluded groups. 30 1 Boyd points out that though
292. Id. at 1031. The authors note, though, that "[tihis is more likely to be the result of the distribution of
ethnic groups among the ranks than to be a direct effect of rank." Id.
293. Id. at 1026.
294. P.A. Zimmerman, G.L. Francis & M. Poth, Hormone-Containing Cosmetics May Cause Signs of
Early Sexual Development, 160 MIL. MED. 628 (1995) (finding, in their study of children for
evaluation of sexual precocity, that all of those using hormone-containing hair-care products were
Black).
295. Chandra M. Tiwary, Premature Sexual Development in Children Following the Use of Estrogen- or
Placenta-Containing Hair Products, 37 CLINICAL PEDIATRICS 733,737 (1998).
296. Id.
297. See Donovan et al., supra note 289, at 756.
298. Id. at 763-62.
299. Id. at 756.
300. 21 U.S.C. §§ 361-63. Color additives are the only cosmetic ingredients which mustbe pre-approved
by the FDA.
301. See generally Marie Boyd, Gender, Race & the Inadequate Regulation of Cosmetics, 30 YALE J.L.
& FEMINISM 275, 289 (2019) (critiquing the underregulation of cosmetics and its disproportionate
impact on women, particularly women of color and low-income women).
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"men use cosmetics, cosmetics are strongly associated with women and
femininity, and, on average, women use more cosmetics." 30 2 Among them,
African-American women spend more than any other group on cosmetic
products.303 Boyd also emphasizes that "[c]osmetic use may not be voluntary for
women," who are under various societal pressures to use them or holdjobs in the
beauty industry involving exposure. 30
4
The FDA's regulation of cosmetic labeling is often the principal legal means
to protect consumers, but the FDA's regulation of placentas may not adequately
safeguard non-expert consumers. The FD&C Act prohibits "misbranding" of
cosmetics, which includes false or misleading labeling by claims about a product
or inaccurate labeling. 305 The FDA recommends that placental extract be
identified by a name other than "placental extract," describing its composition
more accurately on the ground that consumers associate the phrase "placental
extract" with certain biologically active compounds for therapeutic use.3 0 6 This
guidance may not prove protective for consumers unfamiliar with cosmetic
ingredients and the associated jargon.30 7 Products claiming to contain placental
extract may also be deemed to be misbranded cosmetics if the extract has been
prepared from placentas from which the hormones and other biologically active
substances have been removed and the derived substance consists principally of
protein.30
8
Another problem is that manufacturers have little incentive to disclose their
products' hormonal content given that the FDA regulates products listing
hormones as ingredients as new drugs.309 Products regulated as new drugs must
undergo a lengthy and multi-million-dollar approval process, including
conducting several phases of clinical investigations. To compound the issue,
Donovan and her co-authors observed that "manufacturers are not currently
required to disclose ingredients that they consider trade secrets nor are they
required to report on past formulations of their products." 310 Until a few years
302. Id.
303. See Rajiv Shah & Kelly E. Taylor, Concealing Danger: How the Regulation of Cosmetics in the
United States Puts Consumers at Risk, 23 FORDHAM ENVTL. L. REv. 203, 212 (2011).
304. See Boyd, supra note 301, at 290-91.
305. Food, Drug, and Cosmetic Act § 602,21 U.S.C. § 362.
306. 21 C.F.R. § 301.530 (1995).
307. The proliferation of cosmetic dictionaries and glossaries evinces the complexity of cosmetic-related
terminology. See, e.g., RUTH WINTER, A CONSUMER'S DICTIONARY OF COSMETIC INGREDIENTS:
COMPLETE INFORMATION ABOUT THE HARMFUL AND DESIRABLE INGREDIENTS FOUND IN
COSMETICS AND COSMECEUTICALS (7th ed. 2009).
308. See 21 C.F.R. § 310.530 (2019) (stating that "any OTC drug product that is labeled, represented, or
promoted as a topically applied hormone-containing product ... is regarded as a new drug. . . for
which an approved application.., is required for marketing.").
309. See id.
310. See Donovan et al., supra note 289, at 764.
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ago, North American distributor Flawless Beauty and Skin sold human placenta-
based products in the United States, such as Laennec Human Placenta Whitening
and Authentic Relumins Advance Whitening Facial Cream.3" The FDA took
Flawless Beauty to court on the ground that this product as well as a dozen of
others were new drugs, not cosmetics, and were misbranded given that they did
not follow the new drug application process. 312 In the 2017 consent decree
entered by the U.S. District Court of New Jersey the company was ordered to
stop selling, recall, and destroy its incriminated products.313 Of those containing
human placenta, the complaint noted that they "can harbor microbes that can
cause serious infections, including hepatitis, I-V, and herpes, among others."
314
After examining the contrasting ways in which third parties' access and use
of placentas is regulated, the next section explores whether and how people who
grow placentas are allowed to repossess them.
B. The Law ofAccess to One's Placenta
1. The Regulation of Placenta Release
A number of formal and informal laws and regulations at the state, local, and
institutional levels control whether individuals can repossess their placentas
from healthcare facilities and under what conditions.
Since 2006, a few states have enacted laws protecting birthing parents'
access to their placenta. In those states, new parents can now assert a right to
obtain the release of their placenta subject to a set of requirements. The state of
Hawai'i was the first to require explicitly that hospitals allow women or their
designees to take their placentas home. This legal change was the outcome of
311. See Trendy Asian Skin Care ProductReady to Dominate the American Market, PRNEWSWRE (Oct.
10, 2012, 8:30 AM ET), https://www.prnewswire.com/news-releases/trendy-asian-skin-care-
product-ready-to-dominate-the-american-market-173475281 .html [https://perma.cc/724P-QWQG].




313. See Federal Judge Orders Flawless Beauty to Stop Distributing UnapprovedDrugs, Recall Certain
Products, U.S. FOOD & DRUG ADMIN. (Sept. 26, 2017),
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/Ucm577565.htm
[https://perma.cc/T46N-VKVU] (prohibiting Flawless Beauty and affiliated company RDG Imports
from importing, manufacturing, or distributing any drug products until they comply with the Food,
Drug, and Cosmetic Act). Products containing placental extract are considered to be misbranded
drugs when their labeling contains statements implying the prevention or treatment of disease or
effect on the structure or any function of the human body, such as the promise of stimulating tissue
growth and removing wrinkles. See Complaint for Permanent Injunction at 4, United States v.
Flawless Beauty, No. 3:17-cv-07091 -PGS-TJB (D.N.J. Sept. 12, 2017); see also 21 C.F.R. § 201.300
(2019); CTR. FOR FOOD SAFETY & APPLIED NUTRITION, COSMETIC HANDBOOK 12-13 (1989)
[hereinafter COSMETIC HANDBOOK].
314. Complaint for Permanent Injunction, supra note 313.
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mobilization by Native Hawaiian groups after the state Department of Health
decided to classify the placenta as infectious waste in 2005.315 This designation
meant that placentas could be withheld from birthing parents and their families
by healthcare facilities and disposed of as other medical infectious waste despite
the fact that "Native Hawaiians view the placenta with cultural significance in
which the placenta is cared for in respectful ways involving ritual ceremonies
and proper burial back to the earth followed by a planting of a tree symbolizing
the child's connection back to the earth., 31 6 The new Hawai'i statute, passed in
2006, does not grant an absolute right to obtain the release of one's placenta,
however. The law specifies that a placenta will only be released "[u]pon negative
findings of infection or hazard after appropriate testing of the mother" and after
a "release form stipulating appropriate measures" for its "safe release" has been
signed by the woman or her designee.317
Through this language of infection, risk, and safety, the placenta is legally
constructed as a biological hazard, even in a state with an extensive history of
safe placenta burial practices. No case of disease transmission has been reported
in association with Native Hawaiians' long tradition of handling the placenta.
This safety record raises the question whether the health risk rhetoric reflects
medical and legal institutions' histories of restricting women's agency over their
bodies under the guise of protecting them, their children, and the general public.
In the context of Hawai'i, this approach also represents an enduring form of
medical colonialism, whereby colonists attempt to impose their views on health
and disease so as to control colonized populations. 318 Women in their
reproductive capacity in particular bear the brunt of past and ongoing medical
colonialism given their crucial role in population renewal and growth. Much like
other aspects of women's reproductive freedom have been constrained-whether
and when to get pregnant, where and how to deliver babies, whether and how
long to breastfeed-the decision of what to do with the placenta continues to be
determined in part by white medical norms and values.
Since 2006, three additional states-Connecticut, Oregon, and Texas-have
enacted legislation allowing the birth family to obtain a placenta from a
healthcare facility.319 Similar to Hawai'i, these states only permit release of the
placenta after the birthing parent has tested negative for infectious diseases,
315. See Lauer, supra note 17.
316. See Celia T. Bardwell-Jones, Placental Ethics: Addressing Colonial Legacies and Imagining
Culturally Safe Responses to Health Care in Hawai'i, 13 PLURALIST 97, 97 (2018).
317. HAW. REV. STAT. § 321-30 (2018).
318. ARTHUR W. FRANK, THE WOUNDED STORYTELLER: BODY, ILLNESS, AND ETHICS 10 (1997) ("Just
as political and economic colonialism took over geographic areas, modernist medicine claimed the
body of its patient as its territory.").
319. CONN. GEN. STAT. § 19a-490v (20.18); OR. REV. STAT. § 459.400 (2018); OR. ADMIN. R. 333-056-
0045 (2018); TEx. HEALTH & SAFETY CODE ANN. § 172.002 (2018); 25 Tex. Admin. Code § 137.38
(West 2019).
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signed a release form, and been instructed on proper handling. They add the
condition that the placenta is for personal, not commercial use. 320 Each
individual state includes its own additional restrictions. For instance, in
Connecticut, physicians can send the placenta to pathology for examination
against the will of the postpartum parent and their spouse. 321 Release after
examination by the pathology department is usually not recommended because
placentas are typically retained for several weeks and fixed in formalin,
rendering them toxic and therefore unusable for ingestion or external
application.322
Short of legislating, a few other states have developed guidelines or different
forms of regulations for placenta release. For example, in 2010, the
Massachusetts Department of Public Health issued a guidance document to
healthcare facilities throughout the state holding that placentas claimed by
patients were not "discarded" materials within the meaning of the state's waste
statute.323 Placentas can therefore be released on similar terms as in Hawai'i,
Connecticut, Oregon, and Texas. So long as no infectious risks have been
established, Massachusetts patients can repossess their placenta after being
provided instructions on safe handling, signing a written authorization, and
packing it in a designated, labeled container.324 Also in 2010, the New York State
Department of Health released an unofficial statement to the effect that hospitals
and medical facilities may, at the request of a patient or patient's representative,
return a "healthy placenta" for disposition by the patient without violating any
New York public health law or regulation. 325 Birthing parents and their families
should no longer need to reclaim their placenta from the morgue or a funeral
director as some facilities used to require.326
Still other states allow for the placenta to be released under more specific
circumstances. Arkansas, for example, permits a physician who has separated
human tissue from other medical waste to "authorize disposition of the human
320. Id.; see also TEX. ADMIN. CODE § 138.3 (2018) (exempting "placentas designated for sale and
obtained from a licensed hospital or a licensed birthing center" from the medical disposal
requirements, but not specifying the process through which a placenta is designated for sale).
321. CONN. GEN. STAT. § 19a-490v (2018).
322. Rebecca N. Baergen, Harshwardhan M. Thaker & Debra S. Heller, Placental Release or Disposal?:
Experiences of Perinatal Pathologists, 16 PEDIATRIC & DEVELOPMENTAL PATHOLOGY 327, 328-
29 (2013).
323. Memorandum from Lauren Smith, Med. Dir. & Chief Med. Officer, and Alfred DeMaria, Med. Dir.,
Mass. Exec. Office of Health & Human Serv., Dep't of Pub. Health, to CEOs of hosp. licensed to
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tissue in a respectful and proper manner," including releasing the placenta to the
patient. 327 Maryland excepts "fetuses and placentas that are released to a funeral
director or parent" from its medical waste requirements, although it is unclear
from the statutes and regulations what the release protocol entails.328 New Jersey
exempts anatomical organs and body parts (which may include placentas) from
the state's medical waste disposal requirements if the owner's intent is to inter
or cremate them. 329 New Mexico requires that freestanding birth centers develop
policies and procedures for "safe handling of the placenta for families requesting
to keep the placenta," permitting its release without a court order.330
Even in states that have no law on the books pertaining to placenta release,
based on the principle according to which everything which is not forbidden is
allowed, birthing parents should be able to obtain the release of their placenta in
the absence of contrary state statutes, regulations, or guidance documents. 331
Doula Courtney Durfee 332 created a google spreadsheet in 2010 to "better
understand the state and regional variations in placenta release regulations and
protocols. '333 Durfee obtained information by contacting state officials (such as
local departments of health and EPA offices) and hospital staff (pathologists,
infection control nurses, and lab directors) to inquire about the policies in place
in their state. The document is not up-to-date, but in most states informers
reported that due to the inexistence of specific legal provisions on the placenta,
327. ARK. CODE ANN. § 20-17-801 (a)(1)(B) (West 2019) (specifying that patients or their designees can
make a written request that their human tissues be returned to them and explicitly defining human
tissue to include the placenta); § 20-17-801(a)(2) (providing that "[h]uman tissue shall not be
delivered except as may be permitted by rules of the State Board of Health," although there do not
appear to be any rules of the State Board of Health related to placenta). Mississippi seems to follow
a similar legal regime. See MISS. CODE. ANN. § 41-39-1 (2019) (providing that patients or their
designees can make a written request that "any tissue of the human body" be delivered to them after
scientific examination by a physician, explicitly including placenta). As suggested by the example
of Jordan Thiering discussed supra p. 5, this Mississippi provision may not have been be consistently
interpreted as supporting the release of placentas. Nevertheless, the Thiering case seems to have led
to a policy change allowing hospitals and birthing centers to adopt their own internal policies on the
release ofplacentas. See Corky Siemaszko, Mississippi Mom Gets State to Change Placenta Policy,
NBC NEWS (Sept. 16, 2016, 12:17 PM MST), https://www.nbcnews.com/news/us-
news/mississippi-mom-gets-state-change-placenta-policy-n649596 [https://perma.cc/PB8V-
ZKAX].
328. MD. CODEREGS. 10.06.06.01 (2018).
329. N.J. ADMIN. CODE § 7:26-3A.6 (2018). This code does not explicitly mention placentas, but may
apply to placentas as organs.
330. N.M. CODE R. § 7.10.2.23 (LexisNexis 2019).
331. See Jeremy Waldron, The Rule of Law, STAN. ENCYCLOPEDIA PHIL. (June 22, 2016),
https://plato.stanford.edu/entries/rule-of-law [https://perma.cc/5FZW-H8GR] (noting "the Rule of
Law generates a presumption in favor of liberty: everything which is not expressly prohibited is
permitted").
332. See About Us, CD DOuLA SERVICES, https://www.cddoula.com/about-me.php
[https://perma.cc/Q5RT-D89G].
333. Courtney Durfee, US Placenta Laws, GOOGLE DOCS (2010),
https://docs.google.com/spreadsheets/d/1 IFz9ePkYlllxSlckq679EF3Iuy44RTB3h-uU23pU6m
[https://perma.cc/S3ZC-PCVL].
Yale Journal of Law and Feminism
patients should be able to obtain its release. Depending on the state, Durfee
reports that individuals need to comply with hospital policies such as testing
negative for diseases, signing a waiver form, or demonstrating that their request
is motivated by cultural or religious beliefs.
In addition to traditional, legally binding rules, the placenta is the object of
a growing body of regulations emanating from healthcare facilities or
intermediaries involved in placenta consumption. OBGYNs, labor and delivery
doctors, midwives, nurses, pathologists, and other medical personnel have
devised policies to allow or prevent patients from taking their placentas home.334
Weill Cornell Chief of Perinatal and Obstetric Pathology Rebecca Baergen and
her colleagues surveyed thirty-six practicing perinatal pathologists in the United
States and Canada in 2013 to investigate policies in place for the release of
placentas. 33 Most respondents (66%) stated that their institution allowed the
release of placentas, but 11% reported that theirs specifically prevented release.
Increasingly, healthcare facilities have developed formal guidelines to address
issues of liability and to comply with the relevant law on the handling and
disposal of infectious waste. These internal rules and policies cover issues such
as whether and under what conditions placental tissue can be released to patients
or used for research or other purposes. They are rarely public, representing a
hidden form of placenta law. Patients typically fird out about how their placental
tissue will be handled only if they are solicited for donation or specifically
inquire about taking it home.
A few healthcare systems have made their placenta release policies public,
however, revealing wide differences in this uncoordinated body of semi-hidden
law. Some restrict the purpose for which the placenta can be released; others
restrict the timing; still others delineate the type of container to be used and the
location where the placenta can be consumed. For instance, the Association of
Washington Public Hospital Districts, which serves as the trade association for
Washington State's public hospital districts, requires that placentas remain
stored at the hospital for one week after delivery so that they can be sent for
pathological examination should the newborn develop complications. 336
Placentas can be released after that, but by then it could be too late for people
wishing to eat or encapsulate theirs fresh. 3 The Naval Medical Center
334. See Bardwell-Jones, supra note 316, at 99 (noting that even before Hawai'i explicitly protected
women's and families' rights to recover their placentas from healthcare facilities, Hawaiian doctors
discretely allowed them to take the placentas off hospital premises); see also Abrahamian, supra
note 55 (reporting that New York hospitals refused to return placentas to patients as recently as
2011).
335. See Baergen, Thaker & Heller, supra note 322.
336. Policy Regarding Placentas, ASS'N WASH. PUB. HOSP. DISTRICTS (Oct. 9, 2000),
https://www.awphd.org/wp-content/uploads/2017/05/Placentas.pdf [https://perma.cc/5LSX-G576].
337. Placenta Encapsulation FAQ, ABC DOULA SERV. (2018), https://www.abcdoula.com/postpartum-
service/placenta-encapsulation-faqs [https://perma.cc/J48Z-QPQ6] (advising women to ask
hospitals that retain placentas for seven to fifteen days postpartum to freeze them so that the
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Portsmouth, the U.S. Navy's oldest hospital, which includes ten branches and
clinics in Virginia, limits release to requests "based on cultural and religious
beliefs." '3 38 Allina Health, a care system that owns and operates thirteen hospitals
and dozens of clinics throughout Minnesota and Wisconsin, issued a
comparatively liberal policy in 2017, allowing patients to take possession of their
placenta so long as they consume it in the delivery room.339
In addition to this patchwork of laws governing placenta release directly,
individuals' access to their placenta may also be regulated indirectly via state
fetal burial laws typically aimed at curbing the right to abortion, which are
discussed in the next section.
2. Fetal Burial Laws
The law of placenta has become embroiled in antiabortion politics via
restrictions on the disposition of fetal remains in a way that highlights the
intersection of reproductive justice and placenta access. In some states, fetal
tissue is assimilated to other forms of medical wastes in terms of hazard
perception and treatment,34 ° and therefore disposed of in the same fashion. It is
typically sent to medical waste disposal companies to be incinerated or disposed
of through other methods.34 1 In other states, fetal burial laws have spread that
allow patients to repossess or direct the disposal of their fetal remains via burial,
entombment, and cremation, or mandate medical facilities to handle fetal
remains in similar ways, excluding them from standard management of medical
waste. As part of the growing movement for fetal legal personhood in particular,
several jurisdictions imposed stringent limitations on the use of fetal tissue
during the 2016 legislative session.342 These laws are often inspired by model
legislation compiled by Americans United for Life, a pro-life public interest
group aimed at treating dead embryos and fetuses as deceased persons for the
placentas can still be consumed upon release or be encapsulated, as the process of encapsulation
must in principle start within twenty-four to forty-eight hours postpartum).





339. ALLINA HEALTH, SYSTEM-WIDE POLICY: PLACENTA HANDLING (Jan. 2017).
340. See Mallory Duncan, Indiana Fetal Remains Bill Puts Spotlight on Fetal Disposal, WISHTV (Feb.
21, 2016, 4:45 PM EST), https://wishtv.com/2016/02/21/indiana-fetal-remains-bill-puts-spotlight-
on-fetal-disposal [https://perma.cc/VX8G-PKJMfl ("Most states treat fetal tissue from an abortion as
medical waste because it's typically considered to be infectious or potentially infectious").
341. See Kimball Key, supra note 197, at 314-15 (2017) (discussing the laws pertaining to the disposal
of fetal remains).
342. Id. at 309-10.
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purpose of disposal laws. 3 4 3 Some versions mandate that fetal remains from
abortions and miscarriages be interred or cremated as the only "dignified" way
to dispose of a fetus, and are backed by criminal sanctions. 3" Providers of
obstetrical services must thus dispose of fetal remains in the same manner as
cadavers, that is, by burial, interment, or cremation. The requirement poses
logistical and financial challenges considering that fetal cremations can cost
around $500 each and burials more than twice that figure.345
Different states define fetal tissue differently, with some explicitly including
the placenta in their definition, others explicitly excluding it, and still others
saying nothing at all about placentas. The resulting paradox is that in some states
legislation that restricts patients' choice when it comes to whether, how, and
when to terminate their pregnancy may result in more choice when it comes to
deciding what to do with their placenta in the context of pregnancy termination
and loss than live or still birth. The relevant Indiana statute,34 6 for example,
empowers patients who had a miscarriage or an abortion to decide the final
disposition of the deceased fetus, allowing them the option to take possession of
the related placenta; yet the state does not guarantee patients who have live or
stillbirths the same option.347 Louisiana permits people who undergo abortions
or experience a miscarriage to arrange for the final disposition the fetal
remains, 348 which presumably include the placenta, 349 but does not codify the
same option for full-term deliveries. Conversely, in other states, patients may
end up having more decision-making autonomy over their dead fetuses narrowly
defined than over their placentas. This is the case in jurisdictions that specify that
fetal remains should be handled separately from medical waste, without
including the placenta in the definition of fetal remains, resulting in patients'
being able to make decisions as to the disposal of the fetus but not its related
placenta. 350 The issue of the disparate treatment between placentas and other
343. Id. at 319.
344. Id.
345. See Dov Fox, I. Glenn Cohen & Eli Y. Adashi, The Law and Ethics of Fetal Burial Requirements
for Reproductive Health Care, 322 J. AM. MED. ASS'N 1347, 1347 (2019).
346. The Supreme Court upheld the portion of the statute excluding fetal remains from the definition of
infectious and pathological waste, thereby requiring abortion providers to bury or cremate fetal
remains in Box v. Planned Parenthood of Indiana and Kentucky, 587 U.S. _, 139 S. Ct. 1780
(2019).
347. IND. CODE ANN. § 16-34-3-2 (West 2017).
348. LA. ADMEN CODE. tit. 48, § 4431 (2019); see also LA. STAT. ANN. § 40:1191.2 (2019).
349. LA. ADMIN. CODE tit. 48, § 4401 (2019) (defining "Products of Conception" as "placenta, amniotic
sac or membrane, embryo, or fetal elements that result from a human pregnancy").
350. Illinois is such a state, as it specifically requires that someone experiencing a miscarriage at less than
twenty weeks of gestation have the "right to arrange for the burial or cremation of the fetus," see
ILL. ADMIN. CODE tit. 77, § 500.50 (2019), but no right to the placenta, which is explicitly defined
as pathological waste andmust "be disposed of by a waste hauler with a permit from the Illinois
Environmental Protection Agency," see ILL. ADMIN. CODE tit. 77, § 265.2050 (2019). See also ALA.
CODE § 26-23F-4 (2019) (providing that "[t]he mother, father, or authorized representative may
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fetal tissues, on the one hand, and between the treatment of fetal tissues and
placentas in the context of abortions, miscarriages and live or still births, on the
other hand, has not been challenged in court. However, in its 2019 Box decision,
the Supreme Court upheld Indiana's statute requiring interment or cremation of
fetal remains in a per curiam opinion, overturning the Seventh Circuit below. 351
The Court applied the rational basis standard on the ground that no fundamental
right was implicated by the fetal remains provision. The statute met the test, in
the Court's view, as states have a "legitimate interest in proper disposal of fetal
remains" 352 and the provision at stake, though "not perfectly tailored," was
sufficiently rational. 3
3. A Fundamental Right to One's Placenta?
Is the Supreme Court correct that no fundamental right is involved in the
disposal of fetal tissues, placenta included? A full discussion of the regulation of
fetal tissues would take me too far afield, but as others have argued, restricting
individuals' decision-making over their placenta infringes upon their individual
rights over their bodies and life.354 Pregnant people grow placentas with their
own bodies and the organ has a symbolic meaning that transcends its materiality.
It is meaning-making in such a way that preventing access to it can profoundly
request the release of the bodily remains to the mother, father, or authorized representative for
dignified final disposition by burial, interment, or cremation," but not stating whether "bodily
remains" include placentas); COLO. REv. STAT. ANN. § 25-2-110.5 (West 2019) (providing that "[i]n
every instance of fetal death, the health care provider, upon request of the pregnant woman, shall
release to the woman or the woman's designee the remains of a fetal death for final disposition in
accordance with applicable law," but not stating whether placentas are included in the definition of
medical waste in COLO. CODE REGS. § 1007-2:1-1.2 (2019)); IDAHO CODE ANN. § 39-9304 (,Vest
2019) (allowing patients and their representatives "to direct the receipt and disposition of [the]
deceased unborn infant's bodily remains" in cases of miscarriage and stillbirth without specifying
whether those remains include the placenta); MICH. COMP. LAWS ANN. § 333.2848 (West 2019)
(entitling parents to direct the final disposition of a dead fetus by interment or cremation); MICH.
COmP. LAWS ANN. § 333.13807 (West 2019) (defining the placenta as a "product of conception"
distinct from the "fetus or fetal body parts"); MINN. STAT. § 137.47 (2019) (defines "fetal tissue" as
not "includ[ing] tissue or cells obtained from a placenta, umbilical cord or amniotic fluid"); MINN.
STAT. ANN. § 145.1621 (West 2019) (providing for the dignified and sanitary disposition of the
remains of aborted or miscarried human fetuses); MISS. CODE. ANN. § 41-39-1 (West 2019)
(allowing "the mother of the dead foetus or her spouse" to object to its disposal as standard medical
waste, but indicating that "a dead foetus is defined as a product of human conception, exclusive of
its placenta"); OKLA. STAT. ANN. tit. 63, § 3129 (West 2019) (providing that a "parent of the child
shall have the right to direct the disposition of the remains"); OKLA. ADMIN. CODE § 310:616-5-2
(2019) (defining placentas as biomedical waste);
351. Box, 587 U.S.
352. City of Akron v. Akron Ctr. for Reprod. Health, 462 U.S. 416,452 n.45 (1983).
353. Box, 587 U.S. at 2.
354. See Lynnea Shrief, Before You Judge or Scrunch up Your Face, Just Let Me Explain Why IAte and
Drank My Child's Placenta, INDEP. (Mar. 20, 2015, 4:09 PM),
https://www.independent.co.uk/voices/comment/before-you-judge-or-scrunch-up-your-face-just-
let-me-explain-why-i-ate-and-drank-my-childs-placenta- 10123099.html [https://perma.cc/7SHY-
D4SS] (framing placenta consumption as a woman's "right").
Yale Journal of Law and Feminism
violate an individual's right to make decisions affecting their body, intimacy,
and privacy.
The right to repossess one's placenta, or at least make informed decisions as
to who can access it and under what conditions, could be understood under a
property or privacy right framework, or both. Radhika Rao has shown that the
property and privacy constructions of the body overlap in that both protect the
same interests-the right to possess one's own body.355 Under a property theory,
interfering with patients' access to their own placentas or taking placenta without
asking for their informed consent would be a deprivation of bodily property or
"taking" requiring the payment of just compensation under the Fifth and the
Fourteenth Amendments. 356 Amber Goeden thus argues in favor of a property
right in placentas granting women full access protected by a carve-out in OSHA
regulations. 357 Another approach would be to conceive of people's interest in
their placentas as falling under the umbrella of constitutional privacy,358 on the
model of the rights to marriage, contraception, or abortion.359 Privacy not only
guarantees individuals a certain degree of autonomy over their bodies, but also
safeguards the freedom to make certain decisions free from governmental
interference-be it to refuse that their fetal remains be cremated or buried or to
take possession of their fetal tissues, including their placenta. Under both
theories, laws or regulations depriving pregnant people of the right to choose
what to do with their placentas would be subject to strict scrutiny.
Restricting people's access to their placentas could also be held to violate
another type of right--collective cultural and religious rights. 360 Current law,
along with mainstream, medically-oriented birthing practices, represent forms of
enduring colonialism for people and communities for whom the placenta has
cultural or religious significance. 361 Writing about the case of Hawai'i, Celia
Bardwell-Jones emphasizes that the placenta must be thought of in the context
of the history of colonization and the rejection of native Hawaiian mothering and
355. Radhika Rao, Property, Privacy, and the Human Body, 80 B.U. L. REv. 359, 366-367 (2000).
356. This theory is likely to fail in court given the Moore precedent. See Moore v. Regents of the Univ.
of Cal., 793 P.2d 479 (Cal. 1990) (finding that the patient had no property interest in his own bodily
cells, while scientists who developed products from the patient's cells had a property interest in
them).
357. See Goeden, supra note 21, at 190-98.
358. Griswold v. Connecticut, 381 U.S. 479, 484 (1965) (holding that various constitutional provisions
"create zones of privacy").
359. Id.; Zablocki v. Redhail, 434 U.S. 374, 384 (1978) (categorizing "the decision to marry as among
the personal decisions protected by the right of privacy"); Roe v. Wade, 410 U.S. 113 (1973)
(establishing a right to abortion as part of the broader right to privacy).
360. See generally Yvonne Donders, Foundations of Collective Cultural Rights in International Human
Rights Law, in CULTURAL RIGHTS AS COLLECTIVE RIGHTS: AN INTERNATIONAL LAW PERSPECTIVE
87 (Andrzej Jakubowski ed., 2016).
361. See supra note 3 18 and accompanying text.
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birthing practices.362 She points out that in native Hawaiian culture, "the moral
virtue of the child is dependent on the proper care of the placenta. Understanding
the placenta as biological waste already places the child in a moral crisis
throughout its life. 3 63 Some medical providers are sensitive to the specific
birthing needs of their patients. For example, the Metropolitan Chicago
Healthcare Council adopted "Guidelines for Healthcare Providers Interacting
With American Indian (Native American; First Nation) Patients and Their
Families," which include "saving of the placenta." 364 But in other medical
settings, securing the release of a placenta, even for cultural and religious
reasons, remains an uphill battle.
Until recently, individuals who valued and retained their placentas for
cultural and spiritual reasons were primarily from African, Asian, Latinx, and
Native American backgrounds. Today, though, affluent, college-educated white
women are the most likely to secure access to their placentas.365 Accessing one's
placenta requires resources-social, financial, and epistemic. Patients typically
need to research whether release is authorized and on what conditions; they must
sometimes pay fees to repossess their placenta, for example when they are only
released to licensed funeral directors commanding a fee or after a court order.366
Birthing parents wishing to ingest their placentas often hire encapsulators, which
is not only costly, 367 but also requires its own administrative labor of researching
and interviewing providers. They and their families are also responsible for
ensuring that the placenta is collected and stored properly. This entails arranging
for a container (and sometimes a cooler when the facility provides neither ice
nor refrigeration) as well as assigning someone the task of transporting the
placenta home soon after the birth.
Accordingly, placentophagy has been critiqued as a neo-liberal or capitalist
form of consumption associated with intensive motherhood, the dominant
362. See Bardwell-Jones, supra note 316.
363. Id. at 106.
364. Guidelines for Healthcare Providers Interacting with American Indian (Native American; First
Nation) Patients and Their Families, METROPOLITAN CHI. HEALTHCARE COUNCIL (2004),
https://www.kyha.com/assets/docs/PreparednessDocs/cg-native-american.pdf
[https://perma.cc/Z9B9-39XS].
365. Granted, I know of no empirical studies quantifying placenta-release requests based on race,
ethnicity, or class. Nor are there data available on the motivations behind requests for release. See
Selander et al., supra note 52; supra note 85 and accompanying text (providing demographics of
women encapsulating and eating their placentas, not of women requesting the release of their
placentas).
366. See Arielle Pardes, Hospital Regulations Are Forcing Women to Steal Their Own Placentas, VICE
(Sept. 24, 2014, 11:08 AM), https://www.vice.com/enus/article/xd57m3/heres-why-women-are-
stealing-their-own-placentas-924 [https://perma.cc/EL2Y-M8X9] (noting that, in Austin, Texas it
would have cost one of the women interviewed $250 to obtain her placenta via a court order and
"slightly less" to have it sent to the morgue).
367. See Farr et al., supra note 67, at 403.
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mothering ideology among middle-class white women. 368 Intensive motherhood
holds individual mothers primarily responsible for child-rearing through a
process which is child-centered, expert-guided, emotionally absorbing, labor-
intensive, and expensive. 369 The temporal range of mothers' responsibility
toward their children's health has been extended by medical advances to begin
prior to conception and to continue throughout pregnancy and beyond. Maria
Fannin has argued that private cord banking promotes a form of "hoarding" of
biological materials by encouraging parents to withdraw their donation from
public banks.370 Her arguments apply equally to placentas. The private banking
of placentas represents an extreme form of intensive mothering. 371 Today's
responsible mother is supposed to protect her children from future diseases and
to preserve potentially valuable biological materials for them. The maternal
experience is also increasingly a consumer's experience, especially for white,
middle-class, cisgender, straight mothers-it's about which products, services,
diagnostic tests they choose to purchase. Placentophagy figures among a range
of products and services aimed at pregnant or newly parent consumers-from
prenatal testing and yoga to postpartum doulas and massages.37 2 Diane Negra
argues that these consumption practices reinforce class exclusions, as this form
of consumerism is only available to the affluent able to devote substantial
amounts of time and money to their children.
373
This Part has argued that the placenta is regulated by a hodgepodge of laws,
regulations, and policies which sometimes conflict and yield counterintuitive
results. Placental economies exhibit convoluted circuits of sourcing, processing,
and distribution, with placentas classified and reclassified alternatively as waste
or highly valuable substance depending on the context and identity of those
seeking to obtain it. The inequities at work in these practices call for further
explorations with an eye toward legal change.
368. See Krolokke, Dickinson, & Foss, supra note 208, at 147-48.
369. SHARON HAYS, THE CULTURAL CONTRADICTIONS OF MOTHERHOOD (1998) (identifying and
critiquing the phenomenon of intensive mothering).
370. Maria Fannin, The Hoarding Economy of Endometrial Stem Cell Storage, 19 BODY & SoC'Y 32
(2013).
371. See KROLOKKE, supra note 30, at 131.
372. See Gillian Hewitson, The Commodified Womb and Neoliberal Families, 46 REv. RADICAL POL.
ECON. 489 (2014); see also MOTHERHOOD, MARKETS AND CONSUMPTION: THE MAKING OF
MOTHERS IN CONTEMPORARY WESTERN CULTURES (Stephanie O'Donohoe et al. eds., 2013) (on
the construction of pregnant women as specific types of consumers).
373. DIANE NEGRA, WHAT A GIRL WANTS? FANTASIZING THE RECLAMATION OF SELF IN POSTFEMINISM
9-10 (2009).
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Ill. ALTERNATIVE PLACENTA REGULATION
Rebecca Yoshizawa asks "who is empowered to define the terms and
conditions under which the placenta is collected and utilized in science and
medicine[?]" 374 To answer her question and identify a range of best practices that
public and private institutions might develop, more empirical data is needed on
the conditions under which placental tissue is collected, processed, and
distributed as well as on donors' attitudes and preferences. What happens to
placentas which remain unclaimed? What percentage are discarded versus
donated or sold? How are the donation or sale agreements negotiated between
healthcare facilities and third parties and what are their customary terms? There
is much more we must know about the circulation of placentas outside the body
and across supply chains before we can reach any firm conclusions about the
best way to proceed. But knowing the possible pathways forward should help
stakeholders make better choices in the present. After presenting various choice
architectures for placenta decisions, including how decisions are framed and
whether donors should be compensated, this Part explores avenues for regulating
third parties' access to and use of placentas.
A. Designing a New Choice Regime
1. Protecting Freedom of Choice
Under current legal regimes, neither federal nor state law recognize
individual ownership rights in human tissue samples used in medical research.375
Though there are state-to-state and healthcare facility-to-healthcare facility
variations, pregnant individuals are usually presumed to abandon their placentas
to the facility caring for them. This is not specific to the context of pregnancy
and placentas. Most medical centers require that patients admitted for treatment
or testing sign blanket consent forms stating that all their data or tissue samples
belong to the doctor or institution.376 In theory, patients can strike clauses they
disagree with, but most may feel be too intimidated and vulnerable at a time
when they might feel sick, pained, or frightened, and the staff may not allow
them to do so.377 This state of affairs fails to provide patients with freedom of
choice in the form of a meaningful opt-in or opt-out. They may be uninformed
374. Yoshizawa, supra note 29, at 11.
375. See, e.g., Moore v. Regents of the Univ. of Cal., 793 P.2d 479 (Cal. 1990); see also Rina Hakimian
& David Kom, Ownership and Use of Tissue Specimens for Research, 292 J. AM. MED. ASS'N. 2500
(2004) (explaining that when a body part or tissue has been extracted for diagnostic or clinical
purposes, it is thought to come under the ownership of the health care provider).
376. See Petrow, supra note 13.
377. Id.
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as to the fate of their placenta, lack the knowledge that they can opt out, or lack
the opportunity to opt out. Considering the demographic characteristics of those
who eat and encapsulate their placentas, there is a possibility that a greater share
of the placentas collected for research and other purposes originate from less
privileged or already marginalized groups. This discrepancy would not be
unprecedented. Michele Goodwin has shown that, in the context of organ
donation, Blacks and Latinxs are the overwhelming majority of presumed-
consent donors in some states. 378 She also suggested that even when women are
consulted on the donation of their placentas, their decision may not be fully
voluntary, writing, "the consent processes involved with these tissue donations
are frequently illusive. Hospitals, for example, may condition treatment on a
patient waiving her right to recover or destroy her tissue, including placentas."
379
In thinking about redesigning placenta decision-making frameworks,
competing values are at stake. Should the new rules be chosen based on whether
they promote patients' autonomy, public health, or third parties' access? Are
there relevant differences among pregnant people that would justify applying
personalized rules for some of them and not others? Various avenues are
available to the "choice architects," Cass Sunstein's term for the people or
institutions who design the social backgrounds against which individual choices
are made.380 The two approaches that secure the most autonomy are default rules
(understood as interventions that do not impose mandates or bans, but
nonetheless incline people's choices in a particular direction) and active
choosing (in which people are asked or required to make decisions on their
own). 38
1
Among default rules, two opposite versions of the background rule could be
set. The first would be for pregnant people to opt in, that is, to be specifically
asked to give their consent for their placenta to be donated, destroyed, or used in
any other way. 382 Consent would not be presumed. The second would be for
them to opt out. Their consent to donating their placenta to the healthcare facility,
whatever its future use, would be presumed. This default would require them to
object explicitly if they do not want to destroy or donate their placenta, but rather
378. Michele Goodwin, Empires of the Flesh: Tissue and Organ Taboos, 60 ALA. L. REV. 1219, 1238
(2009).
379. Id. at 1235.
380. Cass R. Sunstein, Deciding by Default, 162 U. PA. L. REv. 1, 5 (2013).
381. Id.
382. See generally Lior Jacob Strahilevitz, The Right to Destroy, 114 YALE L.J. 781 (2005) (showing that
the concept of property ownership has long included the right for proprietors to destroy their
property, even if current American law has restricted this feature in the past decades on the ground
that valuable resources must not be wasted). A woman's decision to destroy the placenta would
ensure that she permanently excludes third parties from using it. The argument that destroying
women's placentas wastes a valuable social resource is ill-founded given that many legal regimes
classify placentas as waste.
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want it released to them. Alternatively, active choosing would directly elicit
patients' preferences. They would be asked to make an explicit choice among
various options, such as the following: keeping their placenta, donating it for a
variety of purposes (research, medical, or commercial use), or relinquishing it at
the facility for disposal or storage.383 Should they decline to choose, one of the
two default rules could be applied.
These different choice architectures have costs and benefits. Defaults save a
great deal of time and efforts to all involved, but they are notoriously sticky.384
The current law of post-mortem transplantable organ donation is based on an
opt-in default. This results in most transplantable organs in the nation being
destroyed because a majority of Americans have not opted into donation even
though they have no more use for their organs. 385 This is in contrast to certain
European countries where donating organs is the default and people must
affirmatively opt out, resulting in much higher organ donation rates. 386 Similarly,
an opt-in regime for placentas, while protecting patients' agency, could diminish
the number of placentas available to third parties, in particular researchers and
doctors engaged in socially useful activities. An explicit opt-out default would
likely produce significant benefits for third parties by ensuring the continuing
availability and affordability of placental tissue. It could also benefit patients and
their families when placentas remain stored at the pathology department and
become useful for diagnostic or clinical care down the line in cases of pregnancy
complication or when the child becomes sick or develops disabilities.387 An opt-
out framework would differ from the status quo in that pregnant people would
have access to information that explicitly presents the option to opt-out of
keeping a placenta rather presuming that they opt out. Patients' freedom of
choice would be preserved, however, as the default would allow those who have
intense preferences to make their voice heard.388
Overall, active choosing would be most protective of individuals who want
to avoid any kind of steering by the government or healthcare providers. It could
be used to promote learning about the placenta and its uses via information
provided in support of the various options open for choice. That said, active
383. This could take the form of menus that offer decisionmakers a series of options. See generally Ian
Ayres, Menus Matter, 73 U. CHI. L. REV. 3 (2006) (exploring the regulation of menus).
384. See Sunstein, supra note 380, at 12 n.42 (explaining that default rules are often "sticky"--that is,
they establish a "reference point" from which decisionmakers do not like to move).
385. Richard H. Thaler & Cass. R. Sunstein, Libertarian Paternalism Is Not an Oxymoron (Univ. of Chi.
Working Paper No. 43, 2003).
386. See generally Eric J. Johnson & Daniel Goldstein, Do Defaults Save Lives?, 302 SCIENCE 1338
(2003) (comparing organ donation in presumed-consent and explicit-consent countries).
387. See, e.g., Jennifer K. Straughen et al., The Association Between Placental Histopathology and
Autism Spectrum Disorder, 57 PLACENTA 183 (2017) (arguing that placental assessment may
provide important insights into autism spectrum disorder).
388. See Sunstein, supra note 380, at 33-34 (2013) (discussing how people with intense preferences fare
in opt-out systems).
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choosing itself is not neutral and people's decisions may be affected by how the
various options are presented, such as the order and number of options. Active
choosing could also prove burdensome to patients, who already face difficult
decisions, producing confusion and frustration, and wasting time and effort.389
Until more information surfaces on the operation of the placenta markets, I
would favor adopting an opt-out regime all the while consciously experimenting
with the two other approaches so as to track and study the results.
2. How Much Freedom of Choice?
Should the right to obtain one's placenta be unconditional or should it be
balanced against other considerations such as the risk of contamination (to the
patients themselves, but also to their children, or others who handle or consume
the placenta)? Should people be permitted to reclaim their placenta over medical
providers' objections? There are instances in which the medical team believes
the placenta should be submitted to the department of pathology, or at least
withheld for a certain period at the hospital, for future testing. Placenta scientist
Harvey Kliman believes that all placentas should be stored at medical facilities,
creating a placenta archive available for physicians to better care for the birthing
parents, their children, and other family members, among other potential uses.390
Placenta analysis can reveal underlying health concerns for both parent and
child, explain adverse events during childbirth, and even predict, or help manage
future pregnancies. 391 Currently, in the context of hospital childbirth, the medical
392
team may decide to send a placenta to pathology without a woman's consent.
Healthcare facilities typically have in-house guidelines for placenta testing in
case of certain abnormalities,39 3 but some reports suggest that they sometimes
389. Id. at 8.
390. See supra note 150 and accompanying text (not all proposed uses of these archived placentas would
benefit patients and their families as they could also serve as evidence to defend physicians in
malpractice suits or in paternity suits and create privacy risks through their retention of children's
genetic and other information).
391. Baergen, supra note 153 (explaining that examining the placenta provides valuable information on
the cause and timing of many adverse events and conditions). As noted earlier, placentas can also
be tools in obstetric malpractice litigation. See supra note 151 and accompanying text.
392. Placental pathology is used to clarify the causes of adverse pregnancy outcomes. See Gitta Turowski
et al., The Structure and Utility of the Placental Pathology Report, 126 J. PATHOLOGY,
MICROBIOLOGY & IMMUNOLOGY 638 (2018) (explaining why placentas are sent to pathology,
arguing that pathologists write reports using unclear terminology that is hard for clinicians to
understand, and noting that "[s]ubmitting all placentas for pathologic examination is not clinically
indicated and would be fiscally disastrous for most institutions"); see also Deborah J. Gersell, ASCP
Survey on Placental Examination, 109 AM. J. CLINICAL PATHOLOGY 127, 127 (1998) (stating that
fewer than 25 percent of placentas delivered at institutions are sent to pathology).
393. See Farr et al., supra note 67, at 406 tbl.2 (summarizing the nationally accepted guidelines specifying
the indications to submit placentas to pathology).
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get tested needlessly at the expense of patients and the healthcare system. 3 9 4
Should birthing parents have the right to decline testing? Further research on the
costs and benefits of placenta pathology is required to fully address this issue,
but this need not be a zero-sum game. It would be conceivable for pathologists
and birth parents to exercise concurrent access over placentas. In cases in which
both groups want the placenta, the placenta could be sent to pathology for
observation, weighing, and sample excision, before the majority of the tissues
were returned to the family still fresh and unfixed within a twenty-four-hour time
frame.395
Some may challenge the idea of protecting women's decision-making
autonomy over their placentas on the ground that there is no reason to treat
placentas differently from other biological materials-for example, blood, skin,
saliva, urine, and feces-that are collected by healthcare facilities in the course
of diagnostic or therapeutic procedures and used for research, biobanking,
medicine, and other purposes. Some may argue that a new choice architecture
for placenta would create a slippery slope, as it could be extended to these other
materials, making research and medicine more administratively burdensome and
expensive.
Yet, several features of the placenta justify giving its producers greater
decision-making authority. First, patients relinquishing other bodily materials
have no personal use for them, except for rare cases in which for idiosyncratic
or cultural reasons they wish to recover a body part such as an amputated limb.3 96
By contrast, the intense spiritual, cultural, or religious interest some people have
in placentas warrants a right for patients not only to access their placentas upon
request, but also to be provided with information on placental uses and value that
may facilitate an informed decision-making process. Second, this right may not
be as onerous as it seems given the rarity of its exercise. Placentas are not
collected as commonly as other biological materials, and the majority of patients
394. Dr. Redline, Placental Pathology: Is it Time to Get Serious?, CONTEMP. OB/GYN (Feb. 1, 2014),
https://www.contemporaryobgyn.net/modern-medicine-cases/placental-pathology-it-time-get-
serious [https://perma.cc/7GD3-VUDT].
395. Pathologists routinely perform rapid microscopic analyses of specimens or cryosections in the
course of surgeries, so there is no technical obstacle to a fast-paced turnaround for placenta
pathology. See Anthony A. Gal & Philip T. Cagle, The 100-Year Anniversary of the Description of
the Frozen Section Procedure, 294 J. AM. MED. ASS'N 3135 (2005) (detailing the history and
practice of the frozen section procedure). This would require adequate personnel, resources, and
policies.
396. Browning v. Norton-Children's Hosp., 504 S.W.2d 713, 715 (Ky. Ct. App. 1974) (finding that
hospital properly disposed of an amputated leg by cremation in the absence of any indication that
the patients desired otherwise); see also Blake A. Gibson & Richard E. Sobonya, Patients Who Take
Home Their Surgical Pathology Specimens: A Preliminary Study, 6 ACAD. PATHOLOGY 1 (2019)
(one of the first studies of the prevalence and motivation behind patients' requests that their tissues
be returned to them).
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do not want their placentas back.3 97 Even people who are interested in claiming
their placenta will have only a limited ability to exercise the right repeatedly,
given that in the course of their reproductive lives they are unlikely to be
pregnant more than a handful of times. Placentas are therefore quite unlike
biological samples such as blood, urine, skin, saliva, or feces, which could
theoretically be collected and reclaimed thousands of times by the same person.
With placentas, there is little room for the odd patient to drastically increase
costs, providing an intrinsic barrier to a potential ripple effect.
B. Framing Consent
As Elizabeth Emens has shown in the context of name changing, 3 98 "framing
rules" may affect certain decisions in which, like placenta retention, "social
conventions, rather than legal rules, seem largely to drive behavior."399 Framing
rules focus on how the question is asked, not on what the rules are.4°° It is
therefore important to reflect upon the best way to frame informed consent
procedures for placenta collection and donation. For instance, if pregnant people
are told nothing about the placenta or just that it is a waste product of pregnancy
on par with blood and other body fluids, they may be more likely to donate it.
By contrast, merely asking a pregnant person whether they intend to request the
release of their placenta or informing them that they have the right to do so could
lead them to believe that a recommended action is implied.
In other words, how can people's consent to the use of their placenta be made
fully informed and voluntary? Radhika Rao notes that "[t]he true challenge of
informed consent is that this venerable doctrine often functions as a charade, a
collective fiction which thinly masks the uncomfortable fact that the subjects of
human research are not actually afforded full information regarding the types of
research that may be contemplated, nor do they provide meaningful consent."1
The few studies that investigate perceptions about placenta donation suggest that
women are quite willing to donate so long as they are asked in a timely fashion,
by the right person, and provided with adequate information. 402 But this
397. See Baergen, Thaker & Heller, supra note 322, at 327 (stating that the main reason why some of the
hospitals they surveyed did not release placentas was "due to lack of requests").
398. See Elizabeth F. Emens, Changing Name Changing: Framing Rules and the Future of Marital
Names, 74 U. CHI. L. REv. 761, 839-54 (2007).
399. See id. at 839.
400. See id. at 840.
401. See Rao, supra note 26, at 438.
402. The studies were conducted in Brazil, Denmark, Finland, and the United States. See A. Halkoaho et
al., Ethical Aspects of Human Placental Perfusion: Interviews of the Mothers Donating Placenta,
31 PLACENTA 686, 689 (2010) (interviewing Finnish women who donated their placentas for
scientific studies); Claudia A. Kozinetz et al., Consenting Postpartum Women for Use of Routinely
Collected Biospecimens and/or Future Biospecimen Collection, 7 J. COMMUNITY GENETICS 153,
154 (2016) (Texas study of postpartum women's willingness to consent to future and residual
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conclusion cannot be generalized to cultural contexts in which the placenta has
a special cultural and religious value, calling for follow-up research among
different populations. 40 3 Assuming that patients have a real choice between
reclaiming their placenta, having it disposed of, archiving it at the facility, or
donating it, what should be the required framing in terms of timing, identity of
those asking for consent, and informational content? The next subsections
address each of these factors in turn.
1. The Timing of Consent
In her 2012-2013 Brazilian study, Rebecca Yoshizawa reported that 60% of
the women she surveyed "preferred to be approached about donation during
prenatal appointments."A 4 Similarly, Arja Halkoaho and colleagues' 2008-2009
Finnish study suggests that waiting until delivery to ask for consent is
inadequate. They emphasize that due to the nature of labor-which can be long,
absorbing, painful, and emotional-there was sometimes no time at all to discuss
the research project with potential donors and even when there was, women
"gave their consent almost immediately .. . there was usually no in-depth
conversation between the mother and the midwife. Most mothers did not ask any
questions, and those who did only had basic queries such as where would the
placenta go and what would it be studied for.'A 5 Waiting until after labor is over
is not preferable. A study conducted in Texas on seventy-two postpartum women
looked at "the feasibility and acceptability of consenting women post-delivery
before hospital discharge.40 6 The authors found that the majority of women
consented,4 °7 but a major limitation is that the study was conducted on a
vulnerable demographic of women more likely to consent-58% were Latinx,
61% had no college education, 58% were unmarried, 40% had an annual family
income below $30,000, and 49% were unemployed before delivery.40 8 Based on
these studies, I would favor a regime in which pregnant people were informed
collection of biospecimens); Uffe Lind, Tina Mose & Lisbeth E. Knudsen, Participation in
Environmental Health Research by Placenta Donation-A Perception Study, 6 ENVTL. HEALTH 36
(2007) (interviewing Danish women who donated their placentas for scientific studies); Yoshizawa
et al., supra note 15, at 80 (empirical study in 2012-2013 surveying public perspectives of placentas
and placenta donation among Brazilian women postpartum).
403. Sandra Crouse Quinn et al., Improving Informed Consent with Minority Participants: Results from
Researcher and Community Surveys, 7 J. EMPIRICAL RES. ON HUM. RES. ETHICS 44, 45 (2012)
(arguing that practices of informed consent should be adapted to and reflect the preferences of the
groups involved).
404. Yoshizawa et al., supra note 15, at 79.
405. Ara Halkoaho et al., Views of Midwives About Ethical Aspects of Participation in Placental
Perfusion Studies, 28 MIDWIFERY 131, 133 (2012).
406. Kozinetz et al., supra note 402, at 154.
407. Id.
408. Id. at 153.
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about placenta collection, storage, and donation during prenatal appointments,
starting as early as the first trimester of pregnancy. Sometimes, the timing of
consent will need to occur later in pregnancy, for example, when the placenta is
collected to study a condition that developed or was discovered closer to
delivery, such as intrauterine growth restriction, preeclampsia, or premature
labor. But even then, if patients had been aware of the practice of collecting
placentas for various purposes since the first months of their pregnancy, they
would likely be better informed about their options and the costs and benefits.
2. The Identity of Those Asking for Consent
By whom should consent be sought? Yoshizawa reports that in her Brazilian
survey "having their doctor invite them to donate their placenta is respondents'
preference (78%) over any other person and in particular, the vast majority did
not support having the researcher directly approach them." 40 9 In placental studies
conducted in countries where obstetric care is provided by midwives, it is
common for midwives to act as the recruiters. 41 0 In the United States, the
conversation should be initiated by the pregnant person's providers, be they
OBGYNs or midwives. In addition, in cultural contexts in which the placenta
has a ritual meaning for the well-being and future of the entire family or
community-not just the birthing parent and their baby-a conversation should
be initiated as to whether consent should be solicited from the entire group rather
than the individual patient.
3. The Information Provided
How much and which information should be communicated? As Yoshizawa
and her colleagues' research shows, "[d]isinterest in seeing the placenta at birth,
and a lack of spiritual valuation, does not mean women are indifferent to the
organ or its final fate."'11 According to research conducted in England in 2009-
2010, people surveyed about their attitudes toward cord-blood banking thought
that pregnant women had a right to know the value of cord blood and a right to
donate it.4 12 Providing similar information on the placenta would not require that
medical providers endorse any form of placenta self-consumption or use, but
ensure that all patients are aware of its value. The donation solicitation process
.409. Yoshizawa et al., supra note 15, at 79.
410. Halkoaho et al., supra note 402, at 690.
411. Yoshizawa et al., supra note 15, at 81.
412. Laura L. Machin, Nik Brown & Danae McLeod, Giving to Receive? The Right to Donate in
Umbilical Cord Blood Bankingfor Stem Cell Therapies, 104 HEALTH POL'Y 296, 296 (2012).
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should include information on the projected purpose of the placental tissue and
its commercial dimension, if any.413
The risks and benefits of placenta donation should also be discussed. Other-
regarding benefits such as supporting research and contributing to medicine and
patient care are already part of public discourse on placenta donation. By
contrast, the question whether donors themselves reap any medical or other
benefits is rarely addressed. Yet, there is the possibility of a two-way relationship
of reciprocal exchange between placenta scientists and clinicians and donors
since placental tissues are highly useful to investigate the etiology and treatment
of negative pregnancy outcomes. Patients who experience pregnancy loss or
complications, or who seek terminations motivated by fetal abnormalities in
particular may stand to gain from placenta research on how to improve their
outcomes. Similarly, placental examination can be useful in the diagnosis and
treatment of children who develop certain illnesses or disabilities. 414
The risks of donating placentas (or allowing facilities to archive them) are
seldom discussed. This may be because, unlike other types of living donations,
there are no physical risks involved. Placentas are temporary organs naturally
expelled from the body. A donor does not risk pain, complications, or future
health problems. There is no research, however, assessing whether, as in living
organ donation, there are psychological risks in donating placental tissue, such
as sadness, anxiety, or resentment. In addition, other types of risks are associated
with placenta donation. Similar to organ and tissue donation, physicians'
reputational or economic interest in the value of placental tissue may influence
the quality of care women receive.415 There is also a privacy risk for both donors
and their children. As Yoshizawa has pointed out, "if the placenta is indeed a
'diary' of pregnancy, potentially-sensitive information might be obtained."4 16 In
addition to information gathered from the analysis of the placental tissue, the
screening of donors and the creation of individual identifiers generate medical
information.417
To conclude, not only should pregnant people be consulted before their
placentas become usable by third parties, but the consent procedure should be
413. One complication is that biospecimens are sometimes collected for one use and later repurposed. As
a solution, some scholars have proposed the legal recognition of new forms of consent, such as the
idea of "dynamic consent," which relies on new information technologies to keep researchers and
participants in touch via a personalized communication interface and thereby allows researchers to
change their research uses and participants to re-consent. See Jane Kaye et al., Dynamic Consent: A
Patient Interface for Twenty-First Century Research Networks, 23 EUR. J. HUM. GENETICS 141, 141
(2015).
414. See supra note 387 and accompanying text.
415. Who Should Profitfrom the Economic Value of Human Tissue?: An Ethical Analysis, 1 CODE MED.
ETIUCs REP. 124 (1990).
416. Yoshizawa, supra note 29, at 11.
417. See Burton et al., supra note 165, at 18.
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carefully redesigned with an eye to protecting their autonomy through proper
timing, interactions, and information.
C. Should Placenta Donors Be Compensated?
Semen donors, egg donors, feces donors, 418 and blood donors 4 19 are
compensated, but organ and tissue donors are prohibited from earning any form
of payment under state and federal law.420 Where should the placenta stand?
While people give their placental tissue free of charge, it may be appraised and
exchanged for money, not unlike what can be observed with other organs and
tissues. 42 1 The healthcare centers where pregnant patients are treated, the
medical transportation companies that transport placentas, the research
institutions, tissue banks, procurement organizations, or biotech companies that
process, test, and distribute the placentas can each attach charges to it. Why
should these organizations be compensated for their work when donors
themselves are not?
422
This disparity calls into question why, in the few states such as Connecticut,
Oregon, and Texas that explicitly allow women to obtain the release of their
placentas from healthcare facilities, a standard precondition is that the placenta
will be for "personal use" and not for sale.42 3 In Texas, the stipulation appears
418. Rachel Feltman, You Can Earn $13,000 a Year Selling Your Poop, WASH. POST (Jan. 29, 2015,7:00
AM MST) https://www.washingtonpost.com/news/speaking-of-science/wp/2015/01/29/you-can-
earn- 13000-a-year-selling-your-poop [https://perma.cc/M9VS-7PKZ].
419. See Sophia Chase, The Bloody Truth: Examining America's Blood Industry and its Tort Liability
Through the Arkansas Prison Plasma Scandal, 3 WM. & MARY BUS. L. REV. 597, 602 (2012)
420. The National Organ Transplant Act (NOTA) makes the selling of human organs a federal crime.
National Organ Transplant Act, Pub. L. No. 98-507, 98 Stat. 2339 (codified as amended at 42 U.S.C.
§§ 273-274(e) (1988)). But see Russell Korobkin, "No Compensation" or "Pro Compensation ":
Moore v. Regents and Default Rules for Human Tissue Donations, 40 J. HEALTH L. 1, 6 (2007)
(arguing that NOTA's language allows researchers to sell protected organs for research purposes
without offending the terms or purpose of the statute). The Uniform Anatomical Gift Act (UAGA),
which has been enacted in some form by all fifty states, provides for the charitable disposition of
the corpse for research and of organs for transplant. See REV. UNIF. ANATOMICAL GIFT ACT (UNIF.
LAW COMM'N 2006).
421. Michele Goodwin, Expressive Minimalism and Fuzzy Signals: The Judiciary and the Role of Law,
84 CHI.-KENT L. REV. 19, 49 (2009); see also J. Randall Boyer, Gifts of the Heart... and Other
Tissues: Legalizing the Sale of Human Organs and Tissues, 2012 BYU L. REV. 313, 314 (2012)
(critiquing the fact that the "same federal and state laws [NOTA and UAGA] that prohibit donors
from receiving compensation for their organs and tissues facilitate this industry by providing
recovery of costs to anyone who removes, stores, transports, processes, or transplants the organ or
tissue"); supra Part II.A.3.i.a. (noting that the placenta does not meet the federal definition of
organs).
422. Journalist Matilda Battersby posed this question in 2017. Battersby, supra note 235.
423. See CONN. GEN. STAT. § 19A-490V (2018) (providing that "a hospital may allow a woman.., to
take possession of and remove from the hospital the placenta if:. .. [it is] for personal use. A person
removing a placenta from a hospital under this section may only retain the placenta for personal use
and may not sell the placenta"); OR. ADMIN. R. 333-056-0045 (2018) (requiring that the woman
obtaining the release of her placenta sign a form containing "[a]n attestation ... that the placenta
will not be used for commercial purposes"); TEx. HEALTH & SAFETY CODE ANN. §
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all the more one-sided since another statutory provision exempts from disposal
requirements "placentas designated for sale and obtained from a licensed
hospital or a licensed birthing center.", 424 This specification suggests that
placentas can be sold so long as the seller is not the donor themself. This legally
mandated "giftification 'A25 of the placenta contributes to the invisibility of the
reproductive labor involved in producing it. In response to this tendency for
bodies coded as female to be treated as a source of free biological materials,
Melinda Cooper and Catherine Waldby have conceptualized women's embodied
participation in research and medicine--be it as tissue donors, clinical trial
participants, experimental subjects, or surrogates-as a form of "clinical
labor."'426 They point out that donating tissue is work and that donors should be
viewed as workers rather than volunteers. Under this view, placenta producers
should be compensated.
Several challenges could be raised against this view. First, opponents may
point to the risk of exploitation, which have been discussed at length in the
context of organ donation. But given the low risks involved in placenta donation
and the lack of interest many people have in keeping it for themselves,
introducing compensation is unlikely, in and of itself, to lead to exploitation. A
related concern would be that the people most likely to be motivated by financial
incentives will be those constrained by socioeconomic circumstances, who may
decide to get pregnant for the purpose of selling their placenta. An obvious
rejoinder is that the monetary benefit for a single placenta would have to be
extremely high to offset the costs, risks, and burdens of pregnancy, making this
prospect highly implausible.
Second, paying donors may drive up the cost of socially useful activities
such as research and medicine. This is a realistic possibility, but there may be
ways to offset the hike. First, it is likely that not all donors would accept the
compensation. Some may prefer to donate for free, similar to people who give
their milk free of charge rather than selling it.427 Additionally, compensation
172.002(a)(2)(B), (b) (West 2018) (allowing women to take possession of their placenta and
requiring they sign a form acknowledging that "the placenta is for personal use. A person removing
a placenta from a hospital or birthing center under this section may only retain the placenta for
personal use and may not sell the placenta").
424. 25 TEx. ADMIN. CODE § 138.3 (2018).
425. See generally Marisa Gerstein Pineau, Liquid Gold: Breast Milk Banking in the United States 1
(2012) (unpublished Ph.D. dissertation, University of California Los Angeles) (on file with author)
(arguing that over the course of the twentieth century, human milk underwent a process of
"giftification," whereby most milk banks no longer pay donors for their milk even though they
themselves dispense it for a hefty fee to hospitals and a few outpatients).
426. MELINDA COOPER & CATHERINE WALDBY, CLINICAL LABOR: TISSUE DONORS AND RESEARCH
SUBJECTS IN THE GLOBAL BIOECONOMY 17 (2014).
427. See Mathilde Cohen, Should Human Milk Be Regulated?, 9 U.C. IRVINE. L. REV. 557, 617 (2019)
(arguing that people who supply milk banks and companies with milk should have the option to be
paid a living wage).
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could be structured in a way that minimizes the rise in research and care
expenditures. For example, in profit-sharing schemes, profits from the
commercial use of human tissue and its products are shared with patients in
accordance with contractual agreements. Physicians, researchers, biobanks, and
other organizations may offer patients a small percentage of any profits that are
realized on products derived from the patient's tissues. Compensation in the form
of reciprocity could also be substituted for cash payments. Empirical research on
placenta donation indicates that reciprocity is an important factor for donors,
particularly in countries with universal health care. A 2007 study of Danish
women donating placentas for medical research revealed that participants
experienced donation as a way of "giving something back to the Danish health
care system. 'A28 A Scottish study of a population genetic database involving the
collection of thousands of placentas resulted in similar findings. Participants felt
that donation "was an opportunity 'to put something back in' for care.., received
from the UK National Health Service."' 429 Donors exhibited "a desire to
reciprocate" as well as "a wish for reciprocation. '43° In the United States, where
gynecological, prenatal, obstetric, and postpartum care can be prohibitively
expensive and lagging in quality, especially for the most vulnerable populations
of women,43 1 offering donors access to more affordable and higher quality care
could benefit them and their children as well as providers and researchers.
432
D. Regulating Placenta-Based Products
Given the potential harmful effects of some of the placenta-based cosmetic
products, a very different regime is required for personal care products-one that
is less about choice and more about consumer protection and changing norms or
behaviors of corporate actors. Federal and state laws regulate the placenta based
on its use-as waste to be disposed of, research subject, tissue used for
therapeutic purpose, dietary ingredient or food, and cosmetic ingredient.
428. Lind, Mose & Knudsen, supra note 402, at 4 ("Since the Danish health care system is funded through
taxes collected by the Danish state, health care in Denmark is often perceived as both free and as a
collective project. Some of the informants thus stressed that participating was a way of giving
something back to the Danish health care system.").
429. Gillian Haddow, "We Only Did It Because He Asked Us ": GenderedAccounts of Participation in a
Population Genetic Data Collection, 69 SOC. SCI. & MED. 1010, 1013 (2009).
430. Id.
431. See Linda Villarosa, Why America's Black Mothers and Babies Are in a Life-or-Death Crisis, N.Y.
TiMEs (Apr. 11, 2018), https://www.nytimes.com/2018/04/11/magazine/black-mothers-babies-
death-matemal-mortality.html [https://perma.cc/WYE7-X4MW] (exposing some of the inequities
that lead to the glaring racial and ethnic disparities in maternal and neonatal health outcomes in the
United States).
432. But see Goodwin, supra note 378, at 1235 (indicating that some medical practitioners condition
treatment upon patients' waiving their rights to their tissues). This scenario should be avoided in the
imagined compensation scheme by requiring that healthcare facilities deliver care regardless of a
patient's decision about their placenta.
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Consumers of placenta-based drugs and therapies enjoy some protection under
food and drug law even if this body of law may be underenforced.43 3 However,
consumers of cosmetic placental products are especially vulnerable. This is due
in part to the general insufficiency of cosmetic regulation by the FDA under the
FD&C Act.434 Under the FD&C Act, cosmetic products and ingredients, other
than color additives, do not need FDA approval before they go on the market.435
It is manufacturers' responsibility to ensure the safety of their ingredients. The
only requirement is that the cosmetic must not be adulterated or misbranded.4 36
In 2002, the Cosmetic Ingredient Review (CIR) Expert Panel published their
assessment of placenta-derived ingredients (human and animal) in the
International Journal of Toxicology.4 37 Formed in 1976 as a joint effort by
government, industry, and consumer groups, the CIR is one of the cosmetic
industry's self-regulatory programs that reviews and assesses the safety of
ingredients used in cosmetics and publishes the results in peer-reviewed
literature.438 The CIR Expert Panel concluded that the data were insufficient to
make a determination of safety. 439 It has not looked at placenta-derived
ingredients since. Accordingly, the safe use of these ingredients in cosmetics is
not supported. As noted earlier, in 1994 the FDA recommended that placenta-
based ingredients be identified by a name other than "placental extract" so as to
describe them more accurately because consumers associate the name "placental
extract" with a therapeutic use or some biological activity.440 The CIR Expert
Panel 2002 review reiterated the message by advising industry that cosmetic
formulations should not be identified as containing "human placental extract" or
"placental extract" so as to comply with FDA guidelines.44 1 The result is a lack
of clarity and inadequate labeling for consumers who may not be able to tell
whether a product contains placenta.
A first step toward protecting consumers would be to require transparency
by compelling manufacturers to list any ingredients derived from human or
animal placentas as such. In light of the studies mentioned above on the dangers
of placenta-based cosmetics, FDA should also continue to pursue enforcement
433. See supra notes 249-55 and accompanying text.
434. See Boyd, supra note 301 (critiquing this lack of regulation from an intersectional feminist
perspective).
435. See Gabrielle Eriquez, Makeup Call: How Cosmetic Product Use Affects Women Absent Federal
Regulation, 25 WM. & MARY J. WOMEN & L. 221, 223 (2018).
436. Id.
437. Nair & Elmore, supra note 142.
438. See Ivan J. Boyer et al., The Cosmetic Ingredient Review Program-Expert Safety Assessments of
Cosmetic Ingredients in an Open Forum, 36 INT'L J. TOXICOLOGY 5S (2017) (presenting the history
and role of CIR).
439. Nair & Elmore, supra note 142, at 90.
440. COSMETIC HANDBOOK, supra note 313, at 12-13.
441. Nair & Elmore, supra note 142, at 89.
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actions against products established to be harmful even when used as intended
and ban placenta-based products, pending the result of new clinical studies on
the safety of placenta-based ingredients conducted by independent researchers
or by the agency. In March of 2019, the latest version of the Personal Care Safety
Act was introduced in the Senate. If adopted, the Act would go a long way toward
protecting consumers against all dangerous cosmetics by, inter alia, requiring the
FDA to review at least five cosmetic ingredients annually for safety, imposing
"good manufacturing practices," mandating adverse event reporting, and
instituting more extensive labeling requirements, including ingredients not
appropriate for children or for professional use only.
442
In contrast to this pro-regulatory stance as applied to placenta-based
cosmetics, the current non-interventionist FDA regulation of placenta self-
consumption and encapsulation is satisfactory. Consuming one's own placenta
is not risk-free, but the risks which have been documented so far do not warrant
intruding into birthing parents' freedom of choice.443 In addition, contrary to
placenta-based personal care products, which are used over long periods of time
(sometimes years) and by multiple consumers, placentophagy is limited in time
and number of ingestion opportunities, which may lower the risks of adverse
hormonal effects, if any. People who engage in placentophagy rarely share their
placenta products with others, and even more rarely with children, who may be
more vulnerable to potential harmful hormonal effects. 444 As for encapsulators,
regulation would ensure that they are properly trained and follow consistent
guidelines, increasing the safety of placenta pills and other placental products for
self-consumption. But encapsulators are not in the business of putting products
on the marketplace for the general public to purchase. They are hired by
individuals to prepare their own placentas for self-consumption. Any potentially
harmful product would in principle only be consumed by birth parents
themselves. This is a case where the risk is one of self-harm rather than harm to
others, justifying lenient legal interventions, if any, especially considering that
placenta encapsulators already self-regulate.
445
CONCLUSION
This Article argues that the under- and overregulation of the placenta creates
a significant reproductive justice issue. The inequities at stake in placenta
442. Personal Care Products Safety Act, S. 726, 116th Cong. (2019).
443. See supra note 67 and accompanying text.
444. But see Placenta Tincture, TREE OF LIFE PLACENTA SERV.,
https://www.portlandplacentaservices.com/other-placenta-remedies--services.html
[https://perma.cc/53RR-JUNA] (recommending giving drops of placenta tincture to children when
they are "getting sick or in a time of transition").
445. See supra Part II.A.3.
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regulation can be summed up in the following supply and demand chain.
Pregnant people produce placental tissue through their reproductive labor.
Generally constructed by the law as waste products, placentas may be
simultaneously inaccessible to postpartum patients on the ground that they are
infectious and available for use by third parties on the ground that they are
discarded. In states seeking to ban or restrict abortions, however, patients may
have more ready access to their placenta following an abortion or a miscarriage
than after the delivery of a baby by reason of fetal remains being categorized as
cadavers of born persons whose remains must be dignified and cannot be
classified as waste. Finally, while some patients may be denied access to their
own placentas, others may purchase poorly regulated placenta-based cosmetics
and therapies.
To curb this cycle, this Article proposes that pregnant patients' right to
choose what to do with their placenta should be legally protected and that
placenta-based cosmetics should be regulated more strictly. To develop a
comprehensive legal regime pertaining to placentas, data must be collected on
the ins and outs of current placental economies, as there is much we do not
currently know about how placentas are collected, transformed, marketed,
labeled, and more. This Article has broader implications for the law of the body
in general, as it shows that placentas disrupt some of the assumptions
underpinning the functioning and regulation of the bioeconomy. Placentas
contradict the happy story according to which, after diagnostic or therapeutic
procedures, patients do not think about what happens to their tissues, which can
therefore be retained as waste and utilized without obtaining patient consent or
providing compensation. The idea of protecting patients' autonomy over their
placentas could thus serve as a blueprint for exploring whether and how similar
protections should be extended to other body parts and biological materials.
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